var title_f7_20_7488="Innervation of upper airways";
var content_f7_20_7488=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The innervation of the upper airways depicted in a highly schematic diagram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 470px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sympathetic and parasympathetic nerves innervate the airways. Sympathetic nerves innervate blood vessels in the airways and mediate vasoconstriction. Parasympathetic nerves innervate the vasculature as well as the mucus glands of the airways. When activated, parasympathetic nerves initiate mucus secretion and dilatation of airway blood vessels. Parasympathetic nerves also innervate airway smooth muscle. The opposing actions of the sympathetic and parasympathetic nerves on nasal blood flow likely serves to optimize the air conditioning function of the nasal passages. Afferent nerves innervating the nose regulate such homeostatic reflexes as well as defensive reflexes like mucus secretion and sneezing. Upper airway afferent nerves, which arise from the trigeminal ganglion may also initiate reflex effects in the lower airways and may regulate respiration. These interactions between the upper and lower airways are facilitated by the proximity of CNS structures regulating upper and lower airway function.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Canning, BJ. Neurology of allergic inflammation and rhinitis. Curr Allergy Asthma Rep 2002; 2:210. Copyright &copy; 2002 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7488=[""].join("\n");
var outline_f7_20_7488=null;
var title_f7_20_7489="Azapropazone: International drug information";
var content_f7_20_7489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azapropazone: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cinnamin (JP);",
"     </li>",
"     <li>",
"      Debelex (AR);",
"     </li>",
"     <li>",
"      Prolixan (AT, CH, CZ, HU, IT, NL, PT);",
"     </li>",
"     <li>",
"      Rheumox (GB, IE);",
"     </li>",
"     <li>",
"      Tolyprin (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of rheumatoid arthritis, ankylosing spondylitis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Rheumatoid arthritis and ankylosing spondylitis: 1.2 g daily in 2 or 4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 600 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10529 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7489=[""].join("\n");
var outline_f7_20_7489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303300\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977772\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977775\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977771\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821161\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977774\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10529\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10529|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_20_7490="Laser lithotripsy";
var content_f7_20_7490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Laser lithotripsy of a gallstone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large stone grasped with a basket under direct exposure of the laser beam. A greenish \"plasma\" is seen generating shock-waves to break up the surface of the stone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Berlien, Laser und Medizin-Technologie gGmbH (LMTB), Berlin from H, Muller, G. Angewandte Lasermedizin: Lehr- und Handbuch fur Praxis und Klinik, ecomed verlagsgesellschaft 1990.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7490=[""].join("\n");
var outline_f7_20_7490=null;
var title_f7_20_7491="Patient information: Common wrist injuries (The Basics)";
var content_f7_20_7491=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17116\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/13/24789\">",
"         Hand and wrist bones",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/4/42050\">",
"         Patient information: Preventing falls (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25937\">",
"         Patient information: Cast and splint care (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Common wrist injuries (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/common-wrist-injuries-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27926769\">",
"      <span class=\"h1\">",
"       What are common types of wrist injuries?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common types of wrist injuries include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Sprains &ndash; A wrist sprain is when a ligament in the wrist tears or gets stretched too much. Ligaments are tough bands of tissue that connect bones to other bones.",
"       </li>",
"       <li>",
"        Fractures &ndash; A &ldquo;fracture&rdquo; is another word for a broken bone. There are different kinds of wrist fractures. Some wrist fractures involve a break in 1 of the small bones in the wrist. Others involve a break in 1 of the forearm bones near the wrist (",
"        <a class=\"graphic graphic_figure graphicRef69018 \" href=\"UTD.htm?24/13/24789\">",
"         figure 1",
"        </a>",
"        ). One common type of wrist fracture is called a &ldquo;Colles&rsquo; fracture.&rdquo; This fracture involves the end of 1 of the forearm bones. It can happen when a person falls onto his or her outstretched hand.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926784\">",
"      <span class=\"h1\">",
"       What are the symptoms of a wrist injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Wrist injuries can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Bruising",
"       </li>",
"       <li>",
"        Stiffness",
"       </li>",
"       <li>",
"        Weakness in the wrist or arm",
"       </li>",
"       <li>",
"        The arm or wrist to look bent",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sprains usually cause less pain and swelling than fractures, but not always.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926799\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will ask about your symptoms and do an exam. To check for a fracture, he or she will do an X-ray. He or she might also do an imaging test such as a CT or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926813\">",
"      <span class=\"h1\">",
"       How are wrist injuries treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the type of injury you have and how severe it is.",
"     </p>",
"     <p>",
"      If you have a lot of pain or a severe injury, your doctor will prescribe a strong pain medicine. If your injury is mild, your doctor might recommend that you take an over-the-counter medicine for your pain. Over-the-counter medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"       naproxen",
"      </a>",
"      (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"     </p>",
"     <p>",
"      Treatment for a wrist sprain can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Resting your wrist",
"       </li>",
"       <li>",
"        Putting ice on your wrist &ndash; To reduce swelling, you can put a cold gel pack, bag of ice, or bag of frozen vegetables on the injured area every 1 to 2 hours, for 15 minutes each time. You should put a thin towel between the ice (or other cold object) and your skin. You should use the ice (or other cold object) for at least 6 hours after your injury. Some people find it helpful to ice longer, even up to 2 days after their injury.",
"       </li>",
"       <li>",
"        Wearing an elastic bandage (such as an ACE&trade; wrap) or splint",
"       </li>",
"       <li>",
"        Surgery &ndash; Most people with a wrist sprain do not need surgery. But people who tore a ligament might need surgery to fix the ligament.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A wrist fracture is usually treated with a splint or cast. But your doctor might wait for your swelling to get better before he or she puts the cast on your wrist. Swelling usually gets better in a few days. While you wait for the swelling to get better, your doctor will probably have you wear a splint.",
"     </p>",
"     <p>",
"      Before your doctor puts the cast on your wrist, he or she will make sure that your bone is in the correct position. If your bone is not in the correct position, your doctor might do a procedure or surgery to put your bone in the correct position.",
"     </p>",
"     <p>",
"      After your cast or splint comes off, your doctor might recommend that you see a physical therapist (exercise expert). The physical therapist can show you exercises and stretches to make your muscles stronger and help your joints move more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926828\">",
"      <span class=\"h1\">",
"       How long do wrist injuries take to heal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends partly on the type of injury and how severe it is. A mild sprain takes about 1 to 2 weeks to heal. Fractures can take weeks to months to heal.",
"     </p>",
"     <p>",
"      It also depends on the person. Healthy children usually heal very quickly. Older adults or adults with other medical problems can take much longer to heal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926843\">",
"      <span class=\"h1\">",
"       Can I do anything to improve the healing process?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It&rsquo;s important to follow all of your doctor&rsquo;s instructions while your sprain or fracture is healing. He or she will probably recommend that you eat a healthy diet that includes getting enough calcium, vitamin D, and protein (",
"      <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"       figure 2",
"      </a>",
"      ). He or she will also probably recommend that you avoid doing certain things. For example, he or she might recommend that you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Avoid doing certain physical activities.",
"       </li>",
"       <li>",
"        Avoid smoking &ndash; A fracture can take longer to heal if you smoke.",
"       </li>",
"       <li>",
"        Avoid damaging your cast or getting it wet, if you have a cast that shouldn&rsquo;t get wet.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926858\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will tell you when to call him or her. In general, you should call your doctor or nurse if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        You have severe pain, or your pain or swelling gets worse.",
"       </li>",
"       <li>",
"        You have numbness or tingling in your fingers, or your fingers look blue or purple.",
"       </li>",
"       <li>",
"        You damage your cast or get it wet, and it&rsquo;s not supposed to get wet.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27926873\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/4/42050?source=see_link\">",
"       Patient information: Preventing falls (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       Patient information: Cast and splint care (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/20/7491?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17116 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7491=[""].join("\n");
var outline_f7_20_7491=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926769\">",
"      What are common types of wrist injuries?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926784\">",
"      What are the symptoms of a wrist injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926799\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926813\">",
"      How are wrist injuries treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926828\">",
"      How long do wrist injuries take to heal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926843\">",
"      Can I do anything to improve the healing process?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926858\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27926873\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/13/24789\">",
"      Hand and wrist bones",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/4/42050?source=related_link\">",
"      Patient information: Preventing falls (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_20_7492="Papaverine: Patient drug information";
var content_f7_20_7492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Papaverine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"     see \"Papaverine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/61/39891?source=see_link\">",
"     see \"Papaverine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat poor blood flow.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to papaverine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10948 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-AEB5EC0217-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7492=[""].join("\n");
var outline_f7_20_7492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012899\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012898\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012903\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012904\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012906\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012901\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012908\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=related_link\">",
"      Papaverine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/61/39891?source=related_link\">",
"      Papaverine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_20_7493="Basement membrane zone";
var content_f7_20_7493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 704px\">",
"   <div class=\"ttl\">",
"    Schematic of the basement membrane (BMZ) zone and intercelllular desmosomal adhesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 684px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Intermediate filaments composed of keratin 5 and 14 insert on the keratin (cytoskeletal) linker proteins plectin and BPAG1 (BP230) at the superior aspect of the BMZ. Plectin and BPAG1 interact with transmembrane a6b4 integrin and type XVII collagen (BP180/BPAG2), forming hemidesmosomes that attach basal keratinocytes to the underlying basement membrane. Anchoring filaments jut out below the hemidesmosome and include laminin-332 and laminin-311 that associate with type XVII collagen and a6b4 integrin, but also laminin-511, type IV collagen and nidogen, thereby forming the lamina densa. Anchoring fibrils extend perpendicularly as banded projections from the lamina densa and contain polymeric associations of type VII collagen molecules that intertwine between dermal interstitial collagen fibrils. Type VII collagen triple helices attach the lamina densa to papillary dermis and are critical for the integrity of the epidermal-dermal junction through their ability to bind laminin-332. Intercellular junction is mediated by desmosomes whose intracellular protein components include desmoplakin (interacting with intermediate filament network), plakophilin as well as plakoglobin, the latter which connect to the transmembrane cadherin tails (composed of desmoglein, desmocollin).",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7493=[""].join("\n");
var outline_f7_20_7493=null;
var title_f7_20_7494="Female perineal membrane";
var content_f7_20_7494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Female perineal membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inferior view of the urogenital diaphragm.",
"    <br/>",
"    (A) Male; on the left, the inferior fascia of the deep transversus perineus (perineal membrane or inferior fascia of the urogenital diaphragm) is intact, but has been removed on the right to expose the musculature.",
"    <br/>",
"    (B) Female; the fascia of the deep transverse perineus has been removed on both sides to expose the muscle fibers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Oatis CA. Kinesiology: The Mechanics and Pathomechanics of Human Movement. Lippincott Williams &amp; Wilkins, Baltimore 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7494=[""].join("\n");
var outline_f7_20_7494=null;
var title_f7_20_7495="Pregnancy terms PI";
var content_f7_20_7495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Pregnancy terms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 616px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJoAhwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRQabuoAdRTN9IZKAJKKjMgpDKKAsS0VAZh600zClcdizRmqhnFIbgUXCxczSZFU/tA9aQ3IouFi7kUbhVBrketMN170uYfKaO8Uu4Vl/avej7X70cwcpqbhSbxWYbumm7o5g5TU8xaXzFrIN170n2qjmHymx5go3isj7V70ouvejmDlNXeKPMFZX2r3pPtXvRzBymt5go8wVlfaaPtPvRzC5TW3ijePWsoXPvS/afejmDlNTePWjePWsv7T70fafejmDlNXcKNwrMFz70v2n3o5g5TS3CjcKzPtVH2r3o5g5TT3ClyPWswXPvS/ac96OYOU0cijIrP+0U4XFO4cpfyKKpC4qeCUO2M80XFYmooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBH+6apedV48iubNx8zD0JBqZOxUVc0zP70xrj3rMa496YZ/eo5i+U0zce9MNx71mGemmbNLmHymkbj3pjXB9azjLTTL70uYfKaBuD600zn1rPMlIZPei4+U0DOaaZz61R8ymmSlcfKXjOfWmmY1S8yk8yi4WLvnH1pPOPrVLzKDJRcdi55x9aQzH1qmXo30rhylvzj60nnH1qpvpN5ouHKXBMfWl84+tUt9G80XDlLvnn1o841T30bqLhYu+caPP96pb6XfRcLFzzvel873qlvrmviB4pfwnoSahFZLeyPcRW6xNN5Qy7bcltrdPpTvcGrHZ+cfWl84+teQv8Sr9tZs9MGnWtvdrrkelXmJWnj2tGz7o3wh3cY5Xj0rqz488Px3c9tdXstlPDC1y63tpNbfu1OCymRFDDPpmnqLQ7Tzj60ecfWuM/wCE70IWEF4896kVxIsdur6fcLJcMwyPKjMe6QY5yoIqnJ8TvCcdvFP/AGo0kUtq14pitJpMQq5RmYKh24YEEHBGOaNQ0O/84+tHmn1rzvT/AIj2V74wu9FhtLqS3isY76O8ggmlEqsu/hVjOBt6HPzH5RzxW9oXirS9cu7y10+eb7XZ7PtFvcW0tvJGGGVJSRVOCO+KLsNDqBMfWl84+tc/Y+INJv7+4sbDVLC5vbfImt4bhHkjwcHcoORg8c965q58WeIIdZ1HTW0XSkazshftMNSkf92zSKuF8gZbMRyuQOR81AtD0YTH1pwmPrXn2hfEPR7zQ7e6vbl4bz7NbyzQ/ZJlZml4HlIV3SAsGA2bunWt608R6bdaNcarDcN9itxIZmeJ0eLy87wyMAwIweCM0w0OkE5HepILwpMhJ4zzXnN34+srgWQ0SUyyyXtrDKlzbSwsIZmIEihwpIODhhleO9X38caHG92lxc3NrJaxiWRLqynhYoXCAoHQF8sQo25ySB3FF2gsmesUVxi/Ebw9b6fBNez38BaJpXR9Mug8UanDSSL5eY48/wAbAL154NSXnxE8OW93dWgu55LqB5IcLZzmNpkjMhiWQIULlRkKCSewNbHOdfRXC6X8TdHuPBumeIdSt9VsLa6tluJf+JXdyxwfIrtukEWNg3cScKwBIPBx3EbrLGkkbBkcBlYHIIPQ0AOooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkNQDQajcxnpu3D6EZrr65rxLGFvYpB1dMH8P/wBdRU2NKb1MwyU0yVE3Wm5rC5vYm8ykLmoqKB2JN5pNxplFAWHbqN1NooAdmkzSUUALmjNJRQAuaM0lFAwzRRRQAUUUUAFFFFABRRRQAUUUUAFYfjDw1Y+LNIGm6o0wthMkxERXLFDkA7gQQe4xW5WB4wFyYdJ+yQeeRqVuZB5Al2R7/mbBB24H8QwR6ihCexHfeDdGuY9Jit7ZdPg0y8F9DDYokKGQAjkBehyemD71yUXwj8KWd0iXl5dzPdxzWyR3EsKvNvy7fMqK8jLgsCWJAHoK1/hzqGt3dzqEWuSajcbFRknmtTbwkktkIjwRODwMgmQAEfNnNclpei6s2v2VqLvXoJIfEF/O8zWKCOCJ0uSsqOYdjeZuAOSwBYABcgVauupDs+h2Gq/Duw1jS7Ky1jU9R1D7DIr2s1wluzRYGNuPK2OCAM71bpUafDHRl83/AEi7Bk02bSm8qO3hXypWLMwSOJVD88EDHqCea5jUta8fLBpYjW4gJs8tMbKRvMuBK6kSpHbSkDYEOB5f3jhuw7fxxd6na/2WLOW/trKSZheXGnWgup4xsJQBCj/KW4J2HHHTOaWoaMqD4c6ZG4a21DVbcNpaaTKIZkXzoUTapJ2ZDDg5UqCRyCMgz+B/h/pXg69urrS5rl5LmGOBxIsSrhM4OI0UbueSeT1POTXPWt944uNO1O4Y3cVza6VBcW1ubONRcXB87cpyp5wsZZFIIbaMgEg5/wDwkuuiPV7eyu/EWoeTNaIkz6ekE0O+ORnLRi1dtmVUf6pjyOcHNFmGh7Dmsm40O2uNUv793nE15YrYSAMNojVpGBHH3syt6jgcevm0GpeO7vw+1082pWt7a6RLcCFNPQm5uUmkVUYNFn5kVDtUKTkEYrpfiTb3dxF4Zu4JdThW11JZZ30+2E8kSmCVd4Ty3JwWC/dPDHI6EK1h3uSXfgXw9r1msbXMlzHb20OnKyvFKENu7YyCpUuGLKwYEdttaUPheLT/AAZqOhaW6f6RBMiO8MUC7nUjJWGNFx05C5+tcXpY8R6G9xcW66vPaXGpas8lklomVXdNJFIhKbgzsFwWJU7gAKx1uvFWrokmrPr8dpY6laXEU0dhvnVGjlDkKbSMvtbb0iON3UjBqrMm6O7sfBen2kmntrOr3V1qztbLE80sSM32cM6xRhUXKjLseNxHJPFVbD4TaHYtO8d3qDSywiISkQJIhWVJVk3JGC7h41O5yxPOc1N8QUuGuvCV1BLqscVvdyPNdWVibiaJTbSqGMYjfGSwHKcbugrJt5/GGpabeLqTXkKpoXnrD9hjP2m4L3ACOGQjJQRFox0JGMZIJqPQ6v8A4VxpfiHUoH1vULu7v44miS6uLOxnZk3bthSS3ZBg5IKqDyck12x8A6SVVPMuhGuqHVgisijzTCYtmAvCbT0HOe/avJLO88X2uppdwS30cFtf2FvHZCyjWJoHhi85ifL3YVmfkMApBB4GBa0bxh4uvZ2tm1fWIdTl0Oe8uLefRP3drdLcwIFtwkBklUK8g3fvRyGOcEVpB6GM1rc63VPgvo2q6PY6ZqGsaxc2tjaNYW4mS0kMUBVVVV3QEKyheJABJycseK9LsrZLOzgtoixjhjWNS3UgDAz+Vc58Nr3Ur/wwk2tLqQu/OkXdfoqSOoOAwAhhIU9t0at6iupqyAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArI8Rw77RJR1jcfkeP61r1X1CD7TZTw93UgfXtSauhxdmcXIuDUVWH+aNWxyRzUB61zM60JRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsLxb4ii8N2tjPNbT3C3N5Fa4hjeRl3n72EVicY6Y56da3ay/EOjRa3ZRQS3FxbPDPHcRTW5XekiNlSNysp+hBFCE/IwfDvjmyv727s9QkNtcLe3FvButpY42SPLAF2G0PsBYrkHjoK2dD8S6XrkzxadPK0iRrNtlt5IS0bEgOu9RuU4PzLke9UR4L05ooUuJru4Ed7NfN5jKPMkljeNw21R8uJG4GOcc03wb4J03wnJM2msW3xiIbra2RgoPTfHEjt/wMt+fNPQSuQ6F40tbrUb3T9RZobuO/uLWAJay7JBHkhQ+Cpk2qTtBz6CodY8e2UMEbaf55ljvbaC6huLGeOVI5WIBWNlVyTtOMA5I6GpZvANjcXc0lxqOpy28lxPdral41jimlVlZ1KoHyA7YyxxnPWs/TvhbpWnLMbPUNRhnke3l86OO2RlaFmKNtWEKTljkspJwKegveNpvGHhu8sbwzXatbx20k1xHPbSLiJWKSBkZc5B4KY3cjjkZllufD/g7TrYRWkWnW13OI4obKxbMkpUtjy40J3bUPbtise68A273OiKkjTQWt7LfXtxcP+/uWYh9pCqFKmRUYjAH7tQBXUarpMGp3GmTTvKrafdfa4ghABfy3TDZB4xIemOcUtB6mfH4y0GSznukv8wQ2Zv5CYZAUhDMpYjbnIZGBX7wI6VQtPH2ltdavFfrcWcdhfLZCZ7eYxylhHtO/ZtBLSY25JwN33TmqOp/D/Rvsq2b6xqFgt5FNYMEmhVrpZJJJjH8yHJBaQjbg4znIzWrJ4Ls3vbib7dfrDPewag9sDH5fnxGMq4JTdyIlBG7GM4APNPQWoqeNdLElys7yqY50gjhjtbh7h2aFZcGHyg4IVs4AYAYJIOQFXx54daWJEv3cSCJhIttKY1EpxHvcLtTJ4+Yjniquv/D3R9cu7q6vGm+0T3K3W4pDKqMIViwEkRkIKop+YE55BFSQ+A9Li0+6s1luBHcC2D+WsUQHkPvTaqIFXJ64GPTFLQeozSfiFpd3FcG6gv7eWO9ns44lsbiVpvLdxlAseWOELMADs6NiunvdUgs9PW9lju2hYKQsNpLLJz0/dopce/HHfFcrf+ALO8tb20fU79bO6upLwwNDayrHI7MzlDJCxGWYnOSRgYIrT13wpZa14ds9HuJ7pLa1MZRgUkZti7QHEisrgjqGU560aBqQTeP/AA5Haw3BvZmiliknBSzncrGjFHZwEJQKwIO7GO9RaZ4m0Hwx4hgsfDGnWC3upaja215Nb6ewQCRgTumRQu/a24BmJ5zg5qHS/h3pOm6ZLYwT3phksrmwOTGCI55C7kBUABBPGBgDtUv/AAglml7HNDqOpRQJdQ3ptFaPymnjVVDnKbuQgyAwB64zVJpMlpyVme3UVmaFqIvbfZIf9IjGHHr71p1snfU52rOzCiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5HUIhFdTxgY2uSPoef61nOK6DxBGFuUcdZFx+X/wCusKQc1zyVmdMHdEVFFFSaBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzvje51K10u2fS2uo1a6jS6mtIPPmhgOdzJHtbcc7R91uCTg4roqqanfxadam4uEuXjBAIt7aSd+f9iNWb9KEJnms+seMFsbF4P7WkDNKtw7aYvmJa+dhLgJtH78r/AMssHj5igIAa9cat4qOr63punsbiXTIZ72N3iTFwJI820BAAwQ2/PQ4jXJ+Y11OneL9B1Bd1vqUSr5ay5mVocAyNEAd4GDvRl29QcZHIzTu/EvhrT7a7u5UdbWeSRLq5j06Z4maNvKcyusZXAK7dzHGB1xVfIm3mcIPEnilxq8GlXerXxtxp7SNeaeLeeASed5xSNbcseVjHMcmBkjPWrQvvHM+k3Vwt5fLNa6ZLcwrDp/8Ax9TrK+yNxLbo24oFBComeCMA89tot54Y0xhY6LDZ2RmvHtPItbTyt06JuYFVUdFGdx4xjnkVqHWtOXUJrGS8ijuojErRyHZzJnywCeGLbWwBnoaL+QW8zG8e6jqVjoNtJpcOoG6lmRGeyj3NECpJLDyZjt4xxGTkjp1rjINR8d3fh9rp5tTtb210mW4EKaehNzcpNIqowaLPzIqHaoUnIIxXdy+MtFigtp3nuha3BAS5FlOYeXMY3SBNq5YY+YjqD0IJoa58QNM0/T7i5tIb6+8i5jt2MdlcCIkzrE22XyyrFSTwCSSuBzQvQHbuc7cSa3qPjLSP7QXVv9F1tnW2WwxaRW4t5VSXzvLyWJYA5fALEbRgGui8QXupReLYLeS51az0g26NFJp1h9p86YyMHSVvKk2KF2Y4X7x+bjjSi8XaNLqEVks9wtxIyRgPaTIqO67ljdigVHII+RiG5HFbryIhQO6qWYKuTjJ9B70rjS8zx2PxF43lvNV+zW2sJCbKWSFLmy3tDOsqBVBFvGpyrNwGkyBndxW94gt/ErReLLVb6+u7W20nzbVGsIZBdzutxuix5ZDqMRjYAT93J5O70aii4cvmeVxar4yHis28nmWtikgVI/sUskLQ+V94bLYgPu55mXkbdo4rofhtf6xeQXy642oyyRMgWe6g8lJCQc+WjQQuB0yGDYyAGODXZ0UXBIWg0lFIY6GWS3nSeBtsidPQj0PtXa6dex39sJYuD0ZT1U+lcRVnTbxrC7Ey5KHiRfUVcJWInDmR3FFRwTJPCssTBkYZBqStzmCiuX8careW8Vno2hyBNd1ZzFbyFdwt41wZbgg8YRTwDwWZF71zHxWsL1PFPw+1qO0vb2x0m/la8e1t2nlRXi2h/LjUsRkc7V4zQB6fRXy3ZeFfENtf+HNbltfEFjZSeKdSvz9lsPNnt4ZgBHK0Jid1LbSCGUgDsCQa6iHxD8Uj4s1FLtZrW3iurqOO0/s2aWKSAIfJaKRLUruzg5efBPBRe4B75RXheh6p8S9P0rwVquv32pX0WoXinVbSLQ1WWzh8sja6IhflhksFXHsKxo/FPxRHgzw/d3Y1o6mRcm9soNHeK6nPmlYsObSWGMBQDhghI5zzQB9G0VjXket3Ok2R0m8tLC7Kq0x1GzNyfu8giOWMBs9SCR6CsL4seHoNe+G+uxXml2uq6nDpdybT/RBI63BhYAwqdzKxbGMEnpyaAOwN3bi8FmZ4vtZjMoh3jeUBwW29cZIGfepq8Y1rwxqGiaj9p8E2s2iNaeGbiZV03Totk90GRliZTGwLMVGQAHOOCKm0rXfH1x8QoIdQjltNNa5QGA2czQPbmIEkOtqwV9xJy1woBG0oO4B7DRXmfxM8QeJtEvtYXR7fVJ4ptCY6b9i01roLfh35YqjbflMZAf5Tg4BNcrPJ4u0IeKToz6615ca2J5I20/8AdR2rqmZoZFtZN75ATaBIQoJKZBagD3aivJvDF1461V7KK91C6gQWFxOZksPL82VbgCJJDPbxlWKcNiNMgFlAyCM1fFPjO+0W3Ef9tWF3BotqbyabQ5vmvvNQTBAIHOSu4BljdBndtIFAHtdFc98P7y/vvCVjcatHqCXrbw/29VWY4dgCQscWAQARmNDjGVBzXQ0AFFFFABRRRQAUUUUAFFFFAGZr8O+1WQdY2z+B4NcxMOTXbXMYmt5Iz/EpFcVJkqCevQ/WsqiNqTK5opTSVkbhRRRQAUUUUAFFFFABRRRQAUVwvxlur+x8Gi702e6t2hvLd5pbd2UrF5g3kleduOvtXHal421PTtV8b63ot1HqOlC4022sXlkaa0BZdsvl7WAzkjO09cZpqNyXKx7XRXkcfxD8QQ63Ha3UelSwJ4jTQpTHBIjOrgkSLmQhSMcg7s57Vyfw18XXmneG7HRrJ7O8glt9UnuYog6z2RjLujO6vwrkgDhT3B6U+Vi50fRFFfOGo+Ibm3ju9dRM3R8K6fLt+03C8vdKD+8WQS/xH+PJ7k859Kt/HN3J4j160v77SdJi0yaSOKwnt3kvLuNYy3mxjzFyDjICqxwMcdaHEOc9For5v8X/ABEvfFfg3xPptwLOa0Wxtr2C4hiETEG6iUhkE0uOvQkMO4FexfEXxJd+G7TTHs1to0u7xLaa9u1ZoLRCD87gFTjjHUD1Io5QUkzrqK8e8SfEvVdLmnjtLrQrtILSO4gmWJ9urO0m0pbbZTgqODzIcjoB0nm8e+Kze+K57XS9MfTdCjDPA3mi6LNDvUcZU4b73TgH60crDnR61RXkHwp1KTV/iR4kv57yxvJZ9OsnaWxQrEDtOVGXbkdDz1B4HSvTtOl1Z7qddRsrGC2H+qkgvHld+f4lMShePQn+tJqw07mjWL4s8O2vifTEsr2WaKNJVmBiCNkjPDLIrIy8nhlIraopDOHs/hloNta2Nvm6litI7qJVZkUOs5JYMqqB8u5toAAGfpVfV/hVomq6fZ2dxdah5Vtam0BPkyM4LFi5MkbbZCSSWTaefSvQKKfMxcqOX07wwtv43v8AXpBGEe3jgt0ViTuwBJKwIwHIWNeM/Knvin6/4N0zXNUfULxrlbhrRrMGJwoUEkrIOPvrubae248V0tFK7HZHBan8LdD1A2QknvEjtLeG2jQCF8LEcqVZ42ZCf4ihXd3zVi7+HenXd7qN3Nf332i9KlniS3iKMsqSq3yRDeQ0a4Mm/jI7nPa0U+Zi5UcZD8PNLj8RprbTSzX/AJiTSvNa2rmWRQBv3GHchO0H5GUZ5AFWddsRpfh3Twbm5uvsWpWk5mun8yQr9qQvlsdkZgPQYrqqwvHcLz+CtdSH/XfYpmj4/jCEr+oFCeoNaG6Rg4PWikEyXAE8X+rlG9foeRS0hoKKKKBhRRRQAUUUUAaWhaj9hmMUp/0eQ5z/AHD6/SuovLy3srGa9upkitIY2lklY4VUAyWJ9ABXC1l3N1/buuWXhW4lJ0q3dLzUSRww+9DbE+jEb2H91VB4etacujMakOqOl8CWlxqE934r1WF4r3VFVbWCRcNaWY5jjI7M2TI/uwH8ArQ8SaxdWer6FpempCbrUZ3LvMpZY4I13SNgEEscqo7ZbJ6YPQVz/iTR7q81fQtU014RdadO4dJmKrJBIu2RcgEhhhWHbK4PXI1MDB8b/Eay0bRPEH9necuuafY3F3BBf2FxDHN5WAxVnVBIoJXJRjwQc45rYl8c6BDNqSS3Vysem+Z9quDYz/Z4in3l87Z5ZYdNoYkngDNcm/wS8Ovc6hM97qZe9t7q2kYC3V9k5BfMghDyEY+UyM+BxWtqnww0fVdZ1LUdQu72SW+ieJljS3g2BsYO+OJXcrgFfMZ8EZoA6bw94h03xBHctpksxe2cRzRXFtLbyxsQGG6ORVYZBBBIwe1Z1r450S8s5rux/tW7tY8fvrfSLuVJQTjMbLERIM903Dv0q14b8Nx6LJqE8t/fane37q1xc3pjLsFXaqgRoiBQM8BR1JOc1zdz8LrK48PQ6FLrmtPo9s6NaWkgtZEtwmdqANCfMTBxtl3jAHcA0AUPEHxMZStx4cNrdae9iLlJJ4ZFbzBex27qykqVxufIIBDD8K6dvH/hpbq6gk1ExC2Exkmlt5UgPk/60JMVEblcHIViRg+hrE074SaDYaVHp8N1qPkxxPCPmiX5WuluTgLGFHzqAAAAF4x3qpe/Cbwfp51nUb2VLWwuo7hrgyw2kYgEobe4uDEJlxuJGZMDp04oA6Dwd4vHibxDr1tbRSpYWKWzQNPZzW0rGRXLFllCnHyjBCgfWuatvi1FdjQLhNPvLe1u9UurC6RtPupX2xLcbDDiMF2ZoV3Kqts3FTgjNdn4X8LpoN/qN9Jqupape36xLNNfGLOIwwUARxoBwxzxz9c5oaV4BsdN1GxuY9S1OWGxv7jULW1kaLy4ZJ1mEgBEYcqTO5+ZiQQMHGQQB5+IvhcR2ki6jJJFcxJOskdpM6RRuxVWlYIRCCwI/ebeQfQ1Z8V3Pii2u7FvDVnY3lqf+PpJ/lcYkj+628DmPzQODhthPGa5ef4M+GpLmznDTGW3iEJae1tLnzVEjOM+dA+05dhlNpIxnOBXplAHPP408PJptxfPqkIhtxO0iEN5oEMhjkxFjecONvCnJxjORmtL8QPDUN/dWkuoSLJb+cHc2s3lFoVLSosmzY7qqsSiksMHjg1nXnwt8PXeo3V7KbzzrnUotTcLKAAyZPlDj/VMWdmXuWJyOMQ6n8PtDFwwvtZ1CGyu7m5e20954khjubmORZGiym4uRJKQpZgNzYWgC3B8UvCU8qxpfXqk+VkyaZdRqqykLE7M0QCoxIAckKexqp4d+IkepSapp00ROuxX2o2tlbJbSxx3P2eSQKizP+7MhRASA/qcAdNO58AaXcR36PcXoF7bWNrJh04W0dnjI+XqSx3dc8YxUek/D+x0/Xk1M6lqd0sN7dahb2c5i8mCe4LmRl2xq5/1jgbmbAP40AU7XXvFeljR5PFdtpaR3mo/2fKlojBk3IBHKD5jDDSKw29dsidCpz31c/4m0a61rUtCUPDHptleC+uMsfMkeMHykUYxjcQxJP8AABg5yOgoAKKKKACiiigAooooAK5DV4xDqNwg4BO8fQ//AF8119c54oi2XNtMBw4MbfUcj+tRNaF03ZmE1JTnptYHSFFFFAwooooAKKKKACigjFFAjK8R6u2iadJe/wBnXl9DErSSi1MQMaKCSx8x1yOOgyfasOLx9Zx6jYwaxbHRLa7tJLqOfU7qCPdtaIKBtdl+bzSeWB+Q8d66TWrH+09Gv7DzPK+1W8kG/bu27lK5xxnGaw7rwgt3NA73Y/c6PPpQBhznzPL/AHnXjHlkY77uvq1YTv0Nptb0pdTj01tTsRqMihktTcJ5rDGchM5Ixz0qe51Cyt2kjuLy3ikjhNw6ySBSsQ6uQTwo9elcLY/Db7DrUF6upedbJLBcPBKLj/WxRqgZQk6xj7gPzI2OmSMCtTxj4Tudcu5bmw1OOxe506XTJ/NtTNmJyDlfnXaw56569O9Ggrs1J/Ffhy1uHgufEGkxTIMtHJeRqwGN2SC2ehB+nNU7nxto9trVpbT6hp8djd2huYb57xFjkIcKEUnhick5B7dKoWfgRIGVnvFkZNVi1TJt+vlwLEE+9/s7s9s4x3qi/wAO7pbYw2esW0Sy215aTebYGQ+XcXDTHZ+8AVhu25IYHGcdqNBXZv6l4sgs9QS0Ft5i+bPFJJ9oiGwxQCYn72BkEDDlCOp4wTePiTRUuIra41XT4LySITC2kuoxJs27s7d3IwCcjIwM5xXNf8K7Qi5WLU2WOSWd1DQ7iols0tgCd3JGzdnjOccdansvCGp6WupQaXrkNvb3y/vGayLzxyiFYg6SeYAANittZWxyM88Gg02aM/i/TJBp7aRd2eqR3V8lk72t0riIsrNklc8/L04610MjpFG0kjKiKCzMxwAB1JNefaJ8O7iw1E3t5rZu5zd210xMcrZ8lJFxulmkbnzPXA28DnjsfEmkx67oGoaVPI8Ud5C0LOnVdwxn3+lDsNX6lYeLfDZsvtg8QaQbTzPJ8/7bHs34zt3bsZxzjrVmbXdIhl8qbVbCOTaW2PcIDgLvJxnpt+b6c9K5698L61dyWN3LrOmjUbOKa3jddLYwmKVUDAxmY/MCgwwYDBIKkVWt/h1b2+hanpsd8SLuC0hSV4QWT7OiKu7n5wSmSOOpHvRoF2bvhnxNaeIrvWE054J7WwnSBLmCcSpPmJHJBHAwXK4yfu/hW/WB4Z0S70u71i81C+hvLrUp0ncw25hRNsSRgBS7HogPXvW/SY15hRRRQMKKa7rGu52AHvVWS6YqSgCKP4n/AMKRcKcp/Ci4eBk8D1qFrqEcBtx/2RmuQ1rxno2nMVmuzdzj/lnD8+P6CuUvvifK2RYaciDs0z7v0GKXMdkMC38R6s12f4Iv++mqC5aS5t5YXCCORSjYGeCMHrXh9745165yPtvkqe0KBf161kT61qNwf3+oXcn1lap5jpjgYLc9x8IXc7+ENCaSVRINPt1fgffWNVbr/tA1rC4mPSZT+Ar50M0n9j6V875EUqHDHHy3EoUfXYEqFbmRTxJID7Macpaio4WDgrn0mLi4HXYw/wB2nLesPvxZ/wB0/wCNfOsGrX0JzDe3KH/Zlb/Gtez8Y63b4237yKO0qhqXMW8DB7HvCXcLHBYof9oY/XpVjryOleQ6f8RJxgX1jHIO7QttP5Guw0LxHY6lxp9zsl7wuMH8j1/CmpnNVy+UdYnXUVUhvVYhZhsb+92P+FXApJAAyT0A71RwThKDtJGdruprpGmSXfk/aJtyxW9uDgzzOcJGD2yeSeyhm6A1D4d0o6ZpnlXEouL2d2uLu4xjzpm5Zsdh2A7KAO1Z+mkeINfbVsh9L05nt9Px0lk+7NP7jjy0PoHI+/XTVT00M1rqdJ4e1Tzgtpct+/A+Rj/GP8a3a895BVlJV1OVYdQa6zQ9VF8himAW5Qcjs49RWsJ30ZjUhbVHFfEGfXrXX9Rn0TzbUDS7cR3cOmNcOX+0tvjDpDKwJT/YdVzuKGtGx1fWR8KZtSmtNdl1hYJSImjjF47B2Csq+Sq9MFQ0IOMZQnIPdVz174z0Gy14aPc3jrfeZHC2LaVoo5JOY0eUKY0ZsjCswJyOORWhkc58JNT8Taraa9F4m+3KIblVsrm5tjFI0bRKSRut4N2GLcmIc8c4yeH8NT+JdD8K6HpwvfF1rbQpcpevDoSzzQTrjyYo1Nvhomy5MgDDIA3qDXp5+Ivhryo5I7u7mEspgiEOn3MrTSAvuWNVjJcr5bbgoO0YJwCMvfx/4eSysL1ri9FjfKjQ3f8AZ1z5ADvsXfJ5e2MluMOVPI9RQBwsXifx1DGlrqdjqa6pdT6O8YttMMsEUT+ULwNIEKrg+bkM24AgjA5HLeJ9Z8WavpWp6HfS63calf6Hqkl1pL6WI4o5UeNYltmEQeUYcjId85XoTivaNN8caBqWuHSLS7ma98+e2AezmSN5YSRKiysgRmXacgMTgZ6c1w/iTxVo/gzUvHMfh7wxZ2et6fpiagb2LTXEd07iVyJpI0UADy85Z/mLEDlSKAN7TdZ1Xw7q2p2Wvz6nrED3tpbabM1rFHJK0qZcAqERkQqzE9VUHJOKt+PP+Ehm1jRrTQL+/wBPtJIbuS6ntLWKY7kRTEpMiOq5Yntk8j3F238daHc2lzcWx1Ob7NKsM0MWk3bzIzLuUmIRb9pXkPt2n1qjonxE0vWvF0ejabFdXFvPp8N/BfR20xjcSNKNrHy8IAI/vMwyxK/eUigDiotT+IdnodvdSz6teTzaZpuo3EbaZHvt5GuF+1QRqkYJIiLfIdzjHHOBS6z4m8X3Fje3tg2vWsA1adLa3TR5EuJrUQxFNpNpNsG8uQZEG7OCy7TjsZ/H1ppvjbVtG1p/s9tALMW8yWszrum3DEsigogLbQC23r3qp4t+J2l2PhzX7jQrlbjVLC0uZ7dbi1mW3naHhwkhCrKFbg7GOKAOevtX8ZyaZ4maG58R23iGGKc6Zp40mN7VkWMGNjOICrSnklfMA3fKF6Zk1rVda1/WUurfS9ak0qy1izns4pdOe3faLebzCA6K2N+BluASOxrpPEXxDsrLxDpOl6dJ5xfUzZahM9rN5MKrbyysFmwI/MBRMruJALcdx0vh7xFp/iG0a60v7a1uArCSexntxIrDIZPMRd4I7rkdPWgDx3RvEnxFubXV1WLWlyunPaSXunbpIme7VJ0P+iwBsRElgFYKMkP3HuNhBJa2cUM93PeSIMNPOEDvz1IRVX8gK81svizBep4duhp97b2l/c3UFzG2nXUko8tXKeUBGC+Sg3bVbbkg4INdN/wsTwufshj1JpY7qOGVZorWaSKNZTtjMrqhWLceB5hWgDrKKKKACiiigAooooAKKKKACsvxLB52kSsv34cSjH+zyf0zWpSMoZSrDIIwRSaurDTs7nAtTaXYY2kib70TlDn2NJXMdaCiiigYUUUUAFKOv0pPp1p3QYA6UCAj5abTv4Tn0ptAHO+OdbuNC0u2ntmtYfOuo7eS6u1LQ2qNnMjgFeBgD7wGWGSBXJ3njy+tdQSGDUtBu1VLcxLHE+7VfMkKsbbEpAC4x/y05BztFdt4l8Rab4atrW41edIIbi4S2V3dVVWbuSxAwACSewFTQa7pFzqAsLfVLCW+ZBILdLhGkKkZDbQc4wQc00J+pwqeNteS2N5cLpb2066oIIo4JFeNrVnClmMhDBtnIAX2Paq+pePfEGkW0y3UOmzzGKxuBPDCY47dLgyht4kmAIUxAbjIgO4ZxXU+I/HmmaJc6vYySxSanYac2orbvMieeAsjeWvJbdiMk/KcBgea07PxVo11pUmoJrGmC1hwJ5VukKQscfKzZwDz3xT+RPzOK0vx7qN62mx3194f0eOeGSX7ZcMs0N0yzFAkRjn2K20AkeY5BOOcE1k6f4z1bRvDMjXWvaJPcxajdQ3Ed1gXFuommwCklym/IC7V3KVTgB8V6uuq2EmlnUhqFs2nbDJ9qEy+VtHVt+cY981kXXizTg+lf2XcWmow3t/9heW3uVZYW8qSQkkZyf3eMcdc0X8gt5mR451q7h8P+GNSsdUg02OW8ge4uLmB0iCNG3+sXzF2rkjKs3XHPHPPaT4g1fRJLyeBbLULK91m/jWCGJhK8ixSShlfeRhjHtC7T1zuNeh23ijQLqzubu21zS5rW2AM80d3GyRZ6bmBwufegeJ9Bb7Ht1zSyLzP2bF3H+/w207Ofm544zzxRcdutzmvhj4v1DxRJeLfrYMkUUUitayRbkZt2UdEnlIxgYLbSeRtGK5jw/4un0a/1S1ju9PuLYanq8txbQwtJdWipJLIJXAflSQF27VJ3DDV6LqHi/QLKLUC2r2Es9jFJLNbRXMbSqI87ht3ZBBGOcc8Ulr4y8N3FvZSrrulp9sAMKPeRhnJONoG7kg8EDvxR8g+Z5ZL47u9eiga7vNJtl0/VrN4r91RYVWSObmRUuJF4KnjzAecHFdJH471z+zLKcWdncHUmmsrCaKNxHPdLMUjfG4kRPHmTrkBG+YgivT6p3WnWt1fWd5cRb7izLtAxY4Qsu0nGcE4yMkcZOOpoug5X3LSbgi7yC+OSBgE/SnUUCpKCq89xtJSLDN0J7D/ABNRXNyGRtrBYQMs5OMj6+nvXk3jfx0bgNYaDIUg+7JcKMF/ZfQe/epbO3D4Vz1kdV4q8a2OiO8Sk3uoDgxqcBP949voK8s1vxRq2slhd3TLCTxDF8qD/H8axe/PWlCkjPYVFz1YU4wWgnbinqhZCy5OD2plS28gjkDHI9xSLIiMHFFTTQ4UOhyp647VGFycdTQOxZs9jaO0TgtNHdzMqjqYzHCR/wCP+Z+tVpN2QXxkjOKsQwThsxowqxNbvIiM5RX75OKG7ihT5VZFGEDeNwyKnljMeAcZzyakFvGv3pQD7DNSyC3cj52zSuaqJWjbmrKs8bKwJBHKsOKRFt1YEyOMH0qSVoZZCwkOT2IxSLR1/hzxrNblYNVzcQdBJ/Gv19R+tdlquqSz6fbafpNy5fU9yefFyba3GPNkB7NhgijrufcPumvG9q5+8PzrW8Oa9Pol2GRi9ux/eRE8N7+x96qM7M58ThI1o2R7xYQW9rY28FiiR2sUaxxInCqoGAB9AKnrnND1eC8gW6sn8yB+HXup9x6/zrokZZFDocqeQa1TueDWoui7PYWlRnjkWSJikiHKsO1JRTMTs9Iv1v7QScLKvyyJn7p/zzXP6j4DsL7XZtRa/wBSiguLuC+udPikQW9xPDs8t2yhfjy48hWAOwZBqnYXT2N4twmSPuyKP4l/xFdxG6yIroQysMgjuK3hLmRyzhys4DXvA9zbaFo9v4TnmTUdMuZpYLmW9W3ZFm3mQEm3mVgS4G0x9ADuBHODH8FtIl0TSf8AhItTuTc2FnFFNJGIGiUxsZCyNLGzxck5KMm4Abq9frO8SRvN4d1SOJGeR7WVVRRksShwAO5qyDE0nwhpEc+m6lZXdxOkF9d6tA4kRkke63l+QvKYlO3B9Mk96nijwZpOvazqkNxrN7aXGs6Z9ku7G3lhH2iCPeokAdGcbDP1UgZZQQeh880TWPF+meFhb2aeKbq0g06whDyaWLaazuS22RI1a1ZpIlUDcfKlI7Ek5FCHUPGU9zp2r6sPElpqcGn6raRXNnorTyTN9phMCOptgqh1TO4xxZC/wZNAHqPir4aaR4lvbq6vLq9jkuJop3RVhliJjjaNQYpY3RhhifmVsEAjBFM0TwPo/gg2epW2s3tlZ6bYCzn+0SQCGWBHkkUykx/LtaVzlSnbORWVoGseL5/Glp4f1SVY2EUWsXc0ccZEcDRbDadOv2gOQ3XYp5zzWX8d5PEF5aa5o9out/2dcaMfssel6b9qF5clnDxTP5bmMBRGRgoTuOGyMUAd7rHgrTtVl1eS4mu1bU2tGm8t1AU2z7025U4yeuc8dMViXfwp0m7srqxuNT1h9OeG5gt7QyxbLNbg5kMZ8vcTyQN5fAJArLv/ABH4th1mXTI7bVmnGvSASppjNB/Z32dmT97s2H95gdd2Rg8dcXVpvHVt4c0LVkOoXuvy+Gry5kJ0mIvaXZjtSsSgRblZm3koSdzKeMKFUA7uT4d2Tayl9HqurRQx6hJqkdkrQmBLmSN0dxmMsc+YxwWIyenUVd8EeC7HwgdQaxubmd751eUyRwRKCoP3Y4Y40BOSSduT3JwK47WL7xlpF1e2LX+tXWmpqNqr6pBpcc1zHbvA7SeVHHFtcCVUXOxyoc5zjI6j4R6ve674Ds9Q1O5nu7l7i7j86eJYpHRLmVE3KqqAdirnCigB+i+BLPSbzT5o9S1KeLT7i4uLS3mMWyEzB96grGGK/OSNzEjjnHFYMXwY8NQ3OnzwvP5tnDFBuntrS5MqxklSTNA5U84Jj2Z47jNemUUAFFFFABRRRQAUUUUAFFFFABRRRQBxviGH7PrTsAdtwgf/AIEOD/SqFdD4uhzDazjqkm0/Rh/iBXPVzzVmdVN3iFFFFSWFH86QnAJqUKANufm70CGDj0Jpygk880AADJ6D9aaST7L6UAK7A5A/E02iigDG8U6PLrNjbx2t0lrc211FdxSSRGVN0bZAZQykg9OGFYln4MuIdYguJtThks4r99U8lLTbIZ3Qq37wufkyxIXbnGBuIFdpRRcLI5LxP4SuNYv9Unt9SitotS0ptKuI5LYyEL+92ujB1wQZTkEHIGOOtUNb+H66jLcSxam1vKxs2h2I6hGt1kUZKSKxBEh+6ykYHNd6gy4z0qTIHoKd2KyOB1TwndW/wu1nQdOVLq+uYJ9vlmRBJJISes0rkEk8kuecninf8IHe3GoDUbzV4l1A3cdyXtbTyo1EdvLCiqhdsH96W3EnOAMY6d7vGOtGck80XYrHmNr8Lb1LqS9uvEhudQ22xjllt5ZV3wyM4Z1kmckHcflUoAeQBVnXvh5datqgv77V4JJp4EgvI1huYoZQjsy7UjuVxw2MMXGRkYyRXojFuqEZxyKbLuxGW680czFyo4SfwCk0Qja/wPtmoXTFYME/alkXb97+ESde+3oO2dr/AMPtZ1zToLK88TqtulqtsYobWaOM7WyH2LcAFiNoO/eOOAK9Joo5mVyoyX0y6uLPVba91OZ0u5G8h4VEL2sZRQFVl5JDBm3Hn5sdBSeGdSn1Cxki1AIuq2Un2a9VBhTIACJFHZXUhx6bsdVNa9c14j/4kuoReI4gfs6ILfU1UZ3W2SRLjuYmJb/caQDkiha6A9NTpaqXUpcmJPujhj6+1SXUhRQqEFm6EHIA9a4D4j+JDo1itlYvi9uAfmHWNO5+pqGzsw1HnfMzn/iT4tN08uj6c+LdTieRT98j+Ee3rXnlHvRUHsxjyqwVPbqrsQud2OAfyqCnwyGNgygbx0J7UDGsoDEA5A70oHrVlkSRA0C4OfmX0z/SliiA6rvY8AdiaVyrCW67Pmf7jDBU8Aj3q3YWtzez+RplpJNIeyIWY13fhvwJGiRX/ioyKrjdFZKdskg7E/3F/Wu9smjs4PI0m1h0+3PVIB8zfVjyafL3OWpi1HSCv+R51pnwz1a5UNql1a6apGQkzbn/AO+VrctPhfp0bZvdYmuPVbeDbn8WJrsraNQctyT3NaMCq6BlHynpVadjkliqz+1b0MHTvDOiaam2x0eCWT/nreEyk/h0FaLrLHGVht7GLjA22iED8CK01AB6UtyiSR/KdrDoaLs53Jyfvanhvirxzf6Frk2naroGg3jR4Ky/ZihdT0PB4rKHj/Qbsgap4MtMZ5azuXhb8sGuq8deFbXX/En225nljRIVj8uMDJI5zk/WuZvPAmlKuIp7tG9Swb+lPnXU6YqNtL/exsdx4E1Bx5epavpJP8NzbrOoP+8pBx+FXV0Dw00kaJ4zs5S+cLFayM2PpXNS/D/UHcGynikiP8UoKY/xre0jwXcafDlZLdp2HzPk/kPai8OxqpzW03+H+R33gi38K2Nz9htdRvWvLjC/aZUCRMw6Dbnj611amTT7qSCcYQNhv9k+v0rxy40zUbX5jAXUc7ozur0rwnrg8R6E8dwSdW09RvJ6yw9M/Ve/tQtdjOeukndP8PM6miqWnTkgwufmUZUnuPT8Ku007nnTg4S5WFdB4XvMBrJz0y0f07iufp8ErwTJNF99DuHv7fjVRdnczlHmVjvqKitpkuLeOaM5RxuFS10nIFZniHXdP8PWKXerSyRQySpAnlwyTM8jnCqERSxJPHArTrmfH/h+88R6dp1tp979ilt9Rt7tp1270WNskoGRlLegZSPWgCnZ+NvCLXyzWcp/tDUFbcI9PmFxIIHEbCRfL3goXGQ4BUEnhQSHxfEjwtJaT3X9oypBFGkoaSznTzkZwitCGQGYFiADHuySMdRRoXgDStI1Bb5Z727umguoZ5Ll0P2g3EqSSO4VQN2Y1A24UDjFcynwd0rRtHuo/D243g8prRnS1tXgaOVZEP2iO1aRsFR/rBJnHIPWgDpG+JPhlYY3Nzf75JpYFgGl3Rm3xKrSAxeVvG1XUnK9Dnsatv450BJNMDXVz5OpeT9kuhYzm2lMuPLHnhPLBbIABYHJFYfgjwFcacyah4hvpLnWPtV3ckxyq6f6QqIQzeUm4gRryEQZJ+XGKor8FfDy3mk3H23U2OmCzEIcW7n/AEbbs+doi6Z2DcEZVbnjJoA1NQ8Z+A/EFlcWmsSW13YRxy3DLqOnSeQ4hba5Qyx7JCrEDC5IJrQ0vxb4ZtbOK2tvO0u1htpZ4obnTZ7JVhhClyiyRqNqh16ds46HFO8+GWiXemWVhPNftBaQ3cUZEqhv9IcSMxIX7ysoK46Y5zUHifwFPrlnotjf6rc6pBbah9pubq+MaTeR5bK0CiGJFZXOA27szHJIUAA7myuor2zt7q3LNBPGssZZChKsMjKkAjg9CAamqjpenf2eb0/bLy6+03DXH+ky7/K3Afu04+VBjgdsmr1ABRRRQAUUUUAFFFFABRRRQAUUUUAZviSPzdEugOqr5g/4CQf6VyA5Arur6PzrK4j/AL8bL+Yrz+0cyWsTEYJUZrGpub0noTUUUVmbCEfKcdamAUgydiM5qKkwPw9O1AmhSdxyenYUUUUAFB4oAJOB+fpUqqoGMcGgCKijGMg9RxRQAqf6wfjTnAf5QeR2NMB2sp9CKmZMOHGcjtQJkYTZgdaQt8rY6mpJVyjcn1pURQAMYYigRGZP3yADOeKlugdqHB4amygLhtgbbT3PnWzbRyOR9RQBXoo60UFBTZQhicSgGPB3AjII706q142dsfr8zfT/APXSLhHnkonG6fqUfhy2vtN1BisVhF59izEkvaZwqe5jZgn+60fUk149rOozatqlxe3B+eVs4/ujsPyrtPi3rhGrWVtZIkstgTJIrHAk3LtaInsGUkE9sg9QK4W8ijR0ktmaS0nQSwOwwWQ+vowIKkdmUjtSlrqevh4+zfI/l6ESLlHYdh0pMfLn3xToZGRlKhcjoSKnaNJhiEgSZLFM8fgazOsq04cUrrsVQRhjnOaavLKD0JxQNF2A+VDtZcvLzj2969P8GaLb6Dp0Gt6mkc+pXK7rO2cZES9pGH8h+NcT4YsI9Q8TabBcD9zLPGjD2LYxXpPiCTzteu2AwkbmNF7Kq/KAPwFNaK5y4ubVqa67k0c8k9w01w5eVzlmY5JrSS4RV61iIcDrSTXGwcmkcVjYuL792wU8niuljcYAHbivObS5F1qENuHG525GckAcmu+tTuamQ0XwMjNQTHBq0v3azr6QJub+6M02THVnEajc+beXBjBJLnAAzViw8N3U4E9yUiB5VG5P4101hbxxwjCKCw5wMZq9kBak0cuxzLaCA372ZpPYfKKJdBxbtJb5DrztzkGujVctzViJQMjsaEhym0jioIC6gimNYyWeo2+qWI2X0DBhjgSr3RvqOK6CC2C3dwgHyhzj8eatT2gKcCqStqiXLoR6hGsckN5Zf8e8486H2HdT9ORV2N1ljV0+6wzVK2bdpd1aMMtAftEfsMgOP/ZqNMfBeI9PvL/Wr6k1Fz0+brHT5F+iiimcp0HhW5/1tqx4++g/mP8APrXQ1wlncG1uopx/Aefcd67pWDKGU5BGQa2pu6sc9WNncWiiitDIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooARvun6V5xY8Wqe2R+tekGvObYbYiMYw7DH/AjWVXobUepLRRRWRuFJn1padDjc3rgUCGZH/6qcFJ/2R71JznFJjPvQFxDhRinKvrTSqj5nOBSM5PA+Vf1NAhJP9Y2PakoHAwKKBiEZBB6VKso2gSZyP4gM5qOigLEvmx5PzNj/dNO+0IOQHP/AAGoKKBWJjcDtG5/ECozK5XagWNT1xyabTSyjqwH40BZDvYdKKRSG+6c0tAwFYmtaimn6XeahKfljQuP6Cta5YrA2PvH5R+NeafGHUfJ0y106M8ztvcf7K9P1xUs7cHT5nc8ruriW7uZbi4YtNKxdifU1LpiebnTnIxM5ltDn7suPnj9t4G4f7S4HMlVaQjcuN8iMCGR4zhkYHIYHsQQCD6ipTsepUhzL3d1sKRjrT0cAAMDx0IOCKvSlb+0W/VAkr7o7mNBhY5lGTgdlbIdfQNjkqaz1VmPyjNJq2hUJKaUkWZENwiGM5YcEEgGlWCOMhZCWfvgcCmIoi+XG+Y8bR0FdiltZeA9OTVfEkC3OtTgPZaa56D/AJ6SjsPQd6ai5CqVo0ld7kPhVftGv2EdirNctKhC+mCCT/WvUPE9vby6nO9ifnLEuf4c/wCNeTaL8TtSvNRmtpYtOsVvBsElrbiIj0Ukdc11vh++umuBbsmRnHmOcKPfPetIwSVjzcVXlVmpNWsS3Fy1oSJwQ3YDnP0rOmmubsnGYo/QdT+Nd/qXhpZtPMqzvLIAGGAAv0rl7mBYo/l71Mo8plCop7C+ENPWKWa5I5+4v8z/AErv7EcA1g6TbGG1ijxyBk/U810lmmAKhFS2LZ4TNYOqvlWGepC/ma3LhtsZrltYmCtEM8l8/lSkTTRpTTLBblicYFS2efs8YbrtGaw4JjeXyIeUjG5vr2rdh6Cg0sTL94VPj3qBPv0t622DaDhnO0fTv+lUjJ6shtAJJXkxw7ZH07VoFMrVe1Taoq2vSqJkZIkjsdSgnlH7kNtk9NjcNn8DVRwbO/dM/wCplMZ9xnr+WDV/V4BLC6HowI/OqEsxvrDTr1lCtPbiOQf9NIyUb+lHQ1ou8rPZ6f1+JrUVDZuZLWNj1xg/UcVNVHG1Z2Ye1df4dn87S4wTloyYz+HT9MVyFbXhafZdywHpIu4fUdf0P6VUHZmdRXidPRRRXQcwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAE4BNedW5zFn1JP5mvQbg7beQ+ik/pXn1v/x7x/QVlV6G1LqSUUUVkbhQDtYN26H6UUUCJnB3DB/Cms2zjGW9PSmB3C4DD2JHIpBxQKwHJOWOTRRSorSNtTt1Y9BQMSinSxtEwDHIPQ4xTaACnRR+YzfNtC+g602pbb/lqPof0oBjvsv/AE1P5CgW6AndI354pqzAqxPBHBx2p+/+/jPrQTccLeEHld31OadGVVsBFHPYVVRj57bizDPAA/WrMSqXOMj9KBEV7j7Vx/d/rUNS3n/H2f8AdH9aioLRWujmSNPTLH+Qrwf4lah9v8WXQU5jtwIV/Dr+te6zMFmldvuoB+QGa+Z7uY3N3POxy0sjOT9TUSPYwcbRuMRdzKMEg8cUsyeXIVzyKVZWGBnA9hzU4WOdd7Fowo+Ynof/AK9QdxHp84s7l5Z5DHYzqIrlv7gBykuO+wk5/wBhnA5IrVtNJ1TVNV/s3T7GR7pXKFB820g85PQD3qfQ9HivIJb/AFVjZ6Ba/wCvlIyX9EX+8x9Kp3njK/m0C607w/cT2NhZSH90CPOktCQIi8gGW8viM+xj6kk1rGPMtThqVvZTah1/B/8AB/rc37m+0b4dhx+41nxUBgAHdb2TY6k/xuPTtXlWraneatqE15qE8lxdTNlnc5JP+e1VZXJYknJPOa7n4beGTfXCajdpmNT+5Ujqf73+FU2oo53du7d2bHw+8HmFVvr5M3LD5EI/1Q/xNdjqcc9lDugKgDsVzg10un2axRgAUzVYFMD7gCuDmslJ3uTKKkrMy/D2tTX0BhvJi2OgJwPyqwsCy6pGi4MeN7AdOKreE7WwDmTykLj7wY5IrftUieeWaKNUDHaNoxwK1nsYU5e9ZI0bSPJzWxbriqNqmFFXN4Rc1ijSWpHqEuFxXCa/dSyaj9ntoy7xL8x6KueeTXT6lckcry5O1B6mqh09beyaRuXb5mY9SfWi1xp8qKvhKB1tJJpmDyOxJOMcV0Nq2WPFY/hx1NjsB5DMD+dbloqq3NJjvpclZcHIqtOd90Af4V4/GtSNVY4NUbmMJfAf3l/kaszT1J4hhRUy1EvAp+aBMgvf9Wa53R23adqlsG/48tQ3YP8AdlXI/UGt69b5DXJ+GrjzPEniq2AJV7dJfxjI/wATTjq7Fx017WOj0xswyL/db+YzVys/TDieZexUH9a0Ka2M8RG1RhVrS5PK1O1foN4U/Q8f1qrQc4O04bsfftT2MGrnoNFR20omt4pR0dQ35ipK6jjCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKWuSeTo9646iFsfXFcTGMRqPaur8WPt0WVR1kZE/8eGf0zXLVjU3OiktAooorM1CiiigAopFO44RS59hUvlBAHn5H90dPx9aBXGxxtIM8iP8Avdz9P8alV23BFj2p2psrs6qY/mDHjFKAI03s5Cj+EevpQTe4XHEWGOWLDbUNKzM7bm47BfSkoGgqSDIMuOu0H+dR06EgToG+64Kn+lA2OKurkgZYj8DS7wArPhV9T3NSyw5UgEr06GmtCHXY4GByMc0EFNbhFnI2nPYCr0BMg+aPH19KRIlWRm6nHVu1M2N9obnLMB+AoAS8GLs8Y+QfzqKpLkYnQHg+WB+tR0FI5/xPdfZPDuq3OcFYpCD79BXzsik4VeTXuHxLm8rwPeesrIn5tmvEY32MCACQfxrNnv4dWiOjj3M27hE+8a3vCmitr+pYmkFrplsPNubhvuwxjqT7+grJlBlkjtrePMjMBtQZ3MegFb/xAvl8M6DB4PsiovHVZ9WlU9XPzLF9FBGfenFX1YV6jiuWO7/q5h/EbxWniC/jttMj+z6HZZS0gAxkd3I/vGuQt7p7G7iuo41laPIaJjgSoQQ6E9gykjPUdRyBSVDLWietzklFKPKa9roYvdftrW1d5LG4UTxSkYLQnufRhypHZgR2r6C0HTktreNVQKAMADsK8l+EUuLg212oME0xS0lP/LOYgM0WfRwMj/bXA5evcLXCqBWdXcxg3az3LSJtWs7V2HkuD6Grcs6qOtYl7cNNcLs5WNg2D0J64qUruwPTUwURsrCqlLlm2Y6EGu5sIfLVEByFAGfWs+RLa81W3uYlG6JCSehz0wfzraslq6m9iabvG5fjGFpkxZhwC3tViJQRU6IM9KkTdjPtbEtL5swGR90elN11CbN1Qc4rWJwOKrXCCRSDTJvc46S8KX3nWUTCGKMK6Hjcf/rVvWF9DeJuhb5hwyngqfcVi6pE1nIWRtqSEK/HbNRS2ynUM2snlSlAWdT0PPFJmiOxhkKkZNQTSia/JXkIuD9TXO2L30uDJdMVxyAo/nV/TJAsDEkkljyT15oTE463NoNgUGQVmPeBepAqIahETjeCfai4KJcvW+SuT8HIU8f6zFjPm2crY9eAa6N5PMiyARn1rI8Mgx/EtQAP39jIv5A/4VUPiHLSEvQ1tNP+kr/tRn+hrUrJ00ETwZ67MH/vmtamicX/ABAqC+OLK4P+wanpGUMNrDIJGR+NM5jutPiMFjbxN95UAP1xViiiuo4nqFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc14xn+eyth/Exkb6AY/rWHVvX5fP1+XH3YUEY+vU/zqpXPN3Z1QVooKKKKksKKKKALVm4eBVHDoNpX/AD60jyJIpRvl+vf6VVx8wYEqw6MOoqTz5+mYs/3tvP8AhQRYk+S3ALck/dQDmoGZnbdIQT2A6CkA6kklj1J6mloGkFFFFBQUjAMMEZFLSDcWVEGXY4AoEPWSVR8srAehwf504XE4/iiP1T/69DW86jOImH+8RTRDOekan6SCgWg9rmYjBEP5H/Gm+fPyQYhn0Q/40GGcdYf/AB9f8aPKmx/qWx7EH+tAaDDksWdiznqTSN91vpQCGAIPBpJP9W/0NBSPOvi7Js8J2yf37hP0BNeQRnb83UjpXq/xkP8AxItNX1nP/oNc94b8LQWWl/8ACS+LG+zaND80cTcPdN2RR7nvUWbeh7kakacLyGeH4Y/CXh5/FuqKPtTkxaVA3WSXvKQf4V/nXA6XY3vijXXDys08zGWaZxnGeST7mu60iS48eeIZtZ1OEC3hIitLcD93Go7Ae3H416fdfZbDQNOdFXcspV8DvyOa0S6I4p1mpXe7/A4LSPhLZX6OHubuPYMtLkfyxUtp8NdDiiYyRTXKk8PK5Bx9FwK6d/EbQWF9GjqskwVUGeecgn8qp6TrQN/GJbiFY4Rvbc4H0qrIwdSerbMyHwAuk2l1bwvJHa3hDRo7Ylhcch1PUEEKQTyCBXQ+G5r/AFe2k83yEvrV/IvEHygSgZ3KP7rghx6BsdVNUbzxK13qEkwy0CjZGfYdT+dXbO4tbCT+2HeSK5mgMDxrjEw3bo9wxyV+bB7b29aXKnuZynNJS6jzukVt7nqQMHA9Kn1OxTTGjkQkwyAKxJyd/r+P9K5251J0tMYwcd/Wrmqao+o2ogjSSTlSSBgce9JcsS5ObasP0G5DajfjP8Kkfma6uxmBXrzXAWsV1b3azLEFHRhu5IrpbO74DKcg96xk7u6N1FpanWwyCrQkGK5+G8BUc1N9sAHWmmZuJrvKPWoJLgCsqS844NVpLknvSbGolrUTHcRlWAOa5/y5LOZnhVWBHQ1febAJY4FZl3qcQOyLMsn91Of1pXLUC1a3xitwpU+ZjBGOKjS/baILYeYw4J7CqMVnc3sm6clEP8C10+m6csagKoAoBq25UtLGSYhrli59OwrWjtI414UVdjhCjpSSjHFBN7lKZQq8dKyNJyvxF0cp1eKVD9NprVum+U1naB8/xC0bk8RTn/x2rp/EhT+F+hoWP/HxBnrg/wAq1ay7Ff8ASos9QpPP0rUqkRivjXoFOiG6aJfV1H6im1NYrvv7VfWVf55pnMd3RRRXUcYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABQeOtFZniO6NrpMzJ/rJP3afU8fyyaTdtRpXdjkC5mllmPWVy/5mlpFG1QB0Apa5jrCiiigYUUUUAFFITggYJY9FHJNSiDaN1ydi9kU8n6n/CgTdiNQzttjXcR1PQD6mrEFtGzDzS0ufQYWmG4h8toV+QDjbip0cRWTTK24Y44xz/8AroIbKMf3OOmSB9M06kRdiKvoMUtBYVJbf64n+7Gx/lUdT2P+tmJHRVH6mgUthoeQOBgOg+7g9T61Mlxu24Kgt3Pao/JKP5ilgM85PCimyeXjdGMHH8R4AoILA2su4uuB94k96fZ4b7m4L1wOlUYYvNUmUttc4Va0bdAsYAVhjqTxQBmPjz58dPMOKR/uN9DTYzlNx/iJb8zTjyCPag0RjXei2esTWrakhe1sVe7ZB0faPun2NeSeJ4Lnxbrvm6ldzuicRwKQscS9lUDp9a9juZWg0XUpV6iykH54FefeHtImS0OpyqSM7mTuE9f6/ShHoTmo3b9EbxsbPSPDNjLpkSxwQDYyDqAeufcHr9a5HWNdkEUtki7izrMHJ4Tjpj34rY17Vn0+xuDGiyxTrsKsflyRw1chpWn3N7DJfOGMfmBScdR3P0FW2c8Y2XvHR6Xor6xoTlSDcP1Zv7wOcVh3ukeRHudQkiN8ysOhHY13mm/8S23E1uQpwMjs3sa5O8+2a/qEtxIBBC7ZOOnHHHr9aUpKKCnTbk10OeuQ7kxxbiGP3Fzg/hWro+g36sskty9sOuxeW/XgV02l6VBbDMUfz93bkmtqC2UEZFc7qPodfKlpYyrXTUG1mUyOOjyHcf8A61aUVoxxkVpxQrV2KJABxU3uJ6bGM2nkr0rPltpbNywQtG3UDqPcV2iIvQikktEk6jNOxHMcjDcRlfllX8Tg097qNRkyL+ddDJokDnPlqfwqrdaVFGvCAU7CUkzmbnX7aBinzu47Baz5NduZzi3hCD1Y5NSaxZINTc7eqrTrS2GRgCkWkRwwT3RBuZXfP8OcD8q27GwVAAqgU+1twMcVs2sQ9KAcrC2dqBjitiCPGKhgTAFXYximjKbF28VTuOM0atqMtgI/K0nUtR35z9i8j93jH3vNlj654xnoc44ziXGvzH73hjxIv4WB/wDbuq5bmanZ/wDAJrxvlNVPDOf+Exe4AG200+WQ5/2iBVG41vI+bw/4kX/tnYn/ANu6NE1cxLq1zD4e8SzLP5dozeXYr5ZXLFf+PvnIP4VUItO5U5pq2uvkzo7EZunP91P5n/61X65yz1qZfMdPDHiR9xxnFgOn/b3Vn+3rj/oVvEn/AJIf/JdUosyr1FKba/I2qu6Ku/VrYejFvyBrmP7euP8AoVvEn/kh/wDJdX9D169XUN8HhDxLM6ofl3WC9e+Td1SjqYSkrHplFeQfHDVtXfwt4Oexi1LR7u/8SWlpLaNffZZHRvMUxvLbu+1WwDlSxAIOMjFZPjfx14l+Hs2laLZ6XY273NrNdG61LVpL2BpQxCwi5upYCOACckkbhtRsV0HKe60V85f8J54p0/xf4s1F9QsvMPh221Sx0eUvPFK3kl2FuUm2sFIJZ0BDAZ+XrWj/AMLo1e7XWzpJ8MzC10qxu7eW4uhBEZ5gvmIzvIFO0lgELKcjBbNAHvlFcP8ADTxbeeL/AAXcarCIrm8SaWGISW5sopGQDAysk4KE/wDLRWYeg4xXRWkN/qmkTweIbWGxmlJQrpuoyv8AJxgiUJE6t16Dj1oA1qK8Dv8ATJY/D1zc21/qU9/D4xt7G2Oo6ldXcMaLfxeWDG8hBxgcjDYyN3JrWu/HeuwahsuDo/2+yj1eIzySy2tq7W72wRmRpdigiXneWII+VlDHIB7NRXB+D/Fk3iH4f6rqz3EFzNbidN8EPkRkomcKY55Qw5++khGcgYINc74X+IOoT+KtB0a6udKS1u7S2ZIIf9KumZrUSt5hNz5sXOfmaJwQAS+WFAHr1FFFABRRRQAUUUUAFFFFABXJ+KrnzdQitlPywrvb/ePT9P511bMEUsxwAMk15+8v2m5nuiSTM5YZ9Og/QCs6j0sa0ld3CiiisToCiiigAooooAmspoYUIlOyQk5cjhvTn+lPn/fBgrxbex3jn61WphjjJyY0z/uignlJ1MCZEkqE5zhPmP6UXE7T4ULsiU5werH+lRZCLzhV/KgMGzjPHByMUAkLRRRQUFSW0qwzMXbargDcegI9fzqOjII7H1oE1c0XjJjIBJzzxjmqzqirs8vaG455zUETPCf3LYX+4eV/+t+FTi5jlO2UeU54BPKn8aCLWEhby0VBt+TIBJxV2JSIWbcTxk/WoWtlcYOPYgVICYoXQ/dCk5x1oEZcfEafQU6kXhFHsKD0NBoZl/tHh3VGc4xakD3yy1geEb8Wtj5VypMPOGAyV9iO4roL0xf8I9qizHCta+mf4lrndN0iVLIyWU/nL1Eb8E/Rv8auOxvX5eZqRxnjWWITLY20ivEshIZTkYPQfhmt/wAGXC2btbyIWth93HVfw71geIdPNxq42AxqQGfIwVPcY9eK6bR9Lnjg+0WxFxCwzgcMP8alPU0qKPIkyz4ngt0SE6XKAk5IeMHhffHb6VUs7dYkUdgMCo7mVJLxXXBG080G5xwOtY1btmlH3VY0lkAwBU8UvPWsiP7RN/q42P4Vbt7S8dwFjLeuCOKysbcyNZLjFW4J8kVQFlcxx7pI+B1w2cVYtODQJtM14mzVuHJqpEOBV23HNaIwmWlX5Ky9TGFNbKjCVi6s2FaqZlDc4bUAZdTkA7ACrdrBgDiqq/vL2d/9rFa1qmQKg6CzbxdK07dMCoIE6VoQpTJbJolqyOBUaDApzHAqjJ6kczYFZd4/Wrtw9Y97L1qWaQRQu5VUMzHAUZNa1pA1h4f0+CX5ZZA95KvvIflz9FArIsbM6rqltY5wsz/OfRBy36Aj8a37uT7dqDvj5Xfdj0QdB+QFXDRXKuua72WpPaoUt0U9cZP481LQaKs4W7u7Ct7wmmZbqTsAqD9TWDXVeGI9uml/+ejk/lx/SqgveM6jtE0J7u2gnt4J7iGKa5YpBG7gNKwUsQoPJIUE8dgTXP8Ai/xnpvhmWyS7uLMebdRQXJluli+yxyLIRK+ei/umAzgHB54pfH/hRfF2lW1oL2Swmt7lbhLiJdzKMMjqORjdG8i57bs84rB034YwWM6umotIkesRalCjwAiGCJGWK2X5vupvOG7DAxxmug5jp5/GPhi3ispJ/EejRR3o3WrvfRKLgZxmMlvm544zzTPDfjDRfEWo6tp+mXsMl7plw9tcQeahcFcAuFDE7Mnbk45BHauA8RfCC/1XR7rSrfxXLbadcm7aS3EEoQNPcSTbgsc6Biok24cOpCg7RXd+FvD13oOp6zIdQhuNP1C5N2sJtissUhVFbMm8hl+TgbARnqaAOfl+Lnhoi1e2vbMwnWJNJu3mvIo/soVZyJmwSNjGA7clchs9sV1U/izw7BFYyT6/pMcd/g2jPeRqLnJwPLJPz8kdM1zVr4AuYtQtml1aCSwtdfm16CH7ERIHlE++Nn8wgjdPkEKMbcHOcjnr34LLMqCPWgyvBLa3MU0dysU0T3Ms4G2C5i6GZlO4sDgHA5oA7zxd4ts/C9/oUepvbwWepXMlvJd3FwsMduFgklDEtwclAvUfe/A2pfFnhyG4srebX9IjnvkWS1ja9jDXCscK0Y3ZYEggEZzVLxh4cvNZvNBvNL1C2srzSLp7mM3do1zG+6F4sFRIh4EhIO7qBXD6h8Hr650uy0yPxbcLp0Ece6B4ZdvmrMZmdUjnRPmYj5ZFk2hRtxQB1/h74g6HqZ1WK81HTNPvNOuryGW2lvo/MWK3leMzMDgqpC7uRgZ6nrXUQX1pPdSW0F1BJcRokrxJIC6o+drEDkA7Wwe+DjpXAaf8NpIdaFzqOp215pkWoX+pQ2cdkYpGe78wMkkplIdQsrDAVc4GemK0fhN4ZuvDnhsnVjKdUunDS+c6u8cSKI4Yiykg7Y1XJBwWLHvmgDtqKKKACiiigAooooAKKKKAMXxZdGHTRCjYkuG8sY9O/wCn865dQFAA6CtDxFci51hkU5S2XZn/AGjyf6VQrnm7s6aatEKKKKk0CiiigApCwVSx6AZNLSN/CcbtrBseoBoEWo7VRErT7i564bAWmmKDcQGkyOwcc1KLq3fgy7Tno42/zpkkMKsZmcInXIbr/jQRqKyQW6edsyR03Eliew5qoAeSxyxOSfU06RzK+8ghRwinsPX6mkoKSCiik5yFUbnbhV9aBjo082UJztA3OR2H/wBep2iik4QeWeisq/z9acYvJtwqMN5bLN6monlVGAiSRzk5ycYoIbI5FaE4mGPRh900hGRgjirilxgnG0jpTDaK4zETEw6r1WgakVo2eIfuXKj+6eVP4dvwqWW7llhMZjCluGYNkY9u9MljkhGZVwv95eR/9am0DsmFNlOInPopp1Q3ZxAR3YhRSLirtIzNbcQ+F9YkYcLBGmfTdIP8K4rwtqNxBuhindVzwOCPyNdV45k8rwfJHnDXVyoA9VQZP6mvPvDtzp8Ug+2IquhwTkgEetUn0OqrHRza0udBqdu9zePNvDyOMtxjBA9ql0NpIAWid436kf4in3Wv6dOYYrTakEIJJC4DMfSlmvIX0aO4hGZRIQmBywJ6f1p2s7mXNeKTRq6bpNtfGW+liG6Vz8mThSODx7nmtKPS4U+5Eg+gpPDR8uySBiDIvL47E84rcUAGsnqy72VjPg01D/rDn/ZXgVbWBI8KFCr7VNIRHGX7AZOKZPIWtt8WGI+Ye4pWFdsY+I/kIHPT3rJlgEN06qML94fQ1oXjCa0V4zl0+dfeqEsomkiYHOVNSzWBahOcVo244rNthkitWIYFESKhMzYjrntZmCxOxPABNbVw+FxXJ+JJv3BQHlyBTYqaMWyTgsepOa2rVelZ1nGdorXtlwBUmzL8A6VfiHFU4BwKto2KpGcifOBUUr4HWmvJVSaWhsSiMupcA1hXsvJGauXk3Bqpp2nzaxfi3hO1fvSSdo07mpWrsjXSKuzV8M25g0m71F8rJcH7PAe+wH5yPqePwq3Yp8rSn+LhfoKk1CVLmeO2tl2W0S+XGo7IO/41KAAAAMAcAVt5IwqScY2e71/yFooopnOITgE+ldvpMXkabbIeoQE/U81xttF59zDF/fcD8O9d6BgYFaUl1Mar6HIfELV59Im8MG3EWbnVDCxlnkiQAWtw+WKsARlBkOGXvjIBGf8ACXxldeLrfUvt9zp9xcWjRq/9nxL5KFgThZUuJlk6eqMBjKjIFdV4h1200G3gnv2VIZZGQu00cYTbG8hJ3sufljbhcnvjAYin4f8AGGkeIPCC+I9JuI7iy+z+e6LNFvhPlhzFId2xHAIBDMAD1IHNbGB54PijdJ4ZvNUu9b8P298JBENJS08y4sGM2wC5L3UYAwMFm8pQSDkjGeI1jxVdeMdNm1K/jt0uU0PVLZjb48t/Lv7RQwAdxyAOjuPRiMGvoK18T6HcalBpiavpw1aaMSLYfa4jOQV3/cDEn5ecjIxznHNP1bxLoWj3sFpq2taZY3dxgwwXV1HE8mTgbVYgnnjigDyqb4r+II/FWt2S6VYPHYG/C2DTQx3biCOR43UfaDK4kKDgQAAPkMwHOn8JNYbXfHniy+fV9J1Yyadpf7/S42SFebo7OZHJYZ5OR9ARXe3Pi3w5a/aTc+INIhFtkT+Zexr5WHMZ3Zb5cOCvPcEdau6fq+m6kQNO1CzuyYlnAgnWTMbEhX4P3SVYA9DtPpQB5jffE/WLQanp50aN9Ut9RbSY7lVcwfaZJG+zAx53FTFsZjuGCygfe4zNO1/WdAudUCNYS6VqGv6rbCLypEnR1immD+aJAMZi27QoIznd6eqTeKdHhu5YpdQskhhjd5rlruERxFJBGyNl9wIc4Py4B4JBwKa3jHwyukrqjeItGGmNJ5K3hvovJL/3Q+7bn2zmgDxdPHOpeHkvtTs7eDzNSk0tZ7m4IeK2DWCvljNPFnJAUF5R15LHAPs/gTWLrX/CWm6nfx20d1cIS4tpkmiJDEZVkd1IIAOAzYzjJxWvY3dtf2kN3Y3ENzazKHimhcOjqehVhwR7ip6ACiiigAooooAKKKKACq2p3iafYT3UoJWJc4Hc9h+J4qzXFeLdYW41SHSIPmVT5k59xyB/KplLlRUI8zsZ8G8oXm5lkYu+PUnJqSiiuc6wooooAKKKKAEJCgk9BUnkzhc+Vn/ZDDI/Clt08y5UH7qDefr2/r+VW5A+/wCU8Z+7QQ2Z+9SdrHB/usMU0Rxq25UUH1AqxdzCUGJMMgPzOf5D/GoqCkFFApY0eZiIQCB1c/dH+NADWIVST0FWUUWyBpeJpOPXaPSop7aRE3xsZWQhim3BOOeKttKksCzRjzFbpQS3crSzbJAmGYY3EmozJFIwZ88jGSMGrKh3l3ZUcducUjiKBw033+SoHJb3xQSJbxkRkAZB75qXmNS0soT0ziqzXErZEYEKfmx/oKi2jduPLepOTQUolt75Su2AeYem4jCj/GqaLsQKOcDFOooGlYKryZmuFjQZKnA92Pb/AD60kk2/5Yc47uP6VWvLtdOmitVKi9mQsqg/NCncn0Y9vSkdVKDj7z36HK/EG/RrxbBHDx2amPcDwzk5Y/nx+FcdZaLc3Di4Abyj2TkkfSvRtR8MadcwRybBBNkfMCSGJ9R3qez0uSylSJwhUj5WQ9azbd7nV7SPIoo5ax8K20q73klP+zwK1ZdEGEAkkXZ93B6fhXTC3AOcc02SPilzN7mdo9jB02abSZf37ebEx+/jGPrXUC68y1aSDDNjIrCukBUhhlT1rNtb+TTboRFswv8Adz29qaYnE7ezuBcWyuMcjpWel5HaNPAzjEZBUex7VkJfiJplWYRxthxzjGev61jz36mWZoTvduF/xJobJUdTY/tNzbv5a7V3Ngk89eBUunIRGN33j1rJ0+J5NpkOQOgHQV0VpF8oqL3NrcqL9onIrSAwtVrVMYqy/C1aOabuypdPwa47VG+0X4XPCfzrqb19qMfauVtEMszSN/Ec0maQWhct4QqirsK02NOKsRrigbZYiGAKkLYFRrwKjkei4WFkkqlcS4BpZZazbmXOcVLZpGJHOzzSrHGCzscADqTXWJGuh6V9iXb9rmG65kHb0QVDotiNJtFv7tAb6YZgRv8Almv94j19KbEGnlM0pLAHIz/EfWtox5V5mUpJ+89l+LJLWIxqWf77dfb2qaiimckpOTuwooopiNbwzB5uoGQjiJc/ieB/WurrI8M2/laf5pHzTHd+HQf596163grI5ajvIwPFnhweIZNFLXJt1069N4QE3GQGCWLbnI2/63Oefu4xzxQ0bwpeWfw4fwpe6nBcBLA6bBdRWhi2ReUI1LIZG3MOpIKg+gpPiHq8+kS+GWt1DG51QwtmSRRgWtw/RGUNyg4bcvfGQCOItfiJ4oj8OR3t+/hsT3mhWms27urWsMHmyKrI7SzbX4bK/NHlvlyM7qsg6rRPAt7pXim31O31mOGyRVE9pbQSx/aysIiDS5naIn5VO5Ylb5VG7AOcD4i+FNfvvE95/wAI9bvJaaz9hF9NLDCY4hBNniQzrIvyjJURSA9iCTjIT4n6i0DajDJZSk2cKveSRSxWtvuvWgaVo1uJI2jQDJdHO7H3wvTHtfiFqvh2zv5NNuNIvk1LW7131fZGlmWSKDYqiW6jUb9xwTMeFJAbsAemP8PXisI1sNThh1CHXrjXoZ5bPzI/MlaX5JIw4L4WUqGDKcqpGMYrL/4VFBJHZLPrEpKQ3a3nkwCJbmSaVpkYAN+7EUkjuqjPO3njnotT8SanbfD2w8SJa2vmrDb3l/AridVgO0z+U6NhiqlmVgSDt964zWPiXrVpY2d5NNoej297Z3OpWb6jBK32qNXAgt1AkX980ZDnG4/MAEODQBqyfCoS6VbWc2seY62P2WeV7UHz5DdpcySld2BuZWG3nG7qccw+KfB2q6X4gl8S+GxNfarLqEtzHAlpDIkKyWsULBhJcRZP7kEOGyNxG0jNMsvifdvqqaXfx2Fnq8muW9mmnybvPFnJBHJ5hXdnIZ2XdgLxjGa9J0TVrLXNMi1DS5vPs5SwSTYy5KsVPDAHqpHSgDK+G+jXPh7wD4f0i/2fa7Kxigm2HKhwoBAPfnvXR0UUAFFFFABRRRQAUUUHgZPSgDI8S6umk2BYYNxJlYl9/X6CvOdDjL3k87kswG3cepJ5NWPEmonUtWmlBzCh2RD0Ud/xPNL4fUfYS/8Az0kZv1x/SuWUuaR2QhyxNOiiigYUUUUAFFFNkJWNiOuOPrQItWif6O7kZLtkD2HA/rTLgqhKINsrjLHPKr/iasgrBAFbOyJBz64qjksS7/fY5P8AhQStWAGAAOAKKKYx3fLhtpYIzgcDJoK2JoIfP+ZjiH2PL/T2pl7dsQsdsAqEYB6Vdc7eAMKp2qAOntWbboWuTsVkQ8kZ5FBF7klt54hTL5I4PXn6+lWzEwcywOEkIzIGHyP7n0PvUKHYWd8JDjG7oWps0rTjawKxf3T1b6/4UAlcX7U7pmOPymYctkHA9qjVQucdTySeppTRQWlYKKKryyszGOPPHDMP5CkXCLm7IfJOqkqvzuOw7fWoijSqZJmCxL1ZjtRfqar6leW+joEuUMlwwytujYx7ue3061y97c3mrFRdTt5S/cij+VF+g/rSbS3OunTitvv/AMjV1vxPbWUDRaS7SXTcG4xjA9EH9azfD2nlHa/vSTcS8/N1UH+tS2emw26+YkOXA+9jJqCae5aTaA0a+ripvcuUklaJ1EjR3MHllsD1qxaW2wh3mMpA4z2rn7exlnUFrgMw6Ky8Vp6XE8chCq0bofmjLZVh6j0oMTUcCq8mKtOKqSrg0MEzOvVyhrltWUSxvExIJ6EdjXXXHQ1zOqRfOSKjY1WqOLPm3OoQxzuzlWx83YCussossDWHbW//ABM5JD/COPxrpNOGWApyCOhuWMPA4rZt48AZqpYR/KK1Y1AFJImciaGnyn5abHSyfdqzB7mBr0hW3YDq3FULRNoGK09Xt2mj+XqDnFQRQ7FA7ipZumSRjip14qJOKcz7RyaASHO+BVSaWmzz8Gs6ec+tZtmsYkk8w5xW3o2niwRNRv0BlIzbwN3/ANtvQCqGgxWbXU/21w11BGk62RyrMjEhZDnqmQRkZ54PUVpSyS3dwxZ90h5Zj0Uf56CtoRtqzOUlO6vot/8AIRzJdzsZHLMTmRz1+n+elWgAqgAAAcAUkaLGgVRwP1p1WctSpzvyCiiimZhUlvA1zcRwp96Rtv0Hc/lmo63PC9rvnkuWHyp8i/XvTiruxMnZXOjjRY41RBhVAAHtTqKK6TkCiiigAooooAp6zplprOlXWm6jG0tldRmKaMOyb0PVcqQcHoeelW0VURURQqKMAAYAFLRQAUUUUAFFFFABRRRQAUUUUAFYXjDUfsGkuqHE0/7tMdvU/lW7Xm/ji++16yYUOY7YbP8AgR6/0H4VFSXLE0pR5pHNy5EZxW14eBGjW2e65/WsK5bER+hrpdNTy9Ptk9I1/lXLE65bFmiiirJCiiigAoA3PGp7uo/WinRf6+HPTf8A0NAnsTX7ZdIs5H32H8v61XoZ/NkeXs54+nakZtoJIJ9h39qBLRCqrSSCNDgnkt/dHrV0oAnkBF8kjBHt/jVeaOSC0KIMyvyx7E+n0pLS3mSMPO+NoOQTwPrQS3csQyMQYZCTLF97j7y9mH+euaSWZYVxtDTN0Xpx6n0FV7qRZzGY92UORKDj8B7VGqhc47nJJ6mgaQpLOwaRtz9uMAfQUUUUFBRRRQMjnkMcfy/fbhf8ap6rfDQ7OIxYN/MMx558tf7xHqe1W7fynuHuLhsWsKlmb0Ucn8z/AEriJbiXUtQlup+XkOfoOwqZSsjqpwsrff8A5DoYnupmmuGaSVzlmY5JNbdlaKAMAVBZRcDitu2jworNI0kySC3UAcVM9rFIuGQEGpFGKkq0ZNmb9hWH/VLgelTxRkOrdxwfpVo03GKBCEVBOvGasGoJDwaQ0ZdyDzWFqC5zXRXC9ayLyMkGpZojlchZJMdSa1dKPzrWNcZW5cH1rT0t8MKTLWx2tiwCitEOMcVhWcw2jmtBJuKLmbiaCtz1pxbIqmkmeacZeKq5PKEwzVWQAU+SYVUmmGDzSbLjEHcL0NU7ifrzxUVxcZzTLGzudSmMdsmccsx4VR6k1Gr0RsrRV2QvI0jBUBZicAAck1vWGkjTik+pRLJckbo7cnhP9p/6CrFrb2ulKDaP592R81yRgJ7ID/OkCvcNuZm2nkserfT/ABrWMOXV7mc53V3ovxZl6/YXOr3MN7Z3Ag1m0bfBdsuVXP3o3UfeRgMFfTnggGrfh7U4tUsZGWA2l5byeVe2bNua3lxnGf4lI5VujD3BA0lUIoVRgDoBWJrunXIuo9Y0QINWt0MZic7UvIc5MDntk8q3VW56Eg6rXRnDUnzO6VkblFVNJ1G21fT0vbIv5TMY3jkXbJDIvDROOzqeCPoRkEGrdJqxKdwooooGKoZiFQZdjtUepPSu5sbZLS0jhToo5Pqe5rB8M2ReY3cg+RMrH7nuf6fnXS1tTj1OerLoFFFFaGQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVtSuRZ6fcXLYxEhb8QOK8fLM5LyEs7EsxPcnrXovj64MWh+UOs8iofoOT/KvOq5qz1sdVBaXK18D5Lkf3T/Kuttxi3iA6bR/KuUvR/o759DXWQf6mP8A3R/Ks4msh9FFFWSFFFFABTWUOu1uRTqKACn2wD3Sg8iNd+PfoKYFaR0jThmPX0Hc1NcqIBFJbhY5FbYO+5T1B/nmglvoTSyBYxJIzAcgKvVj7VUldpiDIAFHRByB9fU0hLM2+Ri7+p7fQdqKASCiiigoKKKKACo7hikR2/eb5RUlQTfPPGg6gZ/E8CkXTjzSSMjxddiz0W1soyRJeNvfH/PNeAPxP8qxLBOBTfGFwZ/Fc8JOY7VVgQemBz+pNWdPXpWc9zqi7q/c2bRMAVqQjgVn2+MCtCE0IUiwtPpi0rHFUZkUkwWZVJ4wcj3qKC43AhjwoHPv3qlcSFrmQddrDHtxQrnAHf8ArTFc1C4yRnkdapT3QBwuCPX1qNnxGy5OD1J7ms6VjnAJJPAFKw7l0P5q5qne4jjLFWPsozWjbRERjPXFLLEhOxnRWIyAxxmk0UmedaqB9o8xM7ScHPY1LYS7SK09YsUNxIseCrpuBHqK5xZDFJg8EdazZvA6+0nrQjnrlrG6zjJrWjuBjrSuU0bqT8daWS496xxc4HWo5bvAJJwPemTY0Jbrk81SlnLcLyScCrmnaNdXqLPORa2Z/wCWsv8AF/ur1atyL7Dpm06fAPNX/l5m+Zz9B0FUqber0Fz9I6so2Xh1hCtzrDtBGeVhA/eSf4VduLkNGLW3jWG2H3YI+/ux7n60jGe6kMkrMN3JZvvH/CpY41jBCjGep7mtUktEYSqJO71f4IiSDJDS4Pfb2/H1qeiimc8pOTuwooooEc7q9rcaTqEmu6PA9wzqF1CxjwDdxqDhk/6bJn5T/EMoexXcsrq2v7KC8sJ0uLO4XfFKnRx+PIIIIIPIIIPIqauYvFfwvfT6lbI76Hcv5moW0a5Nu563Maj/AMiKOoG4fMPma10Jemp09S2sD3NwkMX33PX0Hc1CrxvGksciSROodJI2DK6kZDKRwQRyCK6zw/p5tYDNMMTyjof4V7CnGN3YUpJK5o2sCW1vHDEMIgwKlooroOUKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDg/iHdb761tR0jQyN9TwP5VyVaviqc3HiG8Y9EYRj6Af45rKrjm7yZ3U1aKIbv/AI93+ldTbHNvEfVB/KuYuRmFx7V0mnNvsLdvWNf5UojkWKKKKskKKKKACiiigCexUNLKSM4UD8yc/wAqhlcSS7l/1a/Kg9u5/GkDOm/Zgb12k+nuPzNAAAAHQUE21CiiigoKKKKACiiigAplgA+qqz/cVwT9FGaeKrWz7FuJTnCxTMcfQ0Lc1pbSfkeby3Bu9Xurk8mWZ3/MmuhsegrlrDhx711Fk3ArJnQtjZtzwK0IDxWVA9Xo5MChEs0VOKjnlVFyTn0x3rPuLs+UQnBJCg0xiWHB4HygelUQCN5qF9uNxJpwXDA1IAAoA7UYpklef7tQRJ84J9aszDioFOD9KYGp5scSDcevSsDWd2oNFMsZCjiLPU+pqS9lK6hagn5XQr+NW7a6he3RfJczxfKUxgAj3qGaJW1MS4ZvtZSTqhK/gR/9aue1W2DuWThq2r6XbfzZILDqR0zjn+dZF1PGqyPKwCJyT6Cs2dEdjMinlgPzKCB3zinyeJEhGFhaRh6NgUkdhfazfw2mnwNM8yrJHsIZWRgCH3DjaQQc9K73QvB2maCUm1COPUtRXkhj+4iP0/iP14rSNPqyZTtotWc5o2neJNdiW4jhh03TmP8Ax9TjqP8AZHVvwFdrpVhZaJh4S15d97u5AJz/ALC9F/nV2WW4vW3yOSOzMOB/ujtTo4ljORkt3Y8mrVl8JhOa+1r5LYbM9xdSF5WIz1Z+T+VOjhSM5HLf3m5NSUUGMqkpK3QKKKKZAUUUUAFFFFABRRWpo+lG+IlmytsD+L+w9vehK+iE2krs5PSIj4Kuobi7iz4Onm+RyeNMlY4HHa3Zj/wBjn7rfL6D4r8S6R4T0SXV/EF6tnp0RVWlKM/LHAAVQSeT2B9a1JYYpYHgljR4XUo0bKCrKRggjuMV598UvAd/451Dw1Y/bIbLw3YTtd3ax4M0kiriEIjxtGVBJzuyMHpxXSlY5JO7O70vULXVdMtNQ0+ZZ7O6iWeGVc4dGAKnnnkGrVeBWHwY11U8Nafqtzo2oaRoP9q28AnLO8kFxGBBuUx7dyvknnAAGM4xVQ/BDxCmi/Zbe70eO4m8MnSLtxLIBPc+eHWRj5eWUIAu4/MMAYxTEe/anfw6ba/aLhLl49ypi3tpJ3yTgfLGrNj1OMDqatV4PqPwa1g2/ie20ubSLW11T+ynihR3RFltipmdlCYBYgkEZJJ5xVyb4S6vP4z/ALQuLjTJIG119Ul1NmZr2a1ZdpsGQptMXb7+Mfw0AemaF4w0bXtL03UdGnubyx1GR4reaKynK7kYq287P3YypGX2g9jXQV4J4U+DetaNpvhSxzodtJo2pzXc1/aO/nXUbhwjFTEPnXeAAWYYHXtXafCPwTeeDrYW+p6XoL3ixOkmt2srNd3pL7v3oaIEe/7xuQOPQA9HorxRfhf4gg8davrmnroMMd79tkY6gV1GR5JYykYVmtkkijGfmTzXXBKgY68/p3wU8WR6f4ghfUtIsf7TtbVWgsm2QSSxSAuGSKCIJG6gjgFhnBLckgH0XUF/dx2NnNdTLM0cS7mWCF5nI/2UQFmPsATWF4W0NLPw5cadNomlaDHMzhrfQ7hlTDKAXEixxMrn1AyMAhvTV0bSrfR7Q21pJeyRly+bu8munycfxyszY46ZxQBzUHxK0C6mhis01eVpLxLEs+l3ECJKzhNrPKiLkEjKgluvHBrrpLmOO8htmWYySq7qVhcoAuM7nA2qfmGASCecZwcef3vgG5v9ImsLz7DPBN4kOrSRyFij25l3lCNvLEcY6e9Y0vwvv1j+zxLYNp0a6vFDaR3T24SK6mheJFYRsECrGwICkDIADAmgD1u4lW3t5ZnDlI1LkRozsQBnhVBJPsASadFIJYkkUMFcBgGUqefUHkH2NcB4Z8H6np/w21rw/cppNvd3iXMcC2UaJEgkj2rvMcMSs2eSwiXjAwcZOd4f8AalpnxAs9bFtpCwRxKlxPJItxO5FuIv3W63V4eQOBMVxu+TLHAB6lRRRQAUjEKpJ4A5NLVDX5vI0S+kzgiFsfXGBSeg0rux5PLK080kznLSOXJ+pptIowoFLXCegMlGY2+lbuiNv0m1P+wB+VYj/dNanhps6Ui/3GZf1qo7ilsatVNS1Gy0u1Nzqd5bWdsCAZbiVY0BPQZYgVbriPH+i6jd+IfCus2Fp/aUGkXEsk9iHRGk3oFWRC5ClkIyASOvUVaM2dhZXdtf2sd1Y3ENzbSjKSwuHRx6hhwanryTxrpPjLVL2zn0a3u9J02SKbzbWxnQXEc7McTPtniRmIwcb3UHOQ2afbeD/FOra3qcmra7r9jaiwtktGgvhCslx5G2RnjjdtpD/MQpwT3YVVl3J5n2PT76+tNPhWW/uoLWJnEavNIEBY8BQT3PYVZrxmz0P4iXHh2S51Ke8i1lruyhS2h1ABVt4sCSTIfbukOS3c9PatPRtI8XRfEVry8XVj4Wa5mMFq+qKzQsVTEkg3ZaIkNtj3Hb6epbzDm8j1OsfUvFGgaVdta6nrmlWdyoBMVxdxxuAeh2sQanuNPuZdTiuk1e+hgTG6zRITE/1JjL8+zCs/xVp11f3/hqS1i8xLPVBcTncBsj8iZM8nn5nUYHPNSimaelarY6tHNJptwlxHDIYndM7d2A3B6EYYHIyOavV5s/hrX7fVLu/wBKkure6n1mSTBu/wBwbZoCA7Rbtp/eBf4S3HpVj4ZaZ4lsLq5bxHLqBDW6KyXDiSNpQTl0Y3MrDOegWNcY+UdKdhJs9BorzPUNL8TvBr6W8WrDWZZZjaX41AfZPJLgoiw+cNr+X8udgw3O/vTPD+geJZJLGLVLnWY7A3czTxtdGJ0jMICgOtzM7KX5Hz7gScYGKLBfyPSbu5gs7aW5u5ooLeJS8ksrhVRR1JJ4AqavMdQ0Pxg1nr9rBd3hjtbW4j0mVL7El08x3KXbIIMY+QFj3z71rWthr6ePHuZF1D/hHWlkMcJvgSku1R5rLnJhPzBY9x2nnaMgKWC53A61VtxnT9QzjH2SXr9KtDrVW1j8wyQ/89I5Y/zU0lub0/hl6Hldo2GFdJYycDmuSR9r4PUHFbljP05rJm6Z00UmBT/POcZrOhmBWpFf56EEi7AfMUA9nzV5CMVn27YWrAeqM2i3upN1VvM96aZfemIsuQRVSTg0jTe9QySA9TQFiPUojc2y+UcTRnch/pVCS/d/vwzpc4w21MhqvGTBqN58LzUtFxdtDFuFaNWZwQzDoTnFUINPutW1OCxs8F5Rkk8BQOrE+gFXb+Qsx9+tdh4dsU0vSd8iYvLlQ0jH+GPqq/j1NEY66lqbvZbmdpQTwbqCaRaSSHQtQIitZ2xuiuCSTCT1EcjEsgzw5I/jGOljgz80wy3Zey/41VvdMt9U064tdSiEkFwhRkPYeuex757ED0qp4cv7kzTaNrEhk1azTes7cfbbfOFm/wB4EhXHZsHo4Fa/Fqcsp8jcYbG5RRRSICiiigAooooAKKKKACjp16Udx1JJwAO5rotI0Xayz3oG4crF1A9z700m9iZSUVdlXRtINzia6UrB/Cp4L/X2/nXUKoRQqgBQMADtS0VvGKic0pOQVxnxI8aP4Qtrc2tnBf3UqSyi1aScSMkYBZlEMEpwMgEsFUZGTXZ1ynjQ+G59R0uw8S6JDqryRXFxb+bYLd+UIlVn2rgtuIIwEUkkY9KokwviDr+oah8NdD1DQFaB9butNjwbtrZ0iuJY8qJUVmUkMFLAZAYsMkAHK8HeMZ9EmutI1GOa4Cy6tMs9xfvN5KWjRgRb5AWcYk+8SDxkjmvUBp1hJYWlt9htjZ2/lvBA0ACRFCDGVUj5SpAI4GMDGMVU1DwxoGoxCPUND0u7jEzXIWe0jkAlb70mCPvHu3U0AcFpnxLu766torHTPOvtUezW1trq9WK3i82y+0sDIsJYYAI5Dlj02jgaHw01/WLnwfpPm6XfalcXH2lnv/tcTQRsJ5QEd3cSkDaoysbcEcdhv+JNK8Jab4bvrjXdI0oaLbRLNcLJYrJGEiTapKBTnaowMA4HAq1ol7pkGr3/AIa0uyFn/ZkEE7RxRLHCFnaXaEC98xuTwOo65OADxHRvEuuL4DtZLu7v47/U9Pg1Uzrqkk4bfeW6EgMgaIkOw8tG8sDsScjbsPibqOjTanpkGkajr98moancEL9okZYUvZY0jj8uGXkBcAMUUAKNwr1weH9GEEUA0jThDFEII4/sybUjDBggGOFDKpA6ZAPaq+o+EfDepxrHqXh7R7tFkkmC3FlHIBI53O4BX7zHknqTyaAOC1HxlqWs+KPDcdjbfYNITxG+nySG8ZLi4aO1nLI8AQAR7sHlycqp28gjpvFnjC80DxHYWJ0lDplwI/M1S5lmjhjZ5Nnl5jhkUN0/1jRgllAOScXtG07wrrNyPEWmaVpk14JpIxf/AGJVmEkTNC3zlQ3BV1z6dODWhfeHdE1DVbfU7/R9NutSt8CG7mtUeWLBJG1yMjBJIwepoA81f4zpDd38cukJNBHZvd2dzbTzeVcgTxwgb5YI1AzKpLIZFAByeOe11/UtesvAOu6hPa2FnrFtaTywpb3bTxqVQlW3tEvPGcFCOBzzVy18H+GrSa5mtfDujQy3SPHO8djErSq5BdXIX5gcDIPXFXdL0TStJ097DStMsbGxcktb21ukUbEjByqgDnvQB5LceNvE+kagdXvtPtbuG38Mx6jd20eqOIwokcmRB5IBlZR93ao4xu6Z0tf+KlxBrdxpGnadBKJRdQW18k0+1LiKB5Nsha38oEFCCFkcjuOtd/aeFfD1nZy2lnoWk29rNE0EkMVnGqPGSSUKgYKkkkg8cmsvXrDwr4evbbW7nw9p51C6vYLNbuGyi8/zJ3EKsXIBx8+Cc5254PSgC58PdQ1TVfBmj3+uR2yXtxaxSloJjIJAyKd5+RApOclQCB2JroapaRpOm6LafZNG0+z0+13F/JtYViTcep2qAMn1q7QAUUUUAFYXjeTy/DlyP75VfzYVu1zHxDYjQ41H8U6g/kT/AEqZ/Cy4fEjz2iiiuI7hG6GrXhZ8NeQns4cfiP8A61VqXRXMWs7e0qFfy5prcT2Onrn/ABL4ij0K7tROszxPb3Nw8cNv5jsIlViFO4YPPTac+oxz0FZWrWGmX19aC+fbe+XKlvsuWhl2sB5mzawPQLyOR7VojNlTSPEkeseHLrVrC1fbEr+XH58EpkKrnhopGTk8YLA+uOtcdYeP9Vd9Bvr3SL821zoct/cWtssB3MvkN5yEyZEeHcBS27kZXOK7TwpZ6MujtPofmS2d8xmeWaSWV5iQFJZpSXPCgc9hTLDwfolhGI7e2m2LbSWaCS6mk2QPs3RruY7V/drgDGMcYyaehNmZEfxM0CXxBb6THJI0s0kUKyb4gN8ihlXYXEh4YDIQqCcE9ak8TeJ7rQvFQjNreXmmppct3NFarEWj2yLmQl2U4C54BJOehrR/4R7Q9JnXUVaawEflhit/NDCxUBE3oHCOcBVywJPA5qbXfC2k67crPqcE8kghNufLupYg8ZOSjBGAZSRyGBFGg9TJn8e2ZErWVhqFxbBzBHeKkYhefy96x8uHyeBkqFzxurJ0H4galdz6B/aGhzw2t7o51G5mUxYXBizKv74nygJGOCDJyuB1rqf+ER0P+0/t4ssTb/N2CaQQ79mzf5O7y923jdtz71Fa+CtCtRZCG3uQLMMkAN7OwWM7cxcvzH8i/uzlOOlO6FZmc3xDs47ZJZtI1iKSYQPbQNHFvuEmkEaMmJCB8xGQxUjI4qfSPHFtqOqW9i+k6rZvPcTWayXCxbBPErM8fySMc7VJyBtPrmlTwv4V0tihixLAkV0Elu5ZZI44H3oVDOWEatj5V+XPGK0dN0jRrlLHU7KDcpmfUreTe4/eTIQz4J7q54IwM9AaWgalLxJ40tNA1C5tbiw1G4W1tEvbme3WMpBCzum5tzhjgoxIUE49eaqXnxF0iz1250qeKb7RDFNKDHNbybxEhdhtWUupKg43quam1fwrpOreMHu9UujK81hHCunCd4w6RSuxd1VwJFzKowykA49aafC3hV9fntjBMdQeOa7aA3M/lqs++OR1TdsUtlwcAHv6GnoGpHYeML2/8WWenw6FfJp1zZfalnk8lWxvUByPNyEweRt3Zxxir+u+MLPR765t5LO+uEtIknvJ4FQx2qOSFL7mDH7rHChiAMmtB/D+nNfWF4IpUuLGPyYXiuJExHx8jBWAdflHDZHFZ/ifRvD095b3utxN5s8kVoNssqrOd+Y0kRDtcBicbwQMnpS0HqVfAGq6lrM+uXWoC9jhjvpraCGUQCJFjkZMIUy5b5fmLnGT8vFdVZSCDUkZx8olGfo3H9ah03TrXTYpo7KLyklnkuHG4nMkjF3PJ7sScdPSlu0BcejjaT79qTetzahvyvqeU67A1nrl9A33o53U/mafaS81t/EawYXsOqxj93drtk/2ZV4YH64B/GuWgkwRzUS0ZvDY6WCfA61dhlB5rnIbj3q9Dcdiako34psEjNTedjisWOfkEmpvtB5wfpTJaNMTDGe9Maas4z54B4FNM/vTJsX2nqGSeqLT+9M833oAuLKT1P4UyaXcD/OqwkqC4mwPXPAHrQBp6LYjUtSCyD/R4R5sx/2R2+p6V2jMbq7Z3AxncwHTPYf59KoaVYnSdLSGUYuZQJp/XP8ACn4Dn6mtOFPLjwfvHlvc1fkS5csebq/yJDWR4i0uW/hguNPlW31ayYzWc7DIVsYKMO6OMqw9D6gGteihaHO1coaHqkWsacLqKJoJVcw3Fs5y9vMuN0bHvjIIP8SlWHBq/XN65HJompN4hs43kgKCPVLaNctLCv3ZlHeSPJOP4lLL1246KKSOaKOWCRJYZUEkckZ3K6kZDA9wQQQabXUSfRjqKKKRQUUUUAFPghknlWOFC7noB/WrGnWE1/JiP5YwfmkI4H+JrrLGygso9sC8n7zHkt9aqMHIzlNRKulaTHZ4llxJcf3uy+w/xrUoordJLY5229WFFFFMQVwvxO8IX/iqMLp81rGRpepWP79mHz3EIRDwp4BHPfHQGu6rgvH2qazp/jLwqmhwpdNLDfNJazXjW0MgVIyCxCPkjnHynk9uTQBiR/C64XU5tTU6dFq7a1Fex38efOjtVto4mjDbcgllc7fukEZPYc9onwe1ex0bUrO9SzvJbiCKEsuoxwx3LpKriWVFsPmb5Sf3pnzuKtkHNdPZfFhr61t9QtdFT+ygunm7eW9CTxteBCgjj2ESAb1ydy55wDiuXufG+tR/DfxBp9gGn1KKw1m+l1C51B4Xt4lvLmKPyiEZnddo2rlQNqjcMigDtpvA17e/Bm98IXi6TFez2s0KC3gVLaNmdmjOFRBkEqSyouWBYKOlYV58K5L5tUu/7I8OaZePa2UWmxWjMyWEkM8skjRt5SFdwdTlVBzuB45PTeGPGN9eeJI9E1HS1sU8s+RPcTTebdhVUl0Bh8pgc5OJSwHUCuW8b+JfFMcnju3txAtlp09gtrJDeGKeMuYTtAEYyHy2SX4zgAigC34N+G+q6H8Q59cvbmK5jae6l+1JcRrLMspJVJUFqHcLkAZnIG0EAD5Ra8Y+Ctf1LWtcfSm0s2GsPp0kr3M8iSwm2lDEKixsG3ADBLDBzweoh1L4q32n3L6ZN4cEmupfS2bQW089xDhIIptweK3aQ5WZBjyhznJAGa0vHuvajP8ACm21mxtr3TNRnuNNb7LKzW8sZe7gVonOMjIJU8cgnjnFAHHXXwf1IaQlhY2fh+CKDU57siIoo1CKR5WjE6yWsqK0QkCqCsgxnBTitO1+Eckuj63aai1s8tzoUOl2Ms0xuntZVW5Uvu8uMEATKoYKDt3DAzzb1P4r3VhZXqyaLZvrFjdXFtPYxXlxMHEUccjPE0Vq5ZcSqCXVAp4JqlpnxC1CHWdT1f7EbnQLubSQElvWEtt9qiiCiKHYQ/zSZYBl7kZoAj1X4deI9bXUptYs9EkluDYCG3i1FjGv2eOZSzmW0kSTJlBCNER3zlQT1useGNYu/hda+H4F0JtRWGCKeNrVFtGCspdURo3VeB8pMbAHB29qb4f+IkOp6p9hvLSHTpbVXXU2nugFs5/P8mGIEqN5lKsy/dyAODuArvKAPEdE+D94LWxtvEEWjXlrarqnl2z4ljia5MJi2gQonymN87UUDIKr6Pj+F2u/2hpM17HoV/PbXOk3B1O5mka6tltVhE0MOYj8rmN2B3Lkudw717XRQAUUUUAFFFFABXIfEcn7DZL2MxP/AI6a6+uO+JP/AB6WH/XY/wDoJqKnws0pfGjh6KKK4ztCoZG8i5guB0jcE/Tof0qamTAMhB6GgDqgcgEcg1x/jHRri88UeHNShtL+6gtDMky2d4YGTft2sR5iBlypyASSOMHpXQ6Fcefp6An54j5bfh/9asnxD4gvNM8TaJp1vp0t3b3yTNK8ZjDJs24ILuowNxJ4PHTmtYvsZSXc4e18KeLNL0C2g0Wa8gupNNnS4SS9Lok3nRlAi78ITH5oBTaOmSDzXX/D2w1i00q+j1qW+DyTFoUu8M0S7APlb7ROxXOT8z5BzwBirXh7xfaa5d28MNlf2yXdu13ZzXCIEuolZQXTaxI++hwwU4YHFczq/jXWEbVUh024jWw162sUmiWJhPEzwbo8M5O9hI2DhQAV5DZqtXoTotTFu9B8YatoUGn6lZakfsmmJDIzakn+mXKXETblKyZyUV8M+05POK0Ro/iw+LrW4ifV7bSFmt2hja4E5hiAXzI5s3YDEnfltkpwQQcgAa2pfFHRdNhT7bb3cF0ZJo5LWWS3jeIxEB8s0oRvvDAVmJzwODXS3fiKyttL03USJZLK/khjjmRRhBLjYz5IwpJUZ55YUXYrLucjpuleJdJt/Dl+66rqN5GZV1K1OoBtwKMIzh5BHhTjOOe/zEVS0PSvFsGoeHZL+LVbho4oUvPPv8QxEE72ylwC7YIyGicEgcgZra1T4m6Nptna3lzBdC0uWYRymW3QsqyFN6xtKJGU4yNqk45x2qzP47tBem3isNQ8p5rm2ivjHGYGlgjd3AHmByB5bDO0AkYz3o1HoU/F+gXd34vi1G3sr+5ifTJbTdb3vlLFIWBUyIZFDIQTkANzjI4GMT/hHvE+k6SlppkOoXMEmm2SSxPqb5iuFdvNMeJkIwu35VdEI4zXRWvj+0ZreOWw1GRD9kSa8SKNYY3uVQx5UyF+S4GAGx3OOTc0Lxxpus+JbjQ4I5I72GJ5uZoJVZVYKf8AVSOVOWHDBTjtwaNQ0Zx3hbw54ig17RNR8Q2uq3LQLdWxZNQ2tErXCPC0g88702hsrukJwoO7ANbXjzRfEV3q17d+Ht0bPYQQCRJArvtuC0iL86EEoeu5euNwPI7DVtZsdI8k6hJNEkuQrrbyyIMY+8yKQnX+IjPOOhp2laxpmrkjSdSsr5h1W2nSRl+oUkj8aLvcLLY8r1LR/G7+HobW2i1SS4zcMkxu2ilgJC+WhAvvmXO4h3kkI6bMdbsmh+JrvWbCXVbPUbmWK/s7lZ1v1W1ihRE8xTD5gzIH3nOw5zw3QV6sQQcHg0Ucwcpw3w5sNcsbnUF1mLUTCyoY7i/ui8sjZbI8tZ5Y14wcr5ec424FdtKgkjKng9j6Gn0VLdylpsZlzBFc2lxa3in7PMAJQBkxsOjj6fqK8t1vTLnR79ra5XDD5lYch1PRgfSvYJotx3ocOPyNUdQ0+z1mwNlfL5br/qZ8fNCfTHdfala+h1qXN7y36nkUcpFW4Z+OGpfEGh3uhXhgvYyAeUlXlJB6g1nJJjsKi1ik09Ub0c4qXzvfNY0c1TLPx1oA0/Oz3pTLxWaJznnP508T7vUUElxpKaJOeKrbvfNO347UwLLS8YroPBGmi6vn1K6H+iWZBQHpJJ2H4dTWX4d0ebW74RKTFbJ8005HCL/iewr0GUx7IbOxj8m2hXag64Hdj7mqStqK3Np06gu64uWmk5AJOfVv/rVPSKoRQqjAHFLQYTlzO4UUUUyQrmdP/wCKa1ZNLfjRdQlP2Bu1rcNkm3PojnJT0Ylf4lA6aqmq6fbarp1xY30fmW86lHXofqD2IPIPYjNNOxLVy3RWJ4c1C5aSfSNXkL6tZKGMxGPtkBOFnH+1n5XHZuejLW9DHJNKsUKF5G6KKTVhp3IyQBk8CtnS9FkuNst0DHCeQvRm/wABWjpeix2zCW5xLMOQP4U+nqfetitY0+rMZ1ekRsaJEipGoVFGAB0FOoorUxCiiigAooooAKgms7ae4huJreGSeEMscjoCyBsBgpPIzgZx1xU9FAGOvhbw+t1Y3S6FpQubBFjtJRZx77dF+6sZxlAOwGMUy+8JeG9Qiiiv/D+kXMUTSNGk1lG4QyMWcgFeCxJJx1JJNbdFAGTYeG9D07U5tR0/RtNtdQmBEt1Baokrg9dzgZPTuaW88OaHe6g1/e6NptxfMgjNxLao8hUEELuIzgEA49RWrRQBk6l4a0LVIp49T0XTLyOeUTyrcWkcgkkChQ7Ag5YKAMnnAAqa40PSbnRRo9zpdjLpIRYxZSW6NAFUgqvlkbcAgYGOMCtCigDBm8GeF57G1spvDeiyWVqzNBbvYxGOEt1KLtwpOBnFPTwl4cj1G31CPw/pC39uqJDcrZRiWJVXaoVtuQAoAAB4HFbdFAGFY+FdLtpdVkmgW9k1O8W+uGu0STMihRGANoACBE29xjOc81u0UUAFFFFABRRRQAUUUUAFcf8AElSbGxbsJz/6Ca7CuU+I0ZbSLZx0S4XP4gioqfCy6fxI4GiiiuM7gprjinUHpQBLoMoh1F4mPyzrkf7w/wDrfyrR1XRbHVLiznu0m8+zcvDJDPJCyk9RlGBIOBkHIPcVz025Srx8SIQyn3FdbaTrdWscydHGceh71cGTNGTovhXR9FvDc6batFN5ZiXdPJIsSFtxSNWYiNc4OFAHApJvCmjzahNevbymaaeK6kUXMojaWMoUk8sNs3AxpzjJAwcjIrdoqrsiyMC68I6NcTGYwXEM5lkmM1tdzQSbpMb/AJ0cHB2r8uccDitHUdKs9S0ibTL+I3FlLF5UiO7EsuO7Z3Z985zznNXqKLhY5nUfA3h7UFjW4sZFjS2Sz2Q3U0KtChJVGVGAYDJxnNZo8AQv4t/taa5QWglnmWzhWZQXmjZHZt0zJkhmJKIhJOSa7iindisjDTwroyQNAtniJnt3K+a/3oNvlHr/AA7F+uOc81Sh8A+HIUmRLGYxy20tmY3vJ2RYZCC6IpchASB93GO2K6mildjshkUaxRJHGMIgCqPQCqOqaHpWrDGqabZXn/XeBXI/MVo0UAc+PCtpCB/Zt7qun46Lb30hjH0ictH/AOO0Cx8R2uTba5a3y9l1CxG4/wDAoWjAPvsP0roKKd2LlRgf2lr1tgXfh+O5UdW06+V2b/gEqxgfTcfrSf8ACW6dESNRh1LTT/092UgQfWRQ0Y/76roKKLhZ9ynpeqafqy7tK1Czvl7m1nSXH12k4qxNFvO4fLIOh/oaoanoGj6qwbU9LsbtxyHmgV2HuCRkVSPhaCEf8S3UtY0/0EN68iD6Ry70H4LRoxqUou6NR2Se2a2vYUuLUn54ZegPseoPuK5XVfAEVy7S+H7pRnkWly2GHsrdD+NaE1l4itGQxarY36t8rfbrLbI3/AomVR/37NV9EvtTS4On3ulIiwttM8F6JgARkEhkRgO3G6j1OyNqi5kmmcFqOmX2lTmK/tZbdx2dcZ+h6GqnmHvXvE91JFDFbSrHPHty8cy7wc9uaw7zR/Dd9Ntn0wQTEZP2aUr+O3pU8qElNq9rnlMb8djUqSDPNekDwf4czkLqH/fxf8Ks2+g+HrRgwsGmI/57zE/oMUuXzC0v5Tzm0jkuZlit4nkkboqLkmuw0rwcY9s+uuYh1FrGcyN/vH+EV1sd0scRh060jtYj1ECbc/U1CsDt/rDtHovU/jTskS9PidvzFEgEK2llDHBAvSNB8q+5PUmpYo1jXA5J6k9TSjZGAo2qOwzinDkZGCPamZTnfRaIKKKKCAooooAKKK0tI0p74iSTKW3qOr+w9vehK+iE2lqzA1Pw5e64sN1pLx2+qWDGW1uZQdm7GGibHJRx8rD056gV1ngbUbPVdFFxbWzWl0jmC8tpTmS3nXh42PfB6HoQQRwRW/FGkMaxxKFRRgAdq43xZbzeHNX/AOEu0yJ5INixazaxDJmgXO2dQOskX5smRyQtdEY2OaU+Zna0VFa3EN3aw3NrKk1vMgkjkQ7ldSMgg9wQalqiAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArG8Y25ufDt2qjLKokH/AAEg/wAhWzTZEWSNkYZVgQR7Umrqw07O54wOlFOmha3mlgcYeNyh/A02uE9AKKM0DFAEMwq/4bugkklo54P7yP8AqP61TkFVCWikWSI7ZEO5T70J2Y2ro7aioLK5S7tY54+jDp6HuKnrUyCiiigAooooAKKKKACiiigAooooAKKKKACiiigCG7/1S/74riPFN/Lpmr/aLZsP5Y3A9GHoa7a7PMa++fy//XXnPiqGbVPEn2K25diqA9lGOSfpzUs78LpDUv6J4g1jxPeSBI4bW2Q/vZ0Uk/RQT1/lXUW8UUAKW65Y/edjlmPqT/n2qGysodNs4bCyXYgHJ7+7H3NQanfm3cWliu64PBOM7f8AE0G1uiLly8MI3XU5UHooPX8BUwhhUbgoAxnOTVKw09YD9ouyZrs/xHnB9BWxFB0aXluoXsP8TQZ1Kkaa1EtVfBLFth+6GOT9aniR7hisR2oDgydfwH+NEUbXTlVJEKnDsO59B/WtONVjjCRgKoGBW0IX1Z5VWrd6EMdlbx8mJWb+843E/iaHsrd+VQRt/eTip8AnnP5U0jaQR37VtZHPdmdNG8EipIdwP3X9fY+9JU+osG8qP+IsG+gH/wBfioK55pJ6HRTba1CiitXRNLN6wmnBFsp4H/PQ/wCFJK7si20ldi6LpRuyJ7gYtx0U/wDLT/63866pQFUBQAAMACgAKAFAAHQClreMVE5ZScmFFFFUSc3oekxeELXVj9tVNARmu4LdkwLJcFpVDZ5jz8wXA25IGRgDxT4c/GTxBPretXHiaOWXS7/T7vVdEgltTbBVgLt5KybB5mYwGLAvjA75FfQmrpZSaVeLqsUU2nmFvtEc0fmI0eDuDLg5GM8Yrmom8Ka1f6NpI0ayu4hpZvrBpLKMxRWzbY9qBhlMqyjaFAxwfSgDz9vjlfJp9xdSeFbcCLRINeCjVCd1vI4Qr/qeHBPToRnkdKvaz8aJNP1HWli8PLPpukz6dFPOb7ZKy3iBlZY/LIJXOCC4z616S3hXw80TRnQdJMbWwsips48GAHIixj7gPIXp7VynjfUvCXhp9QS/8Kx34+xDU7821lbsBDB8sTSb2XcQRtQDcRjsBmgDB074pXa6pcaRb2E2oanc+JL/AEm1F9eRwwoluiuSZI4PlXDfKpV2POXNZ/hP4o694v8AiN4aj0y2htdD1DS5p57OeYbg8c5jeRX8oliNp2qCFYdSp4r1m78LeH7y0ntbvQtKntri4N3NDLZxskk56yspGC57seaydaHhfT/D2n69daDBJbaeYjZK2nLHNa75FVdiSBWiIJUkfKRj1FAHEfDz4p6n4ktNC03S9L+3avd2E2oyy6tqCwKI1uXhADw2+HbK9FjUAYyScmr/AMcNR1mLVvA+k6TI8VvqmqeVc+VqEtm8oVCfLMkal1U8klTngDHOR3Fz4M8L3VjbWVz4b0Waztd3kW8ljE0cW4ktsUrhckknHUmtS802xvZrSa8sra4ltH8y3eWJXaF8Y3ISPlOO4oA8V8B/ES80y+TS9SW41JtV8SavbR3Fxdtm2SAB1QAg5XnaACAP0psXxw82x0TxBcabewWd3o97qD2MNzFImYZjGASYQ5JxnIZQAeVavXbnwn4durcQXOgaTNB9oa78uSzjZfOb70mCMbz3bqadb+FvD9vFDHb6FpUUcMMlvEiWcahIpCS6KAOFYkkgcHPNAHnHwv8AEWta38V/FI1cm2g/sywuIdPivnuYYPMQtlcqoDEEZwvXuetel6dqd3d6lc20+halZQRbtl3cPbmKbDYGwJKzjI5G5V464PFJovhvQ9CeR9E0bTNNaRQjtZ2qQllBJAO0DIBJ/Ol8U63beG/Dmo61fJNJa2ED3EqQgFyqjJCgkDP1IoA4DXV16DxbrFgni/WvsUGjnU1iENmvz+ZIvl7hAGCYUDghv9rPNUNM+IGq2vhWxtdWspIb5LHSLlLm3vhM88dxcpATIZIjtfOSww2QThwcMPU44bC+ubqY2atOAbOWSa2KM6DnYCyjenzHplSSfemvoWkOqB9LsGCRxQqDbocJG2+NRx0VgGUdAeRg0Ac/4U8X3es+Ir7StR0pNLlgV5IopZZvPkRZNm/a0KxlTkHKSOBuAPPTC1T4g6jpR1N4NJlvbW21K5t57q5mdYLRI44mBYwW7sqnexyykDaxZ+grutJ8O6Jo11cXOkaPpthcXPM8trapE8vOfmKgFuSTzUOo+E/DmpuH1LQNIvHEjTBriyjkIkbG5+VPzHauT1O0elAGvBIs0EcqMrK6hgUbIIIzwe4p9AGBgdKKACiiigAooooAKKKKACiiigAooooA848dWRttZ88D93cKGz/tDg/0rlLq8htgvmtgudqqAWZj7AcmvVfGdgb3RZDGuZYD5i+px1H5V45eMtpqX2ucMYGiEYfGREQSST6Bsjn/AGea5KsbSOylK8Swb/apd7a5WMcltgP/AI6Du/SrcUqyIrxsGVhkEdCKzZrszMINPZXmcZMo+ZYgf4j6n0Hen2FxapFHDA37qPESMejEDoD36c1mamkeRVeVanBpkgyKQybQrv7Nd+Q5xFMeM9m/+vXT1w8qZBH+RXTaHem7tNsh/fxYV/f0NXF9CJLqaVFFFWSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU7yURvI7n5Ikyf1J/pXN+ErfzBdatOPnuWOw+iA/4/wAq0PFUxh0bUHX7zDYPxwKlsoBbaVa26DGEAP8AX9TUno0/dggurg2tlLcH/Wvwo/l/jUOi2X2aI3E/+uk556gf4mnXafadUggIzFCu9h79v6VqwKJJST91D+Z/+tQVOahG7JLeIg73HznoP7o/xqaKJro8ZEH8T/3vYf40QxG6laMEiJThyOrH+6P61pDA+VAAq8cVtCF9WeRVquT8wRVRMKAFUYAFSKPlzkbj+lMBNI7BBlyAB1J7Vscw9jwAOnrVe5uFhwMbpCMqg7/4Cqz3rSki2GF/56MP5DvUKqFJPJY8szHJNZyqW2NY029xRuLM8hBkbqR0+g9qWipLaF7m5jghGZH/ACA7k+1Y7m+yLOlWDX9zsORCmDIR6en412UaLGiogCqowAOwqDT7OOytlhi57sx6sfWrNbwjZHNOfMwoooqyAooooAo69p6atoeoadKsbJd28kBEi7lwykcjuOa8ji+EUtzoiWl9pHhq2lt9Bm06BbdmdBeNt2XXMS7WJUksAWB6E9a9Y8TXNzZ+HNVurAIbuG1lkh3ttXeEJGTg8Z9j9K8kh8aeK7N9L1i7srW82eFX1O6tl1N0ikVTGxmA8nHmkZG3bgZxvxQBb0r4Y6za/EK316+vIrxUuUuPtQukjnQCIIYjm1aR06jb56qQc7Qeup8RvhsfFOpa7f29vpP2u80NtOtZ7hP3kU5Z/n3BCVGx9uRzjIxipNJ+J82reLF02w8O38unC6W0lvFjnYxMYw+9sQmIICQMmbdznbiofHPirVfDHjXU721t0vtMsfD4vrm3mvmgVQs0m5o12MGkIAAB25xjd0oAX/hCtfTxPG8baWdGXxE2umZp5BcENAYzH5fl7eCSc7+R2Hfl4/hFraaTp1nPD4e1CeCy0+3S8uppPMsGt33SC3HlHIfHXKHJOc1v6z8US+sy6NbWI+zXSXVvDqEElwGimjt3kKvugWMONhBCSswPUekfh34jalp2hafBrmkpJJBplhfT3UeoGZvs0rCN5pMxgh1xvK5II3HdxyAb3xZ8H3fi2005bC00+4ntXkdTfzKIkLKACYnt5kk/EKR2YZNY2n+BPEVpq9lGW0ZtKh14a080ckiSnNuYzGsPl7VAYkj5+mOmOeqi8UPqHgDVvEMNs9vBHBdTWhSVS80UYbZKCVIXeF3AEMACM56VgWvxHvjqaW7aLG+nR3thp0t419++Ml1DFIrCIRBSAZQD8y9MgdgAVPDXwot7Cy8GwalZ6TcDTLOSHVBtLi7kKIqE7l/eKpU4D9BtwOBjGk+Emsy2F7bBtFtZ2s54Hv4pJGm1WV5kkje6Gwbduz1kPzHBA4PY+LNc1+1+IdlpWmLavpk2i3V1OstwYnVklhXzFxGxLKr8LuUNuOSu0E8l4e+KOpaF4F0Qa9pD3V4+i6fc200d5JcPdmVki3TYiLoxYhjtEhOeMnggGk3w61TXPFo1bxXaaFLZS6oL2ewWV7hDGti1uq/PEoc7yrcgDAP0rC134Ra5e+HF0zyvD+ot/Y502Br+aTGnSCWRllg/dNklHRT90jy1wSOK9L0HxZd6j4Q1LWL3RLqwubLzs2sySx+dsXcGQyxRuVYYGSg5zxxXG+KviVqkkWiQ+HbS1jurtNIvZGluhtEd1cbDCT5TYyAAXxkBywGQAQC7c/DI6l4je61qDS77TGv767NvODICJooUjypXBIMbE+nBGT04PVPBWr2F3o2l3emwa7qxXRkGom3uZGsBbvH5wimaExBG2OxJkRjuIKnKivQIfibfSeJZ9MHhi5lhtLg2d1c2/wBokWKURb2O77OIvLDELuMitghtg6VLpXxJuriDRLjUdEhsrfV9Hn1iBvt+8qkUcLlW/dgAnzTyCcBQSASVUA9IorzrQ/iLd6jq+jQXWix6dp2p28E0N3c3EoErSW4m2REQGNivK4aRGO1iFwOe+sbu2v7SG7sbiG5tZlDxTQuHR1PQqw4I9xQBPRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAARkEHoa8f8ZabPYalPbWrCJJTvjdlztUnnA9RyOa9grnfGmjtqdgskC5uICWUeo7is6keZGlKXLI8L1bT47IKliDbuQSZN53XLHP7vaDyT3bt29oZdW+xXKhbcT3MeEl2kCODPSJT0GO556fl10iGSJ0DsjEEbl4I+nvXL3VhBaXimQwKYlP2aNz+7gT+KV8/eYk/nXKvM7Gux0VleW14rNazJKqHaxQ5wetWSOKztK2i3ja2WZoWY7nlTDSscfvOe3Xt6Y4rTHSkMrSJUdtdPY3Kzx844Zf7w9KtMKrTx5FLYZ2FvNHcQJNCdyOMg1JXI6NqP8AZ85jnJ+yuef9g+v09a60HIBBBB7itE7mbVhaKKKoQUUUUAFFFFABRRRQAUUUUAFFFFAjmfFp/wCJaVP3XuUVvpurWbBlVewx/n9KyvFY/wBEX0F3GT+YrV/5ev8AgOak9OOsV8itYjM13Oe77R9BWnACtsNv3yu76k81n2oxZt6kuf1Naqf6tf8AdH8qEY4p6JFjR5I/sMeG553A9c9/1qxJLBGCzPgd8nArLeCJ33sg3eoODQlvCh3LGu71PJrf2umx5nstdyy+oFxi0jL/AO2eF/Pv+FQMrSnNw/mHrjGFH0H+NPoqHNs0jBIKKKqXt2IMIgDTEZC+g9TUFk8sqxFFPzSSMERB1ZicAV2mj6YmnwnJD3D/AOsk9fYe1eaW5Zb+3nkYvJ58ZJPYBhwPQV65WlLXUyraJIKKKK3OcKKKKACiiigBGUMpVgCpGCDyCKyLLwt4fsLeSCx0LSraCSJ4Xjhs40V43++hAGCrYGR0PetiigDIbwxoDatFqraHpZ1OEKI7w2kfnIAMAB8bhgcDnpS6t4a0LWL2C81bRdMvruAAQz3NpHLJGAcjazAkc88d61qKAMVvCfh1tVk1NtA0k6lISXuzZx+axKlTl8ZOVJHXoSKqy+CdBXw/qmj6Vp1rotrqURhuW0u3it2ZSCp6LjOCRkg4zxXSUUAVksLRNNXTxbRfYVh8gW5UFPL27dm08EY4x6VAuiaUucaZYjMsc5xbpzJGFEb9PvKFUA9QFGOgrQooAz9T0TStVntZtU0yxvZrVt9vJcW6SNC3HKFgdp4HI9KZL4f0aW1FrLpGnPbC2FmImtkKeQMYixjGwYHy9OOladFAFHSNH0zRrL7Fo+nWdhZli3kWsCxR5PU7VAGTWdD4L8LQWtzbQ+GtEjt7lQs8SWEQSUBtwDALhhnnnvzW/RQBiDwj4bF/Bejw9o4vYEWKK4+xR+ZGirtVVbbkALwAOg4qW/8ADOg6hY2dlf6Jpl1Z2QAtoJrSN44ABgBFIwuAABjHFa1FAGLbeFPDtrqMeoW2g6TDfxxiJLmOzjWVUC7AoYDIAUBcZ6DHStOxtLawtIbSxt4ba1hUJFDCgREUdAqjgD2FT0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHnHjbRjY3hvIBi2nbkAfcf/AOv1rjNW0yLU7cKyQecrKVeSPfgBgSPXBxjg969x1Gziv7KW2nGUkGPp6GvJby0lsb2W2nGJEOM/3h2Irmqw5XdHXSnzKzONh1QLDHez3Ecmo3RMcca5KwKOo2A5J6e5JAq9pGoNFMIbuS6nlnl2ruUERnH3cjHPc4zjOKd4itpLcG/s2ggl2+TLI0WSqsw+fI6EVS0iZY9Ujt7BYbwofLln3cInU7AMhRnuTlj69az6Gmx1LComGRip2FRsKkspTxZq1o2rNYYguSWtc/K3eP8AxFIyg1Wli9qV7Ba52sbrIgdGDKwyCOhFOri7C9uNPbEJ3w5yYm6fh6V02n6jBep+7bbIPvRtwwrRSuZuNi9RSA0tUSFFFFAwooooAKKKKACiiigDn/FgP9l3hH8GyT8iP8KuhszQsOjpUHiPDabqIPQQkfjil0399p9jLkgrGD/47gipPRpfAixEuBIn+0fyPNXbc7oIz/sgVTY7Z09HBB+o5/xqe2Yqzoen3l/r+v8AOmjPExvG/Ys0UUUziCiiigRBdz/Z4S2MueFHqayUU5ZmO52OWY9zUk8puJi/8I4Ue1OVeKhu5aViKUEREr1HI/CvWbeUT28cq/ddQw/EV5ZtyCOxrv8AwlP5+g22Tlo8xn8D/hitaL1sY1leKZsUUUV0HMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVgeLNGGp2fmQqPtUXKH19RW/RSaurMabTujxtlKkhlKsDgqex9K5zU7G4to0trC9e3iu7jYiKigoWyzHd1xwxx1zxXrfi3QTODeWaZlA/eIP4/ce9cDeWkV3AYpw2zIIKnaysOhB7EVySi4s7IyU0JZ2kdnaRwQAiNBgZOSfcn1p1PhzFAqSTNM4GDIwALfUDimGoNEJgVHInpUtFAFJ05qNo+QRkMOhHBFXXXmoitKxVyzZ6xcQELcjz4/7w4Yf41t2uoW1zxFKN391vlP5GuZKVG0YPUZpqTRLimdqGpciuTgvruDASYlR/C43Crya244ktwfdG/oarmJ5Gb2RS1if27bL98Sqf8Acz/Kp4tXjlXMEUkn5D+dPmQuVmpRWVJqFyV+SGKM/wC0xb+WKpy6jehv9Yo+iCncFFs6GonnUZCAu3oOn51jQ6pdgYfynPqVx/Km3M91cA5kEa46RjH60rlwgr+8ZfjS6jk0yfTExLJcgrMAeinrn61V8JeI5xpjWWsLLLf2G2OaXGWmjbPlzH13AFWP99Sf4hVpbFA5JXk96oazZT2kkOrWUDT3NmGEkCdbmBseZF9TgMvo6qfWiL6G86lrSj0NrU9Yja3Q2iuXDq+WGBxW3p08F/bLNC3Q8juh9DXMokM8MU9rIs9rOiywyqMCRGGVb247dulLDbTW83m2sjxP3K9/rS1TCVTnW52dFc6mpaknDeS/1TH8jUi6jftyRAo/3D/jT5jn9mzerL1G6ExNvC2VziRh/wCg/wCNZ0lzc3O5POYg8EoNqj/GrVvAI41VRgCle4uWw5FqZVpyrUirQAwLXVeBmxBeQ/3ZA2PqP/rVze2tjwe5TWJkzxJDnHqQf/r1pDSSM6msWdnRRRXScgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAEZHNcp4n8NLeBrixxFddT/AHX9j/jXV0UpRUlZjjJxd0eKTObe5e3uVMU6cMjU4HPStv4laej69BIV2+bBww9Qf/r1xjNd2LfOPMi/vCuOS5XY7oS5lc2KKqWt9FOvDYPpVoMDUlCkZqMjmpKQigBmKNtOApQKQyPy6Qx1YAoxTApPDURhIO5SVPqDitPbTTGDSsFyvBdzRHE371PyYf41oweVcIWhYN6juPqKqGAelRNagkNjkd+hp3A1RAP7tBtiemRWYsci9JJf++zT9rkYMkv/AH2adwuaH2U5qaO1OBmstRKpyk8w/wCBZ/nUwu7xejq3+8tO4m2ylpsC6Lrb6TIANPv2e4sG7RzcvNB9G+aVffzR6VvCBPSsDW4bjV9Oe2ZlhlDLLBcRg74JVIZJF9wwB/TpT9KvpdbsRPcgRXUTmC8tk+7DOoG4D1Ugh1J6qy+9U3dXIXuuxozTRKxWJfMcenQfU1AIWlP75twz90cAVZjhwAMcVMqVJVyKOJVHAqwi05UqVVpktjVWnhacFp2KYhuKu6A3l67anOA25T+Rqpin2reXqFpIeAsy5/PFNaMT2sehUUUV1HGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHHfEiHNrYzj+CQofxH/1q4evS/HMBm8N3JUZaIrIPwIz+ma80rlrL3jroO8SrNYwynIXY3qvFQi2uIv9XKHHoa0KKyNikJ5k/wBZGfwqeGcScYwampuxc5wM0AKKeKQdaeBQAAU4LSgU4CgBAtOC08CnAUxEYSneXntUoFOC07CIfL9qBFz0qyEpwQUWC5WEQ9Kd5IParQSlC07BcrLCB2rC1fGhaqmtZC6dMq2+pjsiZ/d3H1jLEN/sO390V1G2kkhSaJ4pUV43UqysMhgeoIprQl6oaYSjlWHIODTlSs/RNOubDRhp0tyXFvuitZ87nEP/ACzDZGCyD5c85CgnkmvK/DfjjxBfaxZaLfXiQ3mifbJtfuHjRUkjiOI+dpCq2RkqM4BIp8t9iea257OFp4WvJj8ZIoLfVpLnRy32KzjvIXt5pTHcq8ixjaZIYyBlh820g84JqzffES++13Fjc2Bsbqx1axsZTZ3qSrIJwT1eH7oxyAAT2Yd3yMXOj1IClxXmdj8Ummv7RLrR4rawuNQudOFyb3JR4RncylAApHfdxz173vBPxE/4STxPJo0mnxw5sft0F1BLK8UyBwh2+ZDGTyfvAFTzzxRysOZHfYqG7BFu5HUciq9vf3MupyWr6RfQwJnbeO8Bif6BZC/Puo6Vy+oQ6q3xAt9NTxHqSWNxY3F8YVitcKUliUICYS2zEjdSW4HNK1yr2PdLWTzbaKT++gb8xUleF+EPidqHh/wHpj6/pb3YbTJbu1uI7xp5bjy544Ssi+XlOZkwVL/KDxnivTvAniS88SWV5JqOjXOlTW8/lBZY51SZdoIdDNFE5HJByg5U9Rg11I42dNRXiPgP4lajpvgnRIfENtbvcy6HHf295PqEsrXR8yOLE22FnR2aRdu0SFunWprf4g61r+uaHPpmmJb3NvPqVpdWFzfTW0DmKOFw7M8IcYD8B4gQSeg5oA9oorzTS/imNSOkxQ6LKl3rEdlPp0Mk+PPimDGVydvHlCOQnGcgIeN/Gj8QvHk/hbVNP03T9Fn1W+u4JrkIizkBIyoIHkwysWJcdVCjuw4yAd1RXnTfEadvEcOhHRjb3tzaLfxmW7VGS3MRZt6FNyzKwx5WDkZbdgNjC8J+O/FV7DqN9FpaatZRaPpt7Dbm7H2ndPDuPEduAxJyWxjG35VOdoAPYqKwfBWvP4i0X7bNFbwTLK8MkMMkr+WynlW82KJ1b1UoMVvUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAVdUg+1abdQA4MkTKPqRXjsJJiUnr3r2yvINVtxaate26/djmYD6E5H86wrrZnRh3uirRRRXOdIUUUUAOFSAVGKlUUAOUU9RSAVIopiFApwFAFPApoQKKkApFFPApiFAp4FCinCgQAU4CinCmAmKUCnAUuKBDQK5jSb/AMO3+sQtpllA8+tWDXxu1tlT7RCrImJCQGJ/eLgEdM9K6eWJJonimRZI3BVkYZDA8EEdxXk2kfCt0sLW01LTdA2Wul3NmrRZbz7h/K2XDAxjDYRsnLEcYJ7UrEtvod4/g3QVsbq30/StP043MRheW1soA2wnOMMhUjI6MCPaqnhj4f6F4fiukjt1vGuLhLl2uYYsB0GEKoiKibecbVGM1i3Hw/urqy1g3Elm+o3MNslvO5ZipjiRJQSRlRJtZSV5Ktz6UzT/AAVrOm6jbapp1totq8F5LNHpUU8i20MbwCM7XEf3tw3kBFByR70/mL5HcJoGkIYymk6evlytcJi2QbZG+8444Y9z1NZ3g+y8Ov8Aab3QdEstPlhnnsHkitI4nJjlKuAV/hLJn34JFeWal4N1LTE07S59Nt9Yv3gsoorhbe4k+w7JiX8qTyjGobqcvGR3B4z3mh+ApdO8R2mrolglyNT1C6uZo8iSWCcyGOMnbzgshKk4BBIzRYL+R1kWqQP4huNHCS/aobWO7ZiBsKO7oADnOcxtnj0q4bOBrtbowRG5RDEsxQbwhIJUN1wSqkj2HpXE+OPAMviPVtVv0Swa4k0yG1sZZ877edJZXMgO07eHXDDng/jjy/DLVn8RaxfNcwS/a/tpiuDOiPtmjdVjkUWxdkXcBjzsDaCFGAtOyBtntHh3RdKk0iOCTS7FkhSW1VTboQsTkMyAY4VsLkdDgZ6VraJoek6DbPb6Hpdjptu7+Y8VnbpCrNgDcQoAJwAM+1eIap8JLzU/sq6YLIwRWghngM0cBE5xuuEke1nPmHaBvAR/lX5u1eleP/C95r9joccMNhqcdhcia40/VJSsF6vlOg3sqNkqzBxlCCR0HBGsdjCW4/wjovg7VfDcs+keF9KtdNvy8U9udPhQTeXIy4dVBDDcpIzntVm/8H+D4dPt7W58K6PJZCceXAmkpKiSSbU3bFQ7eigvgABckgDjzeT4X+J7Xw1cadpn9gmW+0OfR51e4liit988sqtGFiO4bZiuDtxgdeldFJ8Npma4uimnHUn8QW2pJcsWLJaxywO8YbbkE+STtHBO3J9KJO3Ph2xPiOz1kh/PsrR7O2hAURQo7KWKgDIYhEXrjC4AGTmbXNA0fX4ootd0nT9TiibdGl5bJMEPTIDA4NeR6j8Kryx0Ay2EllZ3wsdSTULi0WVpbrzZFkiU+WnmSAKpUgfMN2FBrf8Agpp8ttP4nvB4ft9Asbq6hFva29vJBGQkKqzKssUT8nqTGuTnGcZIB3a+HdEVQq6PpoUSrOALVMCRU2K/T7wUBQeoHHSq114P8M3fl/avDujTeXbraJ5ljE2yFekQyvCDsvSuB+Hfw+1/QPiBNr2qNo0cM1pPBOunBIxPI0qOjmNLePHCtne8jAnhuTXrdAFTS9NsdIsks9Ksraxs487ILaJYo1ycnCqABVuiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzXxzbmHxFJJjCzRK4PuOD/IV6VXGfEWMZsJMc/OpP5H/ABrOqrxNaLtI4min7aQiuQ7BtFLikxQA4dKlTpUSjipo6AJFFSrTFHFSAVRLHAU8CmqKkApgKBTwKQCngUEiinAc0gFPUUwACngUAU4CgQAU4ClApwFMRHJuEbmNQzgHapOAT6Z7VwEPxHFzYyTW2nxLLBHEk8c1w/7u7eRkNqBHE7u42OeFP8PHzceihaozaDpNzbXNvc6XYzW9zJ508UlujLLJx87gjDNwOTzwKat1E/I8/tvibcXunSS2Whxfara3u7m7iurxoFjS3k2MFJi3sxPZkXHfBq5beNr+fXJLDT9NW6uLi4SOJLm8EUcQNnHOcFYS2PmI53HPOQCANnxD8OdD1ywtrEW8Wn2cBkIhs7O2AJfG4gvExQ8dUKnnrkDHS2mhabbSxywafapMmCsoiG8EIIwd3XOwBc5zgY6VWhOp53dfFNIdP0y+h0xJobiCCe5iWWVpbXzZNgzthaMDqQXkTdg4HrpaZe3j/D7xhcvdXDXFvdausUpkJaMJLKECnqAoAAx0wMV1sng/w9O9u0+gaTI1soSAvZxsYlByAuR8o5PArXi0mzS2ntks7cW87O00QjUJIXJLlhjBLEknPXJzT06CuzzLTfGd+raZpepWZgvc6cxltrwTCSO4ZlHmF4vlb5CSo5IPD96fbeLvEuraj4Rn07SrC20/VXnBinvzvlCRsTnEB2gbdwwcngELXoumeE9C06HytP0TTLSLzVn2QWsca+Yv3XwB94dj1FXJvDGjXVlbWd1pGnTWls4kggktkZImHRlUjCnk8iqSJbOA+Ffi+8tY7Gz8QRRraXkd/cRalLfF2C28x3earKAihXGDvbhecV7DFIk0SSROrxuAyupyGB6EHuKyovD+keUsTaVYNEkcsSobdCqpL/rFAx0f+Id++a1Yo0hiSOJFSNAFVFGAoHQAdhVozY6iiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoo70UABrD8Y2wuNHZsfNE4cfy/rW4ahu4hNaSxsMhlIpSV1YcXZ3PKmgPpUZiNb8tpgkY6VXe19q5eU7FIxTGabsrWa19qjNtz0qeUrmM4JxUkamrht/anpb4osFyuqmpApqwICKeIaaQrkCrUgWphFT1i9qdhXIQtPC1OIqcIvaiwrkIX2p4SpxFUixU7CuV1SnqlWUhPpU6W/tTsJspiM1IIj6VeW29qlWD2quUnmM9YjUqw1fWD2qVYPanyk8xRSCp0gq6sI9KlWIelUokuRUSCp0hqwqCnhapIlsjWMCpAtOApadhXBaWkFLTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABooooAKZJnaQKfSMM0AYNxbfvDx1qs1r7VvSxgmoGirNxNFIwntPaomtPat8wio2gHpS5SuYwvsntSi09q2vIHpThbj0pcoc5iC19qUW2O1bf2f2pPs/tRyhzmMLf2pwt/atb7OPSl8j2o5Q5jLEHtThB7VpiD2pwgp8ocxmiD2qVIPatAQ1KkNPlE5FFLf2qykHtVpYxTwlUokuRWEPtThFVnbS4p2JuQCMU4JUuKXFFguRhacBTsUYpiEApaXFGKAEopaKAAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA0rmozGfSiigBDEfSmmFvSiilYdw8lvSnCI+lFFFguL5R9KTyj6UUU7BcPKPpR5J9KKKVguHlH0pfK9qKKLBccE9qcFoopiFxS4oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7495=[""].join("\n");
var outline_f7_20_7495=null;
var title_f7_20_7496="Medical management of Eisenmenger syndrome";
var content_f7_20_7496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of Eisenmenger syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7496/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7496/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7496/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7496/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7496/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7496/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7496/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/20/7496/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Centers specialized in the management of adult patients with congenital heart disease provide the optimal combination of clinical expertise, facilities for advanced diagnosis and therapy, structured care, and access to new and evolving therapies. Care of adults with congenital heart disease-related pulmonary arterial hypertension should be performed in centers that have shared expertise and training in both adult congenital heart disease (CHD) and pulmonary arterial hypertension (PAH) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The triad of systemic-to-pulmonary communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The diagnosis of Eisenmenger syndrome implies that the development of pulmonary arterial disease is a consequence of increased pulmonary blood flow, and requires exclusion of other causes of PAH.",
"   </p>",
"   <p>",
"    In the past, the management of patients with Eisenmenger syndrome was primarily conservative, with an emphasis on regular informed cardiovascular follow-up. Subsequent clinical research evaluated the use of therapies designed to improve patient survival and functional capacity. Pulmonary vasodilator therapy may improve hemodynamics and quality of life in some patients. Other important aspects of management include avoidance of high-risk situations outlined below, extreme caution when undertaking noncardiac surgery, and specific attention to hematologic issues. Heart and lung transplantation, or lung transplantation with repair of the cardiac defect, is appropriate in some patients with severe disease.",
"   </p>",
"   <p>",
"    Management of Eisenmenger syndrome patients includes treatment pertinent to all patients with cyanotic heart disease as well as recommendations specific to CHD-PAH and Eisenmenger syndrome. Issues specific to CHD-PAH and Eisenmenger syndrome will be reviewed here. Recommendations for patients with cyanotic heart disease (including those with Eisenmenger syndrome) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link\">",
"     \"Medical management of cyanotic congenital heart disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CARE OF PATIENTS WITH CHD-PAH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with congenital heart disease (CHD) and pulmonary arterial hypertension (PAH) should be seen by a CHD-PAH trained provider at least yearly. All planned interventions should be discussed with the provider.",
"   </p>",
"   <p>",
"    The following evaluation is recommended at least yearly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comprehensive evaluation of functional capacity and assessment of secondary complications",
"     </li>",
"     <li>",
"      For Eisenmenger syndrome patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hemoglobin, platelet count, iron studies, creatinine, and uric acid",
"     </li>",
"     <li>",
"      Digital oximetry, both with and without supplemental oxygen therapy. Oxygen-responsive hypoxemia should be investigated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with Eisenmenger syndrome should seek prompt attention for arrhythmias and infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Medication review",
"    </span>",
"    &nbsp;&mdash;&nbsp;All medication changes should be rigorously reviewed for potential impact on the systemic blood pressure, loading conditions, intravascular shunting, and renal or hepatic perfusion or function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     THINGS TO AVOID",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several situations that are associated with a markedly increased risk in patients with Eisenmenger syndrome and should therefore be",
"    <strong>",
"     avoided",
"    </strong>",
"    , particularly pregnancy, volume depletion, isometric exercise, and high altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in patients with Eisenmenger syndrome is associated with significant maternal and fetal morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Because of the high risk of maternal mortality, pregnancy is CONTRAINDICATED in women with Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Maternal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported rate of maternal mortality in Eisenmenger syndrome has ranged from 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,4-8\">",
"     2,4-8",
"    </a>",
"    ], a value that has not changed significantly in the past 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/4,5,7,8\">",
"     4,5,7,8",
"    </a>",
"    ]. The mortality risk cannot be predicted in an individual patient.",
"   </p>",
"   <p>",
"    The majority of maternal deaths occur during or in the first week after delivery but can occur during gestation, labor, or more than one week after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,4,6,8\">",
"     2,4,6,8",
"    </a>",
"    ]. The fixed pulmonary arterial resistance cannot accommodate to the hemodynamic fluctuations of labor, delivery, and the puerperium. Most deaths are due to thromboembolism, volume depletion, which can augment the right-to-left shunt and precipitate intense cyanosis, and preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,4,5\">",
"     2,4,5",
"    </a>",
"    ]. In addition, a sudden increase in systemic vascular resistance may fatally reduce cerebral blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fetal issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial fetal risk because of maternal cyanosis that increases during the course of pregnancy because the fall in systemic vascular resistance enhances the right-to-left shunt. Only 15 to 25 percent of pregnancies progress to term and at least 50 percent of infants are born prematurely [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,4,5,7,8\">",
"     2,4,5,7,8",
"    </a>",
"    ]. Spontaneous abortion occurs in 20 to 40 percent of pregnancies, at least 20 to 30 percent of infants born have intrauterine growth retardation, and perinatal mortality has ranged from 7 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,4-8\">",
"     2,4-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another issue in the fetus is recurrence of CHD. In a literature review of studies published between 1985 and 2007, recurrence was noted in 1 of 20 completed (&gt;20 weeks gestation) pregnancies in women with Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Contraception methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with severe CHD-PAH, especially those with Eisenmenger syndrome, and their partners should be counseled about the absolute avoidance of pregnancy in view of the high risk of maternal death, and should be educated regarding safe and appropriate methods of contraception.",
"   </p>",
"   <p>",
"    Given the risks associated with pregnancy, we recommend women with Eisenmenger syndrome use a nonreversible method of contraception, such as hysteroscopic sterilization [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This procedure is performed transcervically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12665?source=see_link\">",
"     \"Hysteroscopic sterilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An intrauterine device (IUD) is an option for acyanotic or mildly cyanotic women who want a reversible method of contraception and are at low risk of acquiring a sexually transmitted infection. IUD use in this setting is consistent with CDC guidelines. For women with valvular disease with pulmonary hypertension, the CDC concluded there is no restriction on the use of any contraceptive method, except estrogen-progestin contraceptives (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=see_link\">",
"     \"Insertion and removal of an intrauterine contraceptive device\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The levonorgestrel-releasing intrauterine device (Mirena&reg;) is the preferred IUD in this setting because it reduces menstrual blood loss by 40 to 50 percent and may induce amenorrhea.",
"     </li>",
"     <li>",
"      A copper-containing IUD is not recommended in cyanotic women with hematocrit levels above 55 percent because intrinsic hemostatic defects increase the risk of excessive menstrual bleeding, which is more common with the copper-containing IUD than the levonorgestrel-releasing IUD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another good option for these women is progestin-only contraception, such as depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) injections or the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/1/35863?source=see_link\">",
"     etonogestrel",
"    </a>",
"    implant (Implanon&reg;), which are highly effective reversible methods of contraception (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=see_link\">",
"     \"Etonogestrel contraceptive implant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For many of the alternative methods of contraception, the theoretical or proven risks usually outweigh the advantages of using the method (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination (estrogen-progestin) contraceptives (pill, patch, ring) are contraindicated because of the increased risk of thromboembolism and resultant risk of paradoxical embolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Barrier methods, such as condoms and diaphragms, have high &lsquo;typical use&rsquo; rates of failure (",
"      <a class=\"graphic graphic_table graphicRef70218 \" href=\"UTD.htm?12/56/13197\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tubal ligation, which is performed in an operating room under general or regional anesthesia, should be considered cautiously given the potential risks associated with even minor surgery. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Noncardiac surgery'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pregnancy termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with CHD-PAH who become pregnant should receive individualized counseling from cardiovascular and obstetric caregivers with expertise in the management of CHD-PAH and should undergo the earliest possible pregnancy termination after such counseling.",
"   </p>",
"   <p>",
"    Termination in the first trimester appears to be safer than allowing pregnancy continuation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/11\">",
"     11",
"    </a>",
"    ]. Dilation and curettage in the first trimester is the choice of most experts. Prostaglandin F2 alpha should be AVOIDED due to reports of arterial oxygen desaturation in pregnant patients with pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Second or third trimester termination may carry a risk equal to or greater than continuation of pregnancy, but may be reasonable after the risks of termination are balanced against the risks of continuation of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ]. For the patient who chooses to continue with pregnancy, ongoing consultation with a congenital heart disease specialist and hospitalization at 20 weeks are advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Management of pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    beginning at 20 weeks of pregnancy has been recommended by some because of the increased risk of thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. However, the risk of exacerbating the intrinsic hemostatic defects appears to far outweigh any theoretical benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Hemostasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The routine insertion of pulmonary artery catheters is CONTRAINDICATED in Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. These catheters provide no useful data, have a high potential for hemorrhagic and other complications, and do not improve maternal outcome.",
"   </p>",
"   <p>",
"    Both cesarean and vaginal delivery in women with Eisenmenger syndrome are associated with maternal cardiovascular risk; selection of the most appropriate method of delivery should be individualized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The recommended approach is controlled vaginal delivery, with narcotic epidural analgesia and vacuum extraction or low forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,18\">",
"     2,18",
"    </a>",
"    ] or scheduled cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supplemental oxygen should be given because of its beneficial effects on pulmonary vascular resistance and shunt flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. Peripartum hypotension should be treated promptly with fluids and pressors to prevent an increase in the right-to-left shunt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Endocardial pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pacing via an endocardial lead is NOT recommended in patients with congenital heart disease-related pulmonary arterial hypertension (CHD-PAH) with persistent intravascular shunting. Alternative access (epicardial) for pacing should be considered on an individual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Volume depletion, exercise, and excessive heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion, moderate to severe strenuous (particularly isometric) exercise, and vasodilatation (hot tubs, hot baths or showers, excessive alcohol) should be AVOIDED in patients with Eisenmenger syndrome because the associated fall in systemic vascular resistance can result in an increase in the right-to-left shunt with subsequent reduction in cerebral blood flow and possible cardiovascular collapse due to reduced cardiac output. This recommendation is consistent with the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines on the management of adults with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Special management is imperative around the time of any invasive procedure, including angiography. We recommend preprocedural hydration and special postprocedural care and follow-up, ideally with the assistance of a cardiologist with expertise in the management of adults with congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Noncardiac surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     High altitude",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Eisenmenger syndrome should AVOID high altitude because the low oxygen tension leads to further desaturation. The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend avoidance of chronic high-altitude exposure (particularly an elevation greater than 5000 feet above sea level) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that it is safe for Eisenmenger patients to travel in commercial airlines as long as the airplanes are adequately pressurized [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Supplemental oxygen should be available, although its efficacy is unproven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;As for other patients with cyanotic heart disease, iron deficiency should be avoided in Eisenmenger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=see_link&amp;anchor=H4#H4\">",
"     \"Medical management of cyanotic congenital heart disease in adults\", section on 'Erythrocytosis and anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Air emboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of air embolism in Eisenmenger patients, the 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend exclusion of air bubbles in intravenous tubing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ]. Meticulous care of intravenous lines is important and filters should be placed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=see_link\">",
"     \"Air embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PULMONARY ARTERY THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In situ thrombosis of the pulmonary trunk and its proximal branches has been identified by computed tomography in some patients with Eisenmenger syndrome. In two reports, significant proximal pulmonary artery thrombus was seen in 21 and 29 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Some patients may also have distal arterial thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/22\">",
"     22",
"    </a>",
"    ]. Pulmonary parenchymal findings included embolic infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structural and functional changes in the pulmonary vasculature probably play a role in the development of in situ pulmonary artery thrombosis. The large arteries dilate and become aneurysmal, contributing to stasis and thrombus formation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, endothelial damage due to increased shear stress, increased blood viscosity, and hypoxemia may all contribute to a prothrombotic state [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The consequences of pulmonary artery thrombosis in Eisenmenger syndrome are not clearly established. Massive thrombosis can lead to asphyxic death and augmented right-to-left shunts by increasing flow resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/21\">",
"     21",
"    </a>",
"    ], while the presence of more distal thrombosis and intraparenchymal infarction raises concern that pulmonary artery thrombosis may contribute to the progression of pulmonary vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONCARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any surgical procedure, even if relatively minor, is potentially life-threatening in patients with Eisenmenger syndrome and is associated with a perioperative mortality of up to 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/2\">",
"     2",
"    </a>",
"    ]. The risk is especially increased when the operation is lengthy and associated with hemodynamic instability necessitating large-volume fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgery or cardiac catheterization should be performed only at a center with expertise in the management of Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ]. In emergent or urgent situations in which transportation is not feasible, caregivers in centers with expertise in the care of patients with Eisenmenger syndrome should be consulted throughout care. A multidisciplinary approach is imperative and should include involvement of a senior cardiac anesthesiologist, an experienced surgeon, and a cardiologist experienced with the care of Eisenmenger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The preoperative clinical assessment should include routine laboratory evaluation. The ideal hematocrit for the Eisenmenger patient undergoing noncardiac surgery is uncertain, but is likely to be less than 65 percent. In patients with higher values, preoperative phlebotomy may improve the coagulation status. The phlebotomized blood should be preserved for potential transfusion.",
"     </li>",
"     <li>",
"      Volume depletion should be avoided before, during, and after surgery.",
"     </li>",
"     <li>",
"      After surgery, patients should be transfused if the hematocrit is inappropriately low for the oxygen saturation.",
"     </li>",
"     <li>",
"      Intraoperative and early postoperative cardiac rhythm monitoring is suggested. In most cases, an intraarterial line and pulse oximetry provide sufficient information regarding systemic hemodynamics and oxygenation. Swan-Ganz monitoring is seldom necessary and should be avoided, if possible, because of a high potential for hemorrhagic and other complications [",
"      <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A fall in systemic blood pressure should be avoided to prevent an increase in the right-to-left shunt. If the systemic blood pressure does fall, it is better managed with volume repletion than vasopressors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precautions should be taken against paradoxical air emboli. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Air emboli'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early ambulation and perioperative deep venous thrombosis prophylaxis are recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADVANCED THERAPY FOR PULMONARY HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin-1 triggered smooth muscle constriction results in diffuse vasoconstriction in the pulmonary arterial bed in Eisenmenger syndrome. Thus, the use of advanced therapy to promote pulmonary vasodilation is conceptually appealing.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    , a dual endothelin receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    , a prostacyclin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , a phosphodiesterase-5 inhibitor, have been evaluated in limited numbers of patients with Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/27-32\">",
"     27-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data come from the BREATHE-5 trial in which 54 patients with World Health Organization functional class III Eisenmenger syndrome were randomly assigned to 16 weeks of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary safety end point, systemic pulse oximetry (systemic arterial blood oxygenation), did not worsen on therapy.",
"     </li>",
"     <li>",
"      The primary efficacy end point, pulmonary vascular resistance index, fell significantly by 472 dynes-sec-cm(-5), and the mean pulmonary artery pressure fell by 5.5 mmHg.",
"     </li>",
"     <li>",
"      A secondary efficacy end point of exercise capacity increased significantly by 53 meters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar beneficial effects on pulmonary vascular resistance, mean oxygen saturation, and exercise tolerance were noted in smaller observational studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/29,30\">",
"     29,30",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/28\">",
"     28",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that pulmonary vasodilator therapy may be beneficial for patients with Eisenmenger physiology because of the potential for improvement in quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A later retrospective study assessed the relationship between advanced therapy and mortality in 229 patients with Eisenmenger syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/32\">",
"     32",
"    </a>",
"    ]. Sixty-eight patients (30 percent) received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    . During median follow-up of 4 years, 52 patients died, only two while receiving advanced therapy. Patients on pulmonary vasodilator therapy had a lower risk of death after adjustment for baseline clinical differences by propensity score regression adjustment (hazard ratio, 0.16; 95% confidence interval 0.04 to 0.71) or propensity score matching (hazard ratio 0.10; 95% CI 0.01 to 0.78).",
"   </p>",
"   <p>",
"    The general role of advanced therapy in pulmonary hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart and lung transplantation or lung transplantation with intracardiac repair are treatment options in Eisenmenger patients. Transplantation should be reserved for severely symptomatic patients, since overall survival with medical management is usually quite good even in patients with severe pulmonary arterial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/3,33\">",
"     3,33",
"    </a>",
"    ]. In one report of 37 patients with Eisenmenger syndrome and severe pulmonary arterial hypertension (PAH), the one and three year survival rates were 97 and 77 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes are also reasonably good in patients who undergo transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The largest transplantation experience comes from a review of 605 Eisenmenger patients in the United Network for Organ",
"    <span class=\"nowrap\">",
"     Sharing/International",
"    </span>",
"    Society for Heart and Lung Transplantation joint thoracic registry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/34\">",
"     34",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eisenmenger syndrome was associated with atrial septal defect in 171, ventricular septal defect in 161, multiple congenital anomalies in 68, and patent ductus arteriosus in 32. The most common procedure was heart-lung transplantation (430 patients) compared to 106 bilateral and 69 single lung transplants.",
"     </li>",
"     <li>",
"      Patient survival was greater with heart-lung transplantation compared to isolated lung transplantation (81 versus 68 percent at 30 days and 70 versus 55 percent at one year). The benefit of heart-lung transplantation was greatest in patients with a ventricular septal defect as the cause of Eisenmenger syndrome, while the outcomes were worst in patients with an atrial septal defect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longer term follow-up was provided in a series of 51 patients with Eisenmenger syndrome who underwent heart-lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/35\">",
"     35",
"    </a>",
"    ]. Eight patients (16 percent) died early and the one, five, and ten-year survival rates were 73, 51, and 28 percent, respectively. These outcomes were the same as those in patients undergoing heart-lung transplantation for other indications.",
"   </p>",
"   <p>",
"    Despite the potential limitations of registry data, heart-lung transplantation appears to be the preferred procedure, particularly in patients with unsuccessfully repaired or uncorrectable lesions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severely depressed left ventricular function. However, the choice of procedure in an individual patient must take into account other factors. Advantages of isolated lung transplantation include shorter time on cardiopulmonary bypass and better use of the limited supply of donor organs, since the cardiac defects in the native heart can be repaired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of donor organs can be further optimized with single lung transplantation, which may be associated with late reversal of arteriopathy in the remaining native lung. However, cardiac repair with bilateral lung transplantation has a more manageable postoperative course and greater functional reserve than single lung transplantation. At the least, heart-lung transplantation is warranted if the cardiac repair is not straightforward. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with congenital heart disease who may require lung or heart-lung transplantation should be evaluated and managed in tertiary care centers with medical and surgical personnel with experience and expertise in the management of congenital heart disease and lung or heart-lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6801610\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The triad of systemic-to-pulmonary cardiovascular communication, pulmonary arterial disease, and cyanosis is called Eisenmenger syndrome. The diagnosis of Eisenmenger syndrome implies that the development of pulmonary arterial disease is a consequence of increased pulmonary blood flow, and requires exclusion of other causes of PAH. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with congenital heart disease (CHD) and pulmonary arterial hypertension (PAH) should be seen by a CHD-PAH trained provider at least yearly. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several situations that are associated with a markedly increased risk in patients with Eisenmenger syndrome and should therefore be avoided, particularly pregnancy, volume depletion, isometric exercise, high altitude, and endocardial pacing. Iron deficiency may be present in patients with Eisenmenger syndrome, resulting in relative anemia even in the face of elevated hemoglobin levels, and must be managed with care. Meticulous care of intravenous lines is required to avoid the risk of air emboli. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Things to avoid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any surgical procedure, even if relatively minor, is potentially life-threatening in patients with Eisenmenger syndrome. The risk is especially increased when the operation is lengthy and associated with hemodynamic instability necessitating fluid resuscitation. Surgery or cardiac catheterization should be performed only at a center with expertise in the management of Eisenmenger syndrome. In emergent or urgent situations in which transportation is not feasible, caregivers in centers with expertise in the care of patients with Eisenmenger syndrome should be consulted throughout care. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Noncardiac surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advanced therapy for pulmonary hypertension to promote pulmonary vasodilation in patients with Eisenmenger syndrome may improve quality of life and retrospective data suggest a survival benefit. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Advanced therapy for pulmonary hypertension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heart and lung transplantation or lung transplantation with intracardiac repair are treatment options for severely symptomatic Eisenmenger patients. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/1\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/2\">",
"      Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/3\">",
"      Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/4\">",
"      Gleicher N, Midwall J, Hochberger D, Jaffin H. Eisenmenger's syndrome and pregnancy. Obstet Gynecol Surv 1979; 34:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/5\">",
"      Yentis SM, Steer PJ, Plaat F. Eisenmenger's syndrome in pregnancy: maternal and fetal mortality in the 1990s. Br J Obstet Gynaecol 1998; 105:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/6\">",
"      Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998; 31:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/7\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/8\">",
"      B&eacute;dard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/9\">",
"      Mi&ntilde;o M, Arjona JE, Cord&oacute;n J, et al. Success rate and patient satisfaction with the Essure sterilisation in an outpatient setting: a prospective study of 857 women. BJOG 2007; 114:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/10\">",
"      Famuyide AO, Hopkins MR, El-Nashar SA, et al. Hysteroscopic sterilization in women with severe cardiac disease: experience at a tertiary center. Mayo Clin Proc 2008; 83:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/11\">",
"      Elkayam U, Gleicher N. Cardiac problems in pregnancy. I. Maternal aspects: the approach to the pregnant patient with heart disease. JAMA 1984; 251:2838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/12\">",
"      Hankins GD, Berryman GK, Scott RT Jr, Hood D. Maternal arterial desaturation with 15-methyl prostaglandin F2 alpha for uterine atony. Obstet Gynecol 1988; 72:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/13\">",
"      Kelion AD, Webb TP, Gardner MA, et al. The warm-up effect protects against ischemic left ventricular dysfunction in patients with angina. J Am Coll Cardiol 2001; 37:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/14\">",
"      Avila WS, Grinberg M, Snitcowsky R, et al. Maternal and fetal outcome in pregnant women with Eisenmenger's syndrome. Eur Heart J 1995; 16:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/15\">",
"      Pitts JA, Crosby WM, Basta LL. Eisenmenger's syndrome in pregnancy: does heparin prophylaxis improve the maternal mortality rate? Am Heart J 1977; 93:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/16\">",
"      Kahn ML. Eisenmenger's syndrome in pregnancy. N Engl J Med 1993; 329:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/17\">",
"      Robinson S. Pulmonary artery catheters in Eisenmenger's syndrome: many risks, few benefits. Anesthesiology 1983; 58:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/18\">",
"      Midwall J, Jaffin H, Herman MV, Kupersmith J. Shunt flow and pulmonary hemodynamics during labor and delivery in the Eisenmenger syndrome. Am J Cardiol 1978; 42:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/19\">",
"      Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart 2007; 93:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/20\">",
"      Harinck E, Hutter PA, Hoorntje TM, et al. Air travel and adults with cyanotic congenital heart disease. Circulation 1996; 93:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/21\">",
"      Perloff JK, Hart EM, Greaves SM, et al. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003; 92:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/22\">",
"      Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/23\">",
"      Altman R, Scazziota A, Rouvier J, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 1996; 19:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/24\">",
"      Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/25\">",
"      Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol 1999; 33:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/26\">",
"      Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/27\">",
"      Gali&egrave; N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/28\">",
"      Christensen DD, McConnell ME, Book WM, Mahle WT. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004; 94:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/29\">",
"      Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/30\">",
"      Fernandes SM, Newburger JW, Lang P, et al. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol 2003; 91:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/31\">",
"      Chau EM, Fan KY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007; 120:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/32\">",
"      Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/33\">",
"      Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/34\">",
"      Waddell TK, Bennett L, Kennedy R, et al. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7496/abstract/35\">",
"      Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001; 72:1887.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1426 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-77.94.48.4-BBE44F2A81-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7496=[""].join("\n");
var outline_f7_20_7496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6801610\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CARE OF PATIENTS WITH CHD-PAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Medication review",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      THINGS TO AVOID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Maternal issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fetal issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Contraception methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pregnancy termination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Management of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Endocardial pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Volume depletion, exercise, and excessive heat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      High altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Air emboli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PULMONARY ARTERY THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONCARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADVANCED THERAPY FOR PULMONARY HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6801610\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1426\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1426|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13197\" title=\"table 2\">",
"      Pregnancy rate during first year of contraception",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38664?source=related_link\">",
"      Air embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=related_link\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12665?source=related_link\">",
"      Hysteroscopic sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/29/34265?source=related_link\">",
"      Insertion and removal of an intrauterine contraceptive device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39478?source=related_link\">",
"      Medical management of cyanotic congenital heart disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_20_7497="Epidemiology and molecular mechanisms of drug-resistant tuberculosis";
var content_f7_20_7497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7497/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7497/contributors\">",
"     Neil W Schluger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7497/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7497/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7497/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7497/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/20/7497/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, and resistance to commonly used anti-tuberculous drugs is increasing. &nbsp;",
"   </p>",
"   <p>",
"    Drug-resistant tuberculosis was recognized shortly after the introduction of effective chemotherapy in the late 1940s.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    was the first drug to be used widely. Patients who received this drug usually had marked and rapid clinical improvement, but treatment failures were common after the first three months of therapy. Isolates of M. tuberculosis obtained from patients with treatment failure were invariably streptomycin-resistant. The rapid development of resistance to single agent therapy led to the principle of multiagent chemotherapy of TB that remains the cornerstone of treatment.",
"   </p>",
"   <p>",
"    The epidemiology and molecular basis of drug-resistant TB will be reviewed here. The diagnosis and treatment of drug-resistant strains of Mycobacterium tuberculosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=see_link\">",
"     \"Diagnosis, treatment, and prevention of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a series of definitions used in describing the different types of drug-resistant TB:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"drug-resistant TB\" refers to cases of TB caused by an isolate of M. tuberculosis that is resistant to one of the first-line anti-TB drugs:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The term &ldquo;multidrug-resistant TB&rdquo; (MDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and possibly additional chemotherapeutic agents.",
"     </li>",
"     <li>",
"      The term &ldquo;extensively drug-resistant TB&rdquo; (XDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and fluoroquinolones, as well as either aminoglycosides (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"       kanamycin",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/59/11189?source=see_link\">",
"       capreomycin",
"      </a>",
"      , or both [",
"      <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The term &ldquo;totally drug-resistant TB&rdquo; (TDR-TB) refers to an isolate of M. tuberculosis resistant to all locally tested medications [",
"      <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. However, the published studies initially describing TDR-TB did not including susceptibility testing for less frequently used agents with activity against TB, including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"       cycloserine",
"      </a>",
"      , terizidone, clofazimine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      or carbapenems. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34743?source=see_link&amp;anchor=H2#H2\">",
"       \"Epidemiology of extensively drug-resistant tuberculosis\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary drug resistance is said to occur in a patient who has never received anti-TB therapy.",
"     </li>",
"     <li>",
"      Secondary drug resistance refers to the development of resistance during or following chemotherapy in patients who had previously had drug-susceptible TB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Drug-resistant tuberculosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Worldwide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precise information about the global incidence of drug-resistant TB is difficult to obtain, since routine sputum culture and drug susceptibility testing are not always performed in resource limited settings where the disease occurs most frequently. Despite these limitations, surveys of worldwide drug-resistance have indicated that drug-resistant TB is a large and increasing problem [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In 2009 the World Health Organization estimated there are at least 500,000 cases of MDR-TB in the world annually; it likely that &le;30,000 are treated appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/6\">",
"     6",
"    </a>",
"    ]. China [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/7\">",
"     7",
"    </a>",
"    ], India, and Russia (and the countries of the former Soviet Union), are estimated to carry the highest number of MDR-TB cases. China and India have approximately 50 percent of the global burden of MDR-TB cases; the Russian and the former Soviet Union have 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/4,5,8-15\">",
"     4,5,8-15",
"    </a>",
"    ]. While there has been a focus on cases arising in Russia and the former Soviet Union, MDR-TB occurs worldwide. As improved culture and drug susceptibility testing becomes increasingly available around the world, MDR-TB will likely be recognized as the major threat to global tuberculosis control efforts over the next several decades.",
"   </p>",
"   <p>",
"    Many MDR cases are reported in individuals who have not received prior treatment, although a history of prior treatment (especially if incomplete or unsupervised) is probably the greatest single risk factor for the presence of MDR-TB in a given patient. The presence of initial drug resistance substantially reduces treatment outcomes, since in general most TB treatment approaches rely on standardized rather than tailored treatment regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one study including data from 103 countries where standardized regimens are used, failure and relapse rates were significantly higher in regions where the initial multidrug resistance prevalence was &ge;3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/17\">",
"     17",
"    </a>",
"    ]. In these areas, retreatment was required in more than 20 percent of cases. High rates of MDR TB among patients requiring retreatment have also been described; in one survey from the Philippines, MDR TB was observed 76 percent of retreatment cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 2002 and 2006, among more than 62,000 M. tuberculosis isolates surveyed from 81 countries, multidrug-resistant isolates represented 5.3 percent of all new and previously treated TB cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/4\">",
"     4",
"    </a>",
"    ]. Based on this data, the World Health Organization (WHO) and the International Union against TB and Lung Disease (IUATLD) estimated that approximately 490,000 cases of TB emerged in 2006, and that the global proportion of any drug resistance was 4.8 percent.",
"   </p>",
"   <p>",
"    In addition, the survey noted that among new TB cases in 72 countries, primary resistance to at least one drug ranged from 0 percent (Iceland) to 56 percent (Azerbaijan) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/4\">",
"     4",
"    </a>",
"    ]. Among previously treated TB cases in 66 countries, resistance to at least one drug ranged from 0 percent (in three European countries) to 86 percent (Uzbekistan). The locales with the highest rates of MDR-TB were Tashkent, Uzbekistan (60 percent) and Baku, Azerbaijan (56 percent). Rates of MDR-TB are increasing in Peru, the Republic of Korea, and parts of the former Soviet Union (Orel and Tomsk). Only six countries in Africa (Cote d'Ivoire, Ethiopia, Madagascar, Rwanda, Senegal, and the United Republic of Tanzania) provided survey data; rates of MDR-TB ranged from 0.7 percent in Madagascar to 3.9 percent in Rwanda.",
"   </p>",
"   <p>",
"    Some resistance data for other countries in Africa has been reported. In Botswana, the rate of drug resistance is increasing, despite implementation of 100 percent coverage of DOTS strategy in 1986. In a 2002 survey of drug resistance among isolates from 1182 patients with newly diagnosed TB, rates of monoresistance and MDR-TB were 10.4 and 0.8 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/19\">",
"     19",
"    </a>",
"    ]. Among 106 patients previously treated for TB the respective rates were 22.8 and 10.4 percent. In Uganda, the burden of drug resistance in previously treated patients with TB is also sizeable. Among 410 patients enrolled between 2003 and 2006, the prevalence of MDR-TB was 12.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of short-course, directly observed therapy (DOT) with a standard four-drug regimen was evaluated by the WHO retrospectively in six geographically distinct countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/21\">",
"     21",
"    </a>",
"    ]. Not surprisingly, Treatment failures were higher among new multidrug-resistant TB cases than among new susceptible cases (10 versus 0.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7697855\">",
"    <span class=\"h3\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substantial drug resistance began emerging in regions of the United States in the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/22\">",
"     22",
"    </a>",
"    ]. The prevalence of drug-resistant TB in the United State decreased between 1991 and 2006 (3.5 to 1.1 percent) and remained stable between 2005 and 2006 (1.2 percent), even as drug-resistant disease increases worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Improvements in hospital infection control measures, the widespread use of an initial four-drug chemotherapy regimen, and directly observed therapy have resulted in a substantial drop in the incidence rates of drug-resistant TB in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single drug resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (the most common type of drug resistance in the United States) occurred in 7.7 percent of cases in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/28\">",
"     28",
"    </a>",
"    ]. The overall rate has remained essentially stable since 1995 but is variable by region; rates of isoniazed resistance ranged from 4.7 percent in Texas to 14.3 percent in New York State [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multidrug resistance decreased between 1993 and 2006 (2.4 to 0.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/28\">",
"     28",
"    </a>",
"    ]. MDR-TB disproportionately affects foreign-born individuals; this group accounted for 85 percent of cases of MDR-TB in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/24\">",
"     24",
"    </a>",
"    ]. MDR-TB cases accounted for 0.4 percent of cases occurring in individuals born in the United States and 1.3 percent of individuals born outside the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In New York State in 1991 MDR-TB accounted for 13 percent of isolates, and New York City alone was responsible for nearly 60 percent of all cases of MDR-TB in the United States. The rate of MDR-TB in New York City in 1991 was 52.4 times higher than the rest of the country where the overall incidence was 3.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/23\">",
"     23",
"    </a>",
"    ]. Since then, the rate of MDR-TB has decreased substantially in New York City; in 2006 2.2 percent of isolates were multidrug resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An exception to the general decrease in the prevalence of MDR-TB in the United States has been in California. Between 1994 and 2003, total TB cases in California declined 33 percent, although in 2003 the state reported the largest number of cases of MDR-TB in the nation and the proportion of California MDR-TB cases of MDR-TB has not decreased (1.5 percent in 2006) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/28,30\">",
"     28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Migration of individuals with TB can alter the prevalence and resistance patterns. Among 10,000 Hmong refugees resettled from Thailand into the United States from June 2004 through January 2005, 37 were found to have active TB, including 4 with MDR-TB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/31\">",
"     31",
"    </a>",
"    ]. Among the 6000 refugees still awaiting emigration from Thailand, TB was identified in 6 percent of individuals; of these, MDR-TB was observed in 6 percent of cases, half of which were smear negative [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/32\">",
"     32",
"    </a>",
"    ]. As a result, enhanced screening for all immigrants and refugees entering the US was implemented by the Centers for Disease Control, beginning with high-priority countries as determined by TB prevalence and immigration patterns.",
"   </p>",
"   <p>",
"    At the peak of the HIV epidemic in the United States, HIV infection was associated with MDR-TB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/22\">",
"     22",
"    </a>",
"    ]. Subsequently, a 2007 review of published studies and surveillance data noted that MDR-TB does not appear to cause infection or disease in HIV-infected individuals more readily than drug-susceptible strains, although HIV infection and MDR-TB may converge in some countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extensively drug-resistant tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of extensively drug-resistant tuberculosis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34743?source=see_link\">",
"     \"Epidemiology of extensively drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FACTORS LEADING TO DEVELOPMENT OF RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each patient with tuberculosis (TB) harbors is a mixed population of organisms with naturally occurring resistance to various drugs. Selection for resistant organisms will occur if only one drug is used in treatment, since approximately 1 in 10(6) to 10(8) organisms exhibits intrinsic resistance to any given drug. The chance that an organism in a population is resistant to two drugs is roughly 1 in 10(14), making resistance much less likely to emerge with combination therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of MDR-TB is favored by an inadequate course of treatment. In the United States, development of MDR-TB reflects poor physician prescribing practices, poorly supervised treatment programs, and poor infection control programs in hospitals and prisons. The HIV epidemic has fueled the spread of MDR-TB by creating a large reservoir of immunosuppressed persons who are more likely to develop active, communicable disease following infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following factors were associated with MDR-TB in the United States in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous TB diagnosis",
"     </li>",
"     <li>",
"      Positive acid-fast bacilli sputum smear",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Asian/Pacific",
"      </span>",
"      Islander ethnicity",
"     </li>",
"     <li>",
"      Time in the United States &lt;5 years at diagnosis",
"     </li>",
"     <li>",
"      An outcome of \"died\" or \"moved\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inappropriate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Thoracic",
"    <span class=\"nowrap\">",
"     Society/Centers",
"    </span>",
"    for Disease Control and Prevention",
"    <span class=\"nowrap\">",
"     (ATS/CDC)",
"    </span>",
"    guideline recommended initial treatment with four-drug therapy in areas where the rate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    resistance exceeds 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/34\">",
"     34",
"    </a>",
"    ]. Nonetheless, one 1995 report noted that approximately 25 percent of new TB cases were initially treated with two or three drug regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prescribing errors by physicians inexperienced in the care of patients with TB can exacerbate problems associated with drug-resistance. One review of patients referred to the National Jewish Hospital in Denver for management of complex MDR-TB noted an average of nearly four prescribing errors per patient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/35\">",
"     35",
"    </a>",
"    ]. This highlights the need for expert management of drug-resistant TB in all cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study in New York City documented that inner city patients with high rates of alcohol and drug abuse discharged from the hospital were unlikely to adhere to TB treatment regimens; among 178 patients, only 11 percent complied with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/36\">",
"     36",
"    </a>",
"    ]. Drugs were taken erratically and often singly, making the emergence of drug resistance more likely.",
"   </p>",
"   <p>",
"    In communities with long-standing programs of supervised or directly observed therapy (DOT), such as Baltimore, Maryland or Tarrant County, Texas, drug resistance has not emerged as a serious problem [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Furthermore, the incidence of MDR-TB diminished in New York after DOT was implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=see_link\">",
"     \"Adherence to tuberculosis treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19584302\">",
"    <span class=\"h2\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interindividual differences in the pharmacokinetics (including absorption, disposition, and elimination of a drug) may lead to development of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. A given dose does not lead to identical concentration-time profiles in all patients, and pharmacokinetic variability to a single drug in a regimen is significantly associated with failure of therapy in patients with acquired drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/41\">",
"     41",
"    </a>",
"    ]. The concentration achieved by a particular dose is determined in part by patient physiology, gene alleles encoding enzymes involved in drug metabolism, dietary considerations, concomitant drug administration, and comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/42\">",
"     42",
"    </a>",
"    ]. Clinical trial simulations suggest that 1 percent of TB patients with perfect adherence may develop MDR-TB due to pharmacokinetic variability alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19584283\">",
"    <span class=\"h2\">",
"     Strain characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Propagation of drug-resistant strains appears to depend on both their fitness and diversity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/43\">",
"     43",
"    </a>",
"    ]. The risk of infection with drug-resistant strains may be amplified in regions where there is reduced cross-immunity between originating strain groups. However, epidemiologic studies and TB vaccine trials indicate that cross-protective immunity to TB can be conferred by infection within the M. tuberculosis complex (eg, by M. bovis, M. microti) as well as by infection within the entire genus (eg, by non-tuberculous mycobacteria), suggesting that antigens common to all organisms within the genus may play a dominant role in immune protection against human TB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nosocomial transmission and HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nosocomial outbreaks of MDR-TB have been reported, primarily from hospitals and prisons in New York and New Jersey [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Most of the cases occurred in HIV-positive individuals, and reported mortality is high in all series. Links between cases were found by contact tracing and confirmed using molecular biologic techniques. Restriction fragment length polymorphism (RFLP) analysis, also known as DNA fingerprinting, can determine the clonal origin of organisms responsible for a case cluster; clonality implies transmission of TB between cases or infection from a common index case.",
"   </p>",
"   <p>",
"    RFLP analysis of MDR-TB case-clusters has demonstrated spread among HIV-infected patients with apparently trivial exposure when proper isolation and infection control measures are not enforced [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. A hierarchy of control measures has been employed to improve infection control practices in hospitals, nursing homes, and other congregate facilities. These include isolation of suspected TB cases, rapid examination of sputum smears, healthcare worker use of particulate respirators, and use of environmental measures such as germicidal ultraviolet irradiation, HEPA filters, frequent air exchanges, and negative pressure ventilation. These measures decrease transmission and nosocomial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many poor countries, these infection control measures are not affordable. Furthermore, isolation of patients is impossible because of the volume of cases. Patients are often kept together in large open wards, creating significant problems with nosocomial transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MOLECULAR BASIS OF DRUG-RESISTANT TUBERCULOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our understanding of the molecular basis for drug resistance in M. tuberculosis is improving. This knowledge is important for new drug design, new therapeutic strategies against MDR-TB, and development of probes for detection of mutations associated with resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Isoniazid resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The burden of mycobacteria within a pulmonary cavity is estimated to be between 7 and 9 log(10)",
"    <span class=\"nowrap\">",
"     cfu/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/52\">",
"     52",
"    </a>",
"    ]. For many years it was believed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    (INH) kills the largest subpopulation of bacilli that are in the exponential phase of growth during the first three days of therapy and that once this population is depleted, INH is no longer effective. An in vitro infection model has shown showed that while most early bactericidal activity does decline by 72 hours, the outcome is best explained by the emergence of drug-resistant isolates which were undergoing exponential-phase growth [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to INH may be conferred by alterations in the katG, kasA, or inhA genes. Strong evidence favors an integral role of inhA genes; one inhA enzyme with introduced point mutations was 17 times more resistant to inhibition by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    than the wild-type enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was observed in the 1950s that strains of M. tuberculosis that do not produce catalase are usually resistant to INH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/55\">",
"     55",
"    </a>",
"    ]. This finding led to the hypothesis that INH is a prodrug requiring alteration by catalase into its functional form. Subsequently it was shown that deletion or mutation in the catalase gene (katG) is responsible for 10 to 25 percent of cases of INH resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Such a mutation would also decrease the survival of the organism, were it not for compensatory hyperexpression of alkyl hydroperoxidase to protect against the toxic effect of organic peroxides [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in another gene, inhA, have also been associated with INH resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/59\">",
"     59",
"    </a>",
"    ]. This gene encodes a protein long-chain enoyl-acyl carrier protein reductase which is involved in the synthesis of mycolic acid, an important cell wall component of mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/60\">",
"     60",
"    </a>",
"    ]. Presumably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    is activated by catalase and then binds to the inhA protein to inhibit cell wall synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/60\">",
"     60",
"    </a>",
"    ]. Upregulation of inhA can overwhelm the inhibitory capacity of INH, and mutations in inhA can prevent binding of isoniazid and therefore lead to drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Rifampin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    is the cornerstone of short-course chemotherapy regimens, so rifampin resistance prolongs and complicates treatment. Rifampin is thought to act against M. tuberculosis by binding to RNA polymerase, resulting in interference with transcription and RNA prolongation. Mutations in the rpoB gene, which encodes the beta chain of mycobacterial RNA polymerase, have been found to cause clinical rifampin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, a mutation in rpoB was identified in 64 of 66 resistant organisms from diverse geographic areas, but in none of 56 sensitive organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/64\">",
"     64",
"    </a>",
"    ]. Rapid detection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    resistance, either by PCR amplification and sequencing of the \"hot spot\" region of this gene, by an",
"    <span class=\"nowrap\">",
"     RNA/RNA",
"    </span>",
"    mismatch assay, or by the use of molecular beacons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/65\">",
"     65",
"    </a>",
"    ] is now possible. These rapid assays permit institution of proper therapy within several days of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pyrazinamide resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     Pyrazinamide",
"    </a>",
"    is a prodrug which is converted to its active form, pyrazinoic acid, by the enzyme pyrazinamidase. Pyrazinamide resistance is due to any of a number of mutations in the gene pncA, which encodes this enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In one report, 33 of 38 pyrazinamide-resistant clinical isolates had pncA mutations; among the five strains that did not contain pncA mutations, four were falsely resistant and one had only borderline resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/70\">",
"     70",
"    </a>",
"    ]. Rapid detection of pncA mutations with molecular techniques should soon be possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ethambutol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     Ethambutol",
"    </a>",
"    inhibits mycobacterial cell wall biosynthesis. Ethambutol resistance in approximately 60 percent of organisms is due to amino acid replacements at position 306 of an arabinosyl transferase encoded by the embB gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/71\">",
"     71",
"    </a>",
"    ]. Arabinosyl transferase is an enzyme, which polymerizes arabinose into arabinan and then arabinogalactan, a mycobacterial cell wall constituent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Increased production of arabinosyl transferase overwhelms the effects of ethambutol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link\">",
"     \"Ethambutol: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Streptomycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     Streptomycin",
"    </a>",
"    acts by inhibiting microbial mRNA translation. Resistance is conferred by mutations in the rpsL and rrs genes, which affect ribosomal protein S12, or the 16S portion of ribosomal RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Streptomycin cannot inhibit protein synthesis in mycobacteria with these alterations in ribosomal structure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Second-line agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance has also been documented in second-line antituberculosis (TB) drugs including fluoroquinolones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     ethionamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Fluoroquinolones inhibit DNA gyrases, which are important in maintaining the proper tertiary structure of DNA. Resistance is caused by mutations in the gyrA and gyrB genes, which encode the target DNA gyrases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Specifically, amino acid changes in a subunit of deoxyribonucleic acid gyrase cause fluoroquinolone resistance in most organisms. Fluoroquinolones are becoming increasingly important in the treatment of TB, but to date resistance to this class of drugs is relatively uncommon in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/16/42244?source=see_link\">",
"     Ethionamide",
"    </a>",
"    is a nicotinic acid derivative similar in structure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    . Mutations in the inhA gene are also associated with ethionamide resistance, although catalase mutations are not [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7497/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7698631\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, and resistance to commonly-used anti-tuberculous drugs is increasing. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term &ldquo;drug-resistant TB&rdquo; refers to cases of TB caused by an isolate of M. tuberculosis that is resistant to one of the first-line anti-TB drugs:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      . The term &ldquo;multidrug-resistant TB&rdquo; (MDR-TB) refers to an isolate of M. tuberculosis that is resistant to at least isoniazid and rifampin, and possibly additional chemotherapeutic agents. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary drug resistance is said to occur in a patient who has never received anti-TB therapy. Secondary drug resistance refers to the development of resistance during or following chemotherapy in patients who had previously had drug-susceptible TB. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In 2009 the World Health Organization estimated there are at least 500,000 cases of MDR-TB in the world annually; it likely that &le;30,000 are treated appropriately. China, India, and Russia (and the countries of the former Soviet Union), are estimated to carry the highest number of MDR-TB cases. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Worldwide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States drug resistance began emerging in some regions in the early 1990s. The prevalence of drug-resistant TB in the United States decreased between the 1990s and mid-2000s and since then has remained stable. Factors leading to development of resistance include inadequate course of treatment, poorly supervised treatment programs, and poor infection control programs. (See",
"      <a class=\"local\" href=\"#H7697855\">",
"       'United States'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Factors leading to development of resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Understanding of the molecular basis for drug resistance in M. tuberculosis is important for new drug design, new therapeutic strategies against MDR-TB, and development of probes for detection of mutations associated with resistance. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Molecular basis of drug-resistant tuberculosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization (WHO). Laboratory XDR-TB definitions. Geneva: Meeting of the global XDR TB task force 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/2\">",
"      Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 2009; 136:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/3\">",
"      Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54:579.",
"     </a>",
"    </li>",
"    <li>",
"     WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world, report no. 4 file://www.who.int/tb/features_archive/drsreport_launch_26feb08/en/index.html (Accessed on April 29, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/5\">",
"      Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012; 90:111.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Global tuberculosis control: Epidemiology, strategy, financing, Geneva, WHO report 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/7\">",
"      Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366:2161.",
"     </a>",
"    </li>",
"    <li>",
"     World Helath Organization. Global tuberculosis control 2011. WHO; Geneva, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/9\">",
"      Poudel A, Nakajima C, Fukushima Y, et al. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal. Antimicrob Agents Chemother 2012; 56:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/10\">",
"      Taype CA, Agapito JC, Accinelli RA, et al. Genetic diversity, population structure and drug resistance of Mycobacterium tuberculosis in Peru. Infect Genet Evol 2012; 12:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/11\">",
"      Tessema B, Beer J, Emmrich F, et al. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/12\">",
"      Singla N, Singla R, Jain G, et al. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis 2011; 15:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/13\">",
"      Loewenberg S. India reports cases of totally drug-resistant tuberculosis. Lancet 2012; 379:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/14\">",
"      Chen L, Li N, Liu Z, et al. Genetic diversity and drug susceptibility of Mycobacterium tuberculosis isolates from Zunyi, one of the highest-incidence-rate areas in China. J Clin Microbiol 2012; 50:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/15\">",
"      Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/16\">",
"      Lew W, Pai M, Oxlade O, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/17\">",
"      Mak A, Thomas A, Del Granado M, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/18\">",
"      Gler MT, Macalintal LE, Raymond L, et al. Multidrug-resistant tuberculosis among previously treated patients in the Philippines. Int J Tuberc Lung Dis 2011; 15:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/19\">",
"      Nelson LJ, Talbot EA, Mwasekaga MJ, et al. Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002. Lancet 2005; 366:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/20\">",
"      Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008; 47:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/21\">",
"      Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/22\">",
"      Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/23\">",
"      Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA 1994; 271:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/25\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:181.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Reported tuberculosis in the United States, 1995. Center for Disease Control, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/27\">",
"      Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. N Engl J Med 1995; 333:229.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Reported Tuberculosis in the United States, 2006. Atlanta, GA: U.S. Department of Health and Human Services, CDC, September 2007 file://www.cdc.gov/tb/surv/surv2006/default.htm (Accessed on June 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/29\">",
"      Hoopes AJ, Kammerer JS, Harrington TA, et al. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008; 168:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/30\">",
"      Granich RM, Oh P, Lewis B, et al. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA 2005; 293:2732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis in Hmong refugees resettling from Thailand into the United States, 2004-2005. MMWR Morb Mortal Wkly Rep 2005; 54:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/32\">",
"      Oeltmann JE, Varma JK, Ortega L, et al. Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005. Emerg Infect Dis 2008; 14:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/33\">",
"      Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196 Suppl 1:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/34\">",
"      Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/35\">",
"      Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993; 270:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/36\">",
"      Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs. Am Rev Respir Dis 1991; 144:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/37\">",
"      Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/38\">",
"      Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/39\">",
"      Fujiwara PI, Cook SV, Rutherford CM, et al. A continuing survey of drug-resistant tuberculosis, New York City, April 1994. Arch Intern Med 1997; 157:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/40\">",
"      Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/41\">",
"      Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/42\">",
"      Dartois V. Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J Infect Dis 2011; 204:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/43\">",
"      Basu S, Orenstein E, Galvani AP. The theoretical influence of immunity between strain groups on the progression of drug-resistant tuberculosis epidemics. J Infect Dis 2008; 198:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/44\">",
"      Beck-Sagu&eacute; C, Dooley SW, Hutton MD, et al. Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients. JAMA 1992; 268:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/45\">",
"      Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med 1992; 117:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/46\">",
"      Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/47\">",
"      Ikeda RM, Birkhead GS, DiFerdinando GT Jr, et al. Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs. Infect Control Hosp Epidemiol 1995; 16:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/48\">",
"      Blumberg HM, Watkins DL, Berschling JD, et al. Preventing the nosocomial transmission of tuberculosis. Ann Intern Med 1995; 122:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/49\">",
"      Maloney SA, Pearson ML, Gordon MT, et al. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995; 122:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/50\">",
"      Stroud LA, Tokars JI, Grieco MH, et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/51\">",
"      Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007; 370:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/52\">",
"      Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/53\">",
"      Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/54\">",
"      Vilch&egrave;ze C, Wang F, Arai M, et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006; 12:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/55\">",
"      MIDDLEBROOK G. Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. Am Rev Tuberc 1954; 69:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/56\">",
"      Heym B, Alzari PM, Honor&eacute; N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/57\">",
"      Zhang Y, Heym B, Allen B, et al. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/58\">",
"      Sherman DR, Mdluli K, Hickey MJ, et al. Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. Science 1996; 272:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/59\">",
"      Banerjee A, Dubnau E, Quemard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/60\">",
"      Rozwarski, DA, Grant, GA, Barton, DH, et al. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/61\">",
"      Telenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax 1998; 53:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/62\">",
"      Donnabella V, Martiniuk F, Kinney D, et al. Isolation of the gene for the beta subunit of RNA polymerase from rifampicin-resistant Mycobacterium tuberculosis and identification of new mutations. Am J Respir Cell Mol Biol 1994; 11:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/63\">",
"      Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/64\">",
"      Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/65\">",
"      Piatek AS, Telenti A, Murray MR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000; 44:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/66\">",
"      Kapur V, Li LL, Iordanescu S, et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994; 32:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/67\">",
"      Telenti A, Imboden P, Marchesi F, et al. Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis. Antimicrob Agents Chemother 1993; 37:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/68\">",
"      Nash KA, Gaytan A, Inderlied CB. Detection of rifampin resistance in Mycobacterium tuberculosis by use of a rapid, simple, and specific RNA/RNA mismatch assay. J Infect Dis 1997; 176:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/69\">",
"      Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 1996; 2:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/70\">",
"      Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/71\">",
"      Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/72\">",
"      Telenti A, Philipp WJ, Sreevatsan S, et al. The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nat Med 1997; 3:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/73\">",
"      Belanger AE, Besra GS, Ford ME, et al. The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc Natl Acad Sci U S A 1996; 93:11919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/74\">",
"      Nair J, Rouse DA, Bai GH, Morris SL. The rpsL gene and streptomycin resistance in single and multiple drug-resistant strains of Mycobacterium tuberculosis. Mol Microbiol 1993; 10:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/75\">",
"      Honor&eacute; N, Cole ST. Streptomycin resistance in mycobacteria. Antimicrob Agents Chemother 1994; 38:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/76\">",
"      Cambau E, Sougakoff W, Jarlier V. Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria. FEMS Microbiol Lett 1994; 116:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7497/abstract/77\">",
"      Cambau E, Sougakoff W, Besson M, et al. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994; 170:479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8027 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7497=[""].join("\n");
var outline_f7_20_7497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7698631\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Worldwide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7697855\">",
"      - United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FACTORS LEADING TO DEVELOPMENT OF RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inappropriate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19584302\">",
"      Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19584283\">",
"      Strain characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nosocomial transmission and HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MOLECULAR BASIS OF DRUG-RESISTANT TUBERCULOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Isoniazid resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Rifampin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pyrazinamide resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ethambutol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Streptomycin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Second-line agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7698631\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10341?source=related_link\">",
"      Adherence to tuberculosis treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32586?source=related_link\">",
"      Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34743?source=related_link\">",
"      Epidemiology of extensively drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=related_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_20_7498="Treatment of intravascular catheter-related infections";
var content_f7_20_7498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of intravascular catheter-related infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Jeffrey D Band, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Anthony Harris, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/20/7498/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/20/7498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheter infections are common. In United States approximately 80,000 central venous catheter related bloodstream infections occur in intensive care units each year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In general, treatment of systemic intravenous catheter-related infection requires determination regarding catheter management (eg, salvage, exchange, or removal) and antibiotic therapy (eg, selection of empiric therapy with subsequent tailoring to culture and sensitivity data).",
"   </p>",
"   <p>",
"    The treatment of intravascular catheter-related infections will be reviewed here. Issues related to hemodialysis catheters are discussed separately, as are issues related to prevention and diagnosis of catheter-related infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=see_link\">",
"     \"Tunneled, cuffed hemodialysis catheter-related bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=see_link\">",
"     \"Prevention of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment guidelines discussed here apply to circumstances in which diagnostic criteria for catheter-related bloodstream infection (CRBSI) are met; these diagnostic criteria are discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, systemic antibiotic therapy is NOT required in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive catheter tip culture in the absence of clinical signs of infection",
"     </li>",
"     <li>",
"      Positive blood cultures obtained through a catheter with negative cultures through a peripheral vein.",
"     </li>",
"     <li>",
"      Phlebitis in the absence of infection; the risk of CRBSI in this setting is very low [",
"      <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link\">",
"       \"Superficial thrombophlebitis of the lower extremity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CATHETER MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the first step for treatment of systemic intravenous catheter-related infection requires determination regarding catheter management (eg, salvage, exchange, or removal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following diagnosis of catheter-related infection, catheter removal is warranted in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1,7-11\">",
"     1,7-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe sepsis",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Endocarditis or evidence of metastatic infection",
"     </li>",
"     <li>",
"      Erythema or exudate due to suppurative thrombophlebitis",
"     </li>",
"     <li>",
"      Persistent bacteremia after 72 hours of antimicrobial therapy to which the organism is susceptible",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nature of the pathogen is also important for guiding decisions regarding catheter removal. Short term catheters (indwelling &lt;14 days) should be removed in the setting of catheter-related bloodstream infection (CRBSI) due to S. aureus, enterococci, gram negative bacilli, fungi, and mycobacteria. Long term catheters (indwelling &ge;14 days) should be removed in the setting of CRBSI due to S. aureus, P. aeruginosa, fungi, or mycobacteria. Removal of long term catheters can be a management challenge, particularly in the setting of surgically implantable intravascular devices. Therefore, it is important to establish true CRBSI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of CRBSI due to organisms of relatively low virulence that are difficult to eradicate (eg, Bacillus spp, Micrococcus spp, or Propionibacteria), removal of both short and long term catheters is appropriate if blood culture contamination has been ruled out (eg, based on multiple positive culture results with at least one sample drawn from a peripheral vein) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Other organisms'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence to support routine catheter exchange. In addition, catheter removal is not necessary for hemodynamically stable patients with unexplained fever in the absence of documented bloodstream infection and without endovascular prosthetic material (such as a prosthetic valve, pacemaker, or vascular graft) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Salvage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following diagnosis of catheter-related infection, catheter salvage may be attempted in the setting of uncomplicated CRBSI involving long term catheters due to pathogens other than S. aureus, P. aeruginosa, fungi, or mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. Salvage is also difficult in the setting of CRBSI due to organisms of relatively low virulence that are difficult to eradicate (eg, Bacillus spp, Micrococcus spp, or Propionibacteria). Catheter salvage in the setting of coagulase negative staphylococcal infection does not influence resolution of bacteremia but may be a risk factor for recurrence (relative risk 6.6 in a retrospective series of 175 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If salvage is attempted, both systemic and antimicrobial lock therapy may be administered through the colonized catheter for the duration of therapy, depending upon the microorganism. The efficacy of antibiotic lock therapy remains uncertain and concerns have been raised about the emergence of antimicrobial resistance and fungal superinfection. The optimal antimicrobial dosing for lock therapy is also uncertain. Antibiotic lock therapy is not warranted for management of catheter infection for devices in place for &lt;2 weeks; these are usually extraluminal infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two sets of blood cultures should be obtained after 72 hours of appropriate antimicrobial therapy (for neonates one set is acceptable); positive cultures should prompt catheter removal.",
"   </p>",
"   <p>",
"    Catheter removal is not necessary for hemodynamically stable patients with unexplained fever in the absence of documented bloodstream infection and without endovascular prosthetic material (such as a prosthetic valve, pacemaker, or vascular graft) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Guidewire exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;For circumstances in which catheter removal is necessary for suspected catheter-related infection and the risk for mechanical complications or bleeding during catheter reinsertion is high, guidewire exchange of the catheter is acceptable (except in the setting of sepsis) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. However, most studies describing successful management of catheter infection via catheter exchange over a guidewire have been small, uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of antimicrobial impregnated catheters is uncertain. Many trials of antiseptic or antimicrobial impregnated CVCs have reported a decreased incidence of catheter-related infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. However, a randomized trial of 780 adult ICU patients managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    coated or uncoated catheters failed to demonstrate a reduction in the rate of bloodstream infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/27\">",
"     27",
"    </a>",
"    ]. Replacement of the catheter with an antimicrobial impregnated catheter should be considered in settings where rates of CRBSIs exceed the National Healthcare Safety Network surveillance data threshold despite adherence to aseptic techniques (eg, &gt;2.5 infections per 1000 catheter days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tip of the removed catheter should be sent for culture; if the results are positive, the newly inserted catheter should be relocated to a new site [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, indications for catheter removal and choice of empiric antimicrobial therapy for children with CRBSI are similar to those for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In a prospective study of chronic venous access devices in over 1000 children with cancer, most episodes of CRBSI were caused by coagulase-negative staphylococci followed by S. aureus (34 and 25 percent of cases, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some pediatricians favor attempting treatment of bacterial CRBSI without catheter removal, given greater difficulty with vascular access among children than among adults. In such cases, both systemic and antimicrobial lock therapy may be warranted. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Antibiotic lock therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The benefits of catheter removal must be weighed against the difficulty of obtaining alternative venous access. Several studies have reported successful CRBSI management among children without catheter removal; close monitoring is required, and the device should be removed in the event of clinical deterioration or recurrence of CRBSI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/30,33,34\">",
"     30,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catheter removal is always necessary in the setting of fungemia. Treatment of catheter associated fungemia without catheter removal has a low success rate and is associated with high mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, empiric antibiotic therapy must be instituted before culture and susceptibility data are available. Subsequently therapy should be tailored to microbiology results as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial choice of antibiotics for catheter-related blood stream infection (CRBSI) depends on the clinical circumstances, including the severity of illness, the risk factors for infection, and the likely pathogens associated with the specific intravascular device (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). In general, coagulase negative staphylococci are the most common cause of catheter-related infection; most isolates are resistant to methicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Empiric therapy of CRBSI in health care settings should consist of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. In institutions with high rates of infection due to MRSA isolates with vancomycin MIC &ge;2",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    an alternative agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     Linezolid",
"    </a>",
"    is not an appropriate agent for empiric therapy of CRBSI [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Addition of empiric coverage for gram negative organisms depends on individual circumstances and the severity of disease. In the setting of suspected CRBSI among patients with neutropenia or sepsis, empiric antibiotic therapy for gram negative bacilli (including Pseudomonas) is appropriate (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). Patients known to be colonized with drug resistant organisms should receive empiric antibiotic therapy selected accordingly; therapy should be tailored depending on subsequent culture data.",
"   </p>",
"   <p>",
"    Empiric therapy for suspected catheter-related candidemia should be administered for septic patients with the following risk factors (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of candidemia in children\", section on 'Antifungal agents and dosing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       Total parenteral nutrition",
"      </a>",
"     </li>",
"     <li>",
"      Prolonged use of broad-spectrum antibiotics",
"     </li>",
"     <li>",
"      Hematologic malignancy",
"     </li>",
"     <li>",
"      Bone marrow or solid organ transplant",
"     </li>",
"     <li>",
"      Femoral catheterization",
"     </li>",
"     <li>",
"      Colonization due to Candida species at multiple sites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate agents for empiric treatment include echinocandin or azole drugs. In children, many clinicians continue to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or lipid formulations of amphotericin, although the azoles and echinocandins appear to be safe in children.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is appropriate for patients without azole exposure in the previous three months and in settings where the risk of C. krusei or C. glabrata is very low.",
"   </p>",
"   <p>",
"    If catheter removal is not possible, antibiotics should be administered through the colonized catheter, although recurrent bacteremia is more likely if therapy is administered through a retained catheter than if the catheter is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/41\">",
"     41",
"    </a>",
"    ]. For multi-lumen catheters administration of antibiotics may be rotated between lumens, although this practice has not been studied formally.",
"   </p>",
"   <p>",
"    Intravenous administration of thrombolytic agents should not be used as an adjunctive treatment for catheter related blood stream infection (CRBSI) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tailoring therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following initiation of empiric antibiotic therapy, therapy should be tailored to culture and susceptibility results as needed once data are available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Coagulase negative staphylococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulase negative staphylococci are the most common cause of catheter-related infection. Interpreting blood cultures positive for coagulase negative staphylococcus can be challenging, since this organism is both the most common blood culture contaminant as well the most common cause of CRBSI. A high proportion of positive blood cultures performed on samples drawn from multiple sites (both peripherally and through the suspected catheter) is the best indicator for true CRBSI due to this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=see_link\">",
"     \"Diagnosis of intravascular catheter-related infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trials have established the optimal approach to management of CRBSI due to coagulase negative staphylococcus. Some experts favor treatment with antibiotics following catheter removal (5 to 7 days). However, such infections may resolve with removal of the catheter in the absence of antibiotic therapy. Therefore, in the absence of endovascular hardware, some experts favor forgoing antibiotic therapy unless fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bacteremia persist after catheter withdrawal. Patients with endovascular hardware should have the catheter removed and more prolonged therapy is warranted. If infective endocarditis is excluded, 3 weeks of therapy is appropriate. If catheter salvage is necessary, antibiotic therapy is warranted (systemically as well as via antibiotic lock therapy in some cases) for 10 to 14 days (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Antibiotic lock therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most patients have a benign clinical course; rarely, severe infection with poor outcome occurs. For example, S. lugdunensis is an uncommon cause of catheter-related infection; however, it can cause endocarditis and metastatic infections similar to those caused by S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12344?source=see_link\">",
"     \"Staphylococcus lugdunensis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     S. aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, management of CRBSI due to S. aureus consists of catheter removal and systemic antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. Following catheter removal, a new catheter may be placed if additional blood cultures demonstrate no growth at 72 hours.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be initiated pending susceptibility data (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). Patients who received empiric vancomycin and are found to have CRBSI due to methicillin susceptible S. aureus should be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    . No randomized trials have established the optimal duration of therapy for CRBSI due to S. aureus; the duration depends on the nature of the infection, as discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/8,47-52\">",
"     8,47-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequency of infective endocarditis (IE) among patients with S. aureus bacteremia is 25 to 32 percent, and many cases are not suspected clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Therefore, in general, transesophageal echocardiogram (TEE) should be pursued in the setting of S. aureus bacteremia to rule out infective endocarditis (IE); transthoracic echocardiography (TTE) is not sufficient for ruling out IE due to S. aureus. Possible exceptions are patients whose fever and bacteremia resolve within 72 hours following catheter removal who have no underlying cardiac predisposing conditions or clinical signs of endocarditis. Valvular vegetations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regurgitation may progress within the first week after onset of bacteremia; therefore some favor performing TEE 5 to 7 days after the onset of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/47,56\">",
"     47,56",
"    </a>",
"    ]. Echocardiographic examination is not used routinely for infants and children with CRBSI who do not have other indicators of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Children'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Hematogenous complications of S. aureus bacteremia (eg, endocarditis, with or without metastatic sites of infection) occur in 25 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Risk factors include community-acquired infection (suggesting longer duration of bacteremia), prosthetic intravascular device (eg, pacemaker or recently placed vascular graft), comorbid immunocompromising conditions (including AIDS, diabetes, or immunosuppressive medication), valvular abnormality predisposing to endocarditis, dialysis dependence, suppurative thrombophlebitis, and delay in catheter removal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/9,57\">",
"     9,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with hematogenous complications of S. aureus bacteremia should receive 4 to 6 weeks of antimicrobial therapy. Positive blood cultures 72 hours following initiation of appropriate antibiotic therapy and catheter removal are a useful predictor for hematogenous complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/9,53,57-59\">",
"     9,53,57-59",
"    </a>",
"    ]. In the absence of hematogenous complications or risk factors, a shorter duration of therapy (&ge;14 days) is appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with catheter tip culture positive for S. aureus in the setting of negative peripheral blood culture should be observed closely. However, some favor antibiotic therapy for 7 days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. Additional blood cultures should be obtained to evaluate for clearance of bacteremia, together with close monitoring for signs of persistent infection.",
"   </p>",
"   <p>",
"    Patients with catheter-drawn blood culture positive for S. aureus in the setting of negative peripheral blood culture should be observed closely. Additional blood cultures should be obtained both peripherally and through the catheter. If both repeat cultures are positive, treatment for CRBSI is warranted. If only the catheter culture is positive, the optimal approach is uncertain. The device should be removed If feasible; otherwise, some favor 14 days of systemic antibiotic therapy with repeat blood cultures, while others favor close clinical observation with repeat blood cultures. Clinical signs of infection should prompt catheter removal.",
"   </p>",
"   <p>",
"    Salvage of CRBSI due to S. aureus using 4 weeks of antibiotic lock therapy combined with systemic therapy has a low success rate; most patients eventually relapse and require removal of the catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. This approach is appropriate only in the setting of major contraindications to catheter removal (eg, no alternative venous access, significant bleeding diathesis, quality of life issues). If possible, guidewire exchange should be performed. Some experts favor replacement using an antimicrobial impregnated catheter with an anti-infective intraluminal surface, though this approach is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Guidewire exchange'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Further discussion of treatment for CRBSI due to S. aureus bacteremia may be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Enterococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, management of enterococcal CRBSI consists of catheter removal (if feasible) and systemic antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. Catheter salvage should not be attempted in the setting of insertion site or pocket infection, suppurative thrombophlebitis, sepsis, endocarditis, persistent bacteremia or metastatic infection.",
"   </p>",
"   <p>",
"    The antibiotic of choice for susceptible enterococci is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be used if the pathogen is resistant to ampicillin (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). In cases of CRBSI due to ampicillin and vancomycin resistant enterococci,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    may be used, based on antibiotic susceptibility results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of enterococcal infections\", section on 'Bacteremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized trials have established the role of combination antimicrobial therapy or the optimal duration of therapy for enterococcal CRBSI. Among patients with uncomplicated enterococcal CRBSI treated with combination therapy versus monotherapy, no significant differences in outcomes have been observed in several retrospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. In the setting of catheter salvage, one large series found that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    was more effective than monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of infective endocarditis (IE) in the setting of enterococcal CRBSI is relatively low if infection is due to E. faecium. In a multicenter study involving over 200 cases of CRBSI due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    resistant enterococci, definite endocarditis was demonstrated in 1.5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/66\">",
"     66",
"    </a>",
"    ]. The risk was considerably higher if infection was due to E. faecalis. Echocardiographic evaluation is warranted for patients with signs and symptoms of IE (eg, new murmur or embolic phenomena), persistent bacteremia, or the presence of a prosthetic valve or other endovascular foreign bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of enterococcal infections\", section on 'Bacteremia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H11#H11\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Enterococci'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic therapy should be administered for 7 to 14 days if no evidence of endocarditis or metastatic infection is present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. This duration is appropriate in the setting of catheter removal as well as in the setting of catheter salvage together with both systemic and antibiotic lock therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Gram-negative rods",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, management of CRBSI due to gram negative bacilli consists of catheter removal (if feasible) and systemic antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. Catheter salvage should not be attempted in the setting of insertion site or pocket infection, suppurative thrombophlebitis, sepsis, endocarditis, persistent bacteremia, or metastatic infection.",
"   </p>",
"   <p>",
"    Empiric antibiotic therapy with activity against gram negative organisms should be initiated (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). Critically ill patients with risk factors for multidrug resistant (MDR) gram-negative infections (such as previous MDR gram negative infection, critical illness, neutropenia, prior antibiotic therapy, or presence of a femoral catheter) should receive empiric therapy with a carbapenem; alternatively, some favor empiric therapy with two antimicrobial agents of different classes with gram-negative activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. When culture and susceptibility data are available, the initial antibiotic regimen can be adjusted to a single agent for the remainder of the therapeutic course (usually 7 to 14 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with gram negative bacillary CRBSI involving a long term catheter and persistent bacteremia or severe sepsis despite systemic and antibiotic lock therapy, the device should be removed and an evaluation for metastatic infection should be pursued. Routine evaluation for IE is generally not necessary in patients with CRBSI due to gram negative rods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Candida",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, management of CRBSI due to Candida species consists of catheter removal and systemic antibiotic therapy. This is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=see_link\">",
"     \"Treatment of Candida infection in neonates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link\">",
"     \"Treatment of candidemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, confirmation of true bloodstream infection due to Corynebacterium, Bacillus and Micrococcus requires at least two positive blood cultures obtained from different sites; isolation of these organisms from a single blood culture is not sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRBSI due to Micrococcus and Bacillus species are difficult to eradicate unless the infected catheter is removed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. The antibiotic of choice for these organisms is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ); duration of therapy must be tailored to clinical circumstances. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Catheter colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of positive catheter-drawn blood cultures for coagulase negative staphylococci or gram negative bacilli and negative concurrent percutaneous blood cultures, an intraluminally colonized catheter may be present. As such, there may be an increased risk for subsequent CRBSI, especially if the device is left in place. In such circumstances we favor following the patient closely and obtaining additional percutaneous blood cultures if the patient continues to exhibit clinical manifestations of CRBSI. However, some clinicians may favor to removing the device or exchange it over a guide wire. Alternatively, antibiotic lock therapy (without systemic therapy) may be administered if removal is not feasible. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Antibiotic lock therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimicrobial therapy for CRBSI depends on the clinical circumstances. In general, for uncomplicated CRBSI with negative blood cultures following catheter removal or guidewire exchange and institution of appropriate antibiotic therapy, the duration of therapy is usually 10 to 14 days (day one is the first day on which negative blood cultures are obtained) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ]. The duration of therapy may be extended to 4 to 6 weeks in patients with recent prosthetic valve placement placed prosthetic valves, even if investigation fails to demonstrate evidence of IE.",
"   </p>",
"   <p>",
"    Patients with persistent bacteremia &gt;72 hours following catheter removal should generally receive treatment for at least 4 to 6 weeks. For patients with complications related to bacteremia (such as suppurative thrombophlebitis, endocarditis, osteomyelitis, metastatic infection) the duration of therapy should be tailored accordingly depending on the nature of infection. (See related topics).",
"   </p>",
"   <p>",
"    Antibiotics can be discontinued in patients with suspected CRBSI if blood cultures are negative and no other source of infection can be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antibiotic lock therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The premise of antibiotic lock therapy (ALT) is to achieve sufficient therapeutic concentrations to kill microbes growing in a biofilm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/76-81\">",
"     76-81",
"    </a>",
"    ]. ALT may be a useful adjunctive therapy together with systemic antibiotic therapy for intraluminal infections due to coagulase negative staphylococci or gram negative organisms in the setting of CRBSI when the catheter cannot be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1,82-88\">",
"     1,82-88",
"    </a>",
"    ]. ALT should not be used for extraluminal infections nor for management of infections due to S. aureus, Pseudomonas aeruginosa, drug-resistant gram-negative bacilli, or Candida.",
"   </p>",
"   <p>",
"    ALT for the treatment of CRBSI is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2121?source=see_link\">",
"     \"Antibiotic lock therapy for treatment of catheter-related bloodstream infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Therapy for children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the approach to treatment of CRBSI in children is as described for adults (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). If catheter removal is not feasible, antibiotic lock therapy should be used for catheter salvage; if antibiotic lock therapy is not feasible, systemic antibiotics should be administered through the colonized catheter. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Children'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Antibiotic lock therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Antifungal therapy should be initiated when yeast is isolated from a blood culture or when the suspicion of fungemia is high [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/34,89-91\">",
"     34,89-91",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Empiric therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of candidemia in children\", section on 'Antifungal agents and dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiographic examination is not used routinely for infants and children with CRBSI who do not have other indicators of endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CRBSI must be monitored closely during and following therapy to detect relapses or signs of metastatic infection. Blood cultures should be drawn after treatment has been initiated to demonstrate clearance of bacteremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Persistent bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeatedly positive blood cultures",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent symptoms 72 hours after catheter removal with appropriate antibiotic therapy should prompt evaluation for sequelae of CRBSI including suppurative thrombophlebitis, endocarditis, and metastatic foci of infection. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LOCAL SITE INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgically implanted tunneled catheters have different insertion and exit sites; the original insertion site is closed after creation of a tunnel and a separate exit site. In contrast, percutaneously inserted catheters have one site that serves as both the insertion and exit site. Up until 6 weeks following tunneled catheter placement the insertion site and exit site may be considered contiguous; after healing has completed they may be considered distinct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Insertion site infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertion site infection of tunneled catheters should prompt catheter removal; guidewire catheter exchange is not appropriate as it can lead to bacteremia and septic emboli. Cultures should be obtained, including culture of the exudate, blood cultures from a peripheral vein, and culture of the catheter tip.",
"   </p>",
"   <p>",
"    Antimicrobial therapy for &le;7 days is sufficient if bloodstream infection is excluded on the basis of the clinical picture and negative blood cultures (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Empiric therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Tailoring therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Exit site infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of suspected exit site infection, site drainage cultures and blood cultures should be obtained. Uncomplicated exit site infections (eg, those without systemic signs of infection, positive blood cultures, or purulence) may be managed with topical antibiotic agents based on culture results (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ointment for S. aureus infection and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or lotrimin ointment for Candida infection).",
"   </p>",
"   <p>",
"    Exit site infections that do not resolve with these interventions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exit site infections accompanied by purulent drainage should prompt administration of systemic antibiotics for &le;7 days. Failure of systemic antibiotics should prompt immediate catheter removal (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Empiric therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Tailoring therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tunnel infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tunnel (or pocket) infection involves the region where a surgically implanted catheter runs beneath the skin. Clinical findings include erythema, tenderness, and induration overlying the subcutaneous tunnel tract (which extends for &ge;2 cm from the exit site). However, signs of exit site infection may or may not be present, particularly in neutropenic patients (in such circumstances patients may complain of pain in the absence of erythema or swelling). The above findings should prompt catheter removal; in some circumstances incision and drainage may also be appropriate. Antibiotics should be administered for &le;7 days (",
"    <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Empiric therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Tailoring therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Thrombophlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombophlebitis in the absence of other signs of infection (purulence, temperature above 38&ordm;C) need not be treated with antimicrobial therapy; warm soaks and elevation of the extremity should be sufficient. Determination regarding catheter removal depends on clinical circumstances including the catheter indication, duration and feasibility of replacement. Superficial phlebitis and septic thrombophlebitis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link\">",
"     \"Catheter-induced upper extremity venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=see_link\">",
"     \"Superficial thrombophlebitis of the lower extremity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=see_link\">",
"     \"Suppurative (septic) thrombophlebitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/33/35345?source=see_link\">",
"       \"Patient information: Central line infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In general, for circumstances in which systemic intravenous catheter-related infection diagnostic criteria are met, treatment requires determination regarding catheter management (eg, removal, salvage, or exchange) and antibiotic therapy (eg, selection of empiric therapy with subsequent tailoring to culture and sensitivity data). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, systemic antibiotic therapy is NOT required in the following circumstances (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for treatment'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Positive catheter tip culture in the absence of clinical signs of infection",
"     </li>",
"     <li>",
"      Positive blood cultures obtained through a catheter with negative cultures through a peripheral vein",
"     </li>",
"     <li>",
"      Phlebitis in the absence of infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following diagnosis of catheter-related infection, catheter removal is appropriate in the setting of severe sepsis, hemodynamic instability, suppurative thrombophlebitis, endocarditis, or persistent bacteremia after 72 hours of antimicrobial therapy to which the organism is susceptible. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type of pathogen is important for guiding decisions regarding catheter management. Long term catheters (indwelling &ge;14 days) should be removed in the setting of catheter-related bloodstream infection (CRBSI) due to S. aureus, P. aeruginosa, fungi or mycobacteria. Organisms of relatively low virulence that are difficult to eradicate (eg, Bacillus spp, Micrococcus spp, or Propionibacteria) should also prompt catheter removal if blood culture contamination has been ruled out. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Removal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter salvage may be attempted in the setting of uncomplicated CRBSI of long term catheters due to pathogens other than those outlined above. For circumstances in which catheter removal is necessary and risk for complications during catheter reinsertion is high, guidewire exchange of the catheter may be appropriate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Salvage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Guidewire exchange'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive antibiotic lock therapy in combination with systemic therapy for intraluminal infections due to coagulase negative staphylococci can be a useful strategy for the treatment of CRBSI when the catheter cannot be removed. Antibiotic lock therapy should not be used for extraluminal infections nor for management of infections due to S. aureus, Pseudomonas aeruginosa, resistant gram-negative bacilli, or Candida. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Antibiotic lock therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2121?source=see_link\">",
"       \"Antibiotic lock therapy for treatment of catheter-related bloodstream infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Empiric antibiotic therapy for CRBSI in health care settings should include activity against methicillin resistant S. aureus;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      is a reasonable agent (",
"      <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"       table 1",
"      </a>",
"      ). Patients with neutropenia or sepsis should also receive empiric antibiotic therapy for gram negative organisms (including Pseudomonas) (",
"      <a class=\"graphic graphic_table graphicRef79387 \" href=\"UTD.htm?3/23/3454\">",
"       table 1",
"      </a>",
"      ). Patients known to be colonized with drug resistant organisms should receive empiric antibiotic therapy selected accordingly; therapy should be tailored based on subsequent culture data. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following initiation of empiric treatment, antibiotic therapy should be tailored to culture and susceptibility results as needed once data are available. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Tailoring therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, transesophageal echocardiogram (TEE) should be pursued in the setting of S. aureus bacteremia to rule out infective endocarditis (IE). Possible exceptions include patients whose fever and bacteremia resolve within 72 hours following catheter removal and have no underlying cardiac predisposing conditions or clinical signs of endocarditis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'S. aureus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, for uncomplicated CRBSI with negative blood cultures following catheter removal or guidewire exchange and institution of appropriate antibiotic therapy, the duration of therapy is 10 to 14 days (day one is the first day on which negative blood cultures are obtained). Patients with persistent bacteremia &gt;72 hours following catheter removal should receive treatment for at least 4 to 6 weeks. For patients with complications related to bacteremia (such as suppurative thrombophlebitis, endocarditis, osteomyelitis, metastatic infection) the duration of therapy should be tailored accordingly depending on the nature of infection. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with CRBSI must be monitored closely during and following therapy to detect relapses or signs of metastatic infection. Blood cultures should be drawn after treatment has been initiated to demonstrate clearance of bacteremia. Repeatedly positive blood cultures",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent symptoms 72 hours after catheter removal with appropriate antibiotic therapy should prompt evaluation for sequelae of CRBSI including suppurative thrombophlebitis, endocarditis, and metastatic foci of infection. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of local site infections depends on the nature of the infection. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Local site infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/1\">",
"      Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/2\">",
"      Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/3\">",
"      Bouza E, Alvarado N, Alcal&aacute; L, et al. A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal. Clin Infect Dis 2007; 44:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/4\">",
"      Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med 1991; 114:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/5\">",
"      Bregenzer T, Conen D, Sakmann P, Widmer AF. Is routine replacement of peripheral intravenous catheters necessary? Arch Intern Med 1998; 158:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/6\">",
"      Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 2006; 81:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/7\">",
"      Rijnders BJ, Peetermans WE, Verwaest C, et al. Watchful waiting versus immediate catheter removal in ICU patients with suspected catheter-related infection: a randomized trial. Intensive Care Med 2004; 30:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/8\">",
"      Malanoski GJ, Samore MH, Pefanis A, Karchmer AW. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 1995; 155:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/9\">",
"      Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/10\">",
"      Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998; 27:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/11\">",
"      Reilly JJ Jr, Steed DL, Ritter PS. Indwelling venous access catheters in patients with acute leukemia. Cancer 1984; 53:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/12\">",
"      Kassar R, Hachem R, Jiang Y, et al. Management of Bacillus bacteremia: the need for catheter removal. Medicine (Baltimore) 2009; 88:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/13\">",
"      Rijnders BJ, Verwaest C, Peetermans WE, et al. Difference in time to positivity of hub-blood versus nonhub-blood cultures is not useful for the diagnosis of catheter-related bloodstream infection in critically ill patients. Crit Care Med 2001; 29:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/14\">",
"      Rello J, Coll P, Prats G. Evaluation of culture techniques for diagnosis of catheter-related sepsis in critically ill patients. Eur J Clin Microbiol Infect Dis 1992; 11:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/15\">",
"      Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/16\">",
"      Raad I, Kassar R, Ghannam D, et al. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis 2009; 49:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/17\">",
"      Raad I, Costerton W, Sabharwal U, et al. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis 1993; 168:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/18\">",
"      Pettigrew RA, Lang SD, Haydock DA, et al. Catheter-related sepsis in patients on intravenous nutrition: a prospective study of quantitative catheter cultures and guidewire changes for suspected sepsis. Br J Surg 1985; 72:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/19\">",
"      Mart&iacute;nez E, Mensa J, Rovira M, et al. Central venous catheter exchange by guidewire for treatment of catheter-related bacteraemia in patients undergoing BMT or intensive chemotherapy. Bone Marrow Transplant 1999; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/20\">",
"      Carlisle EJ, Blake P, McCarthy F, et al. Septicemia in long-term jugular hemodialysis catheters; eradicating infection by changing the catheter over a guidewire. Int J Artif Organs 1991; 14:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/21\">",
"      Shaffer D. Catheter-related sepsis complicating long-term, tunnelled central venous dialysis catheters: management by guidewire exchange. Am J Kidney Dis 1995; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/22\">",
"      Robinson D, Suhocki P, Schwab SJ. Treatment of infected tunneled venous access hemodialysis catheters with guidewire exchange. Kidney Int 1998; 53:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/23\">",
"      Porter KA, Bistrian BR, Blackburn GL. Guidewire catheter exchange with triple culture technique in the management of catheter sepsis. JPEN J Parenter Enteral Nutr 1988; 12:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/24\">",
"      Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. Ann Intern Med 1997; 127:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/25\">",
"      Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/26\">",
"      Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann Intern Med 1997; 127:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/27\">",
"      Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann Intern Med 2005; 143:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/28\">",
"      Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control 2008; 36:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/29\">",
"      Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med 1977; 296:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/30\">",
"      Flynn PM, Shenep JL, Stokes DC, Barrett FF. In situ management of confirmed central venous catheter-related bacteremia. Pediatr Infect Dis J 1987; 6:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/31\">",
"      Wiener ES, McGuire P, Stolar CJ, et al. The CCSG prospective study of venous access devices: an analysis of insertions and causes for removal. J Pediatr Surg 1992; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/32\">",
"      Baltimore RS. Neonatal nosocomial infections. Semin Perinatol 1998; 22:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/33\">",
"      Hartman GE, Shochat SJ. Management of septic complications associated with Silastic catheters in childhood malignancy. Pediatr Infect Dis J 1987; 6:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/34\">",
"      Wiener ES. Catheter sepsis: the central venous line Achilles' heel. Semin Pediatr Surg 1995; 4:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/35\">",
"      Dato VM, Dajani AS. Candidemia in children with central venous catheters: role of catheter removal and amphotericin B therapy. Pediatr Infect Dis J 1990; 9:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/36\">",
"      Jones GR, Konsler GK, Dunaway RP, et al. Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients. J Pediatr Surg 1993; 28:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/37\">",
"      Miragaia M, Couto I, Pereira SF, et al. Molecular characterization of methicillin-resistant Staphylococcus epidermidis clones: evidence of geographic dissemination. J Clin Microbiol 2002; 40:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/38\">",
"      Pottumarthy S, Fritsche TR, Jones RN. Evaluation of alternative disk diffusion methods for detecting mecA-mediated oxacillin resistance in an international collection of staphylococci: validation report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2005; 51:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/39\">",
"      Boucher HW, Sakoulas G. Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007; 45:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/40\">",
"      Pfizer halts pursuit of Zyvox indication based upon mortality signal. The Pink Sheet 2007; 69:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/41\">",
"      Raad I, Davis S, Khan A, et al. Impact of central venous catheter removal on the recurrence of catheter-related coagulase-negative staphylococcal bacteremia. Infect Control Hosp Epidemiol 1992; 13:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/42\">",
"      Atkinson JB, Chamberlin K, Boody BA. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis. J Pediatr Surg 1998; 33:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/43\">",
"      La Quaglia MP, Caldwell C, Lucas A, et al. A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. J Pediatr Surg 1994; 29:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/44\">",
"      Kiehn TE, Armstrong D. Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices. Eur J Clin Microbiol Infect Dis 1990; 9:869.",
"     </a>",
"    </li>",
"    <li>",
"     Byers K, Anglim A, et al. Case fatality rate for catheter-related bloodstream infections (CRSBI): a meta-analysis [abstract 43]. In: Program and abstracts of the Fifth Annual Meeting of the Society for Hospital Epidemiology of America (San Diego). 1995:23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/46\">",
"      Zinkernagel AS, Zinkernagel MS, Elzi MV, et al. Significance of Staphylococcus lugdunensis bacteremia: report of 28 cases and review of the literature. Infection 2008; 36:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/47\">",
"      Rosen AB, Fowler VG Jr, Corey GR, et al. Cost-effectiveness of transesophageal echocardiography to determine the duration of therapy for intravascular catheter-associated Staphylococcus aureus bacteremia. Ann Intern Med 1999; 130:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/48\">",
"      Pigrau C, Rodr&iacute;guez D, Planes AM, et al. Management of catheter-related Staphylococcus aureus bacteremia: when may sonographic study be unnecessary? Eur J Clin Microbiol Infect Dis 2003; 22:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/49\">",
"      Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med 1976; 84:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/50\">",
"      Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987; 9:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/51\">",
"      Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis 1992; 14:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/52\">",
"      Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med 1989; 149:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/53\">",
"      Abraham J, Mansour C, Veledar E, et al. Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J 2004; 147:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/54\">",
"      Fowler VG Jr, Li J, Corey GR, et al. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 1997; 30:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/55\">",
"      Sullenberger AL, Avedissian LS, Kent SM. Importance of transesophageal echocardiography in the evaluation of Staphylococcus aureus bacteremia. J Heart Valve Dis 2005; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/56\">",
"      Sochowski RA, Chan KL. Implication of negative results on a monoplane transesophageal echocardiographic study in patients with suspected infective endocarditis. J Am Coll Cardiol 1993; 21:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/57\">",
"      Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/58\">",
"      Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/59\">",
"      Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/60\">",
"      Marr KA, Sexton DJ, Conlon PJ, et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/61\">",
"      Poole CV, Carlton D, Bimbo L, Allon M. Treatment of catheter-related bacteraemia with an antibiotic lock protocol: effect of bacterial pathogen. Nephrol Dial Transplant 2004; 19:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/62\">",
"      Kuizon D, Gordon SM, Dolmatch BL. Single-lumen subcutaneous ports inserted by interventional radiologists in patients undergoing chemotherapy: incidence of infection and outcome of attempted catheter salvage. Arch Intern Med 2001; 161:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/63\">",
"      Maki DG, Agger WA. Enterococcal bacteremia: clinical features, the risk of endocarditis, and management. Medicine (Baltimore) 1988; 67:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/64\">",
"      Gray J, Marsh PJ, Stewart D, Pedler SJ. Enterococcal bacteraemia: a prospective study of 125 episodes. J Hosp Infect 1994; 27:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/65\">",
"      Sandoe JA, Witherden IR, Au-Yeung HK, et al. Enterococcal intravascular catheter-related bloodstream infection: management and outcome of 61 consecutive cases. J Antimicrob Chemother 2002; 50:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/66\">",
"      Vergis EN, Hayden MK, Chow JW, et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. a prospective multicenter study. Ann Intern Med 2001; 135:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/67\">",
"      Anderson DJ, Murdoch DR, Sexton DJ, et al. Risk factors for infective endocarditis in patients with enterococcal bacteremia: a case-control study. Infection 2004; 32:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/68\">",
"      Fern&aacute;ndez-Guerrero ML, Herrero L, Bellver M, et al. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. J Intern Med 2002; 252:510.",
"     </a>",
"    </li>",
"    <li>",
"     Seifert H. Catheter-related infections due to gram-negative bacilli. In: Catheter-Related Infections, Seifert H, Jansen B, Farr BM (Eds), Marcel Drekker, New York 1997. p.111.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/70\">",
"      Lorente L, Jim&eacute;nez A, Santana M, et al. Microorganisms responsible for intravascular catheter-related bloodstream infection according to the catheter site. Crit Care Med 2007; 35:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/71\">",
"      Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and predictors of mortality. Medicine (Baltimore) 1995; 74:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/72\">",
"      Friedman ND, Korman TM, Fairley CK, et al. Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 2002; 45:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/73\">",
"      Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/74\">",
"      Cotton DJ, Gill VJ, Marshall DJ, et al. Clinical features and therapeutic interventions in 17 cases of Bacillus bacteremia in an immunosuppressed patient population. J Clin Microbiol 1987; 25:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/75\">",
"      Peces R, Gago E, Tejada F, et al. Relapsing bacteraemia due to Micrococcus luteus in a haemodialysis patient with a Perm-Cath catheter. Nephrol Dial Transplant 1997; 12:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/76\">",
"      Gaillard JL, Merlino R, Pajot N, et al. Conventional and nonconventional modes of vancomycin administration to decontaminate the internal surface of catheters colonized with coagulase-negative staphylococci. JPEN J Parenter Enteral Nutr 1990; 14:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/77\">",
"      Simon VC, Simon M. Antibacterial activity of teicoplanin and vancomycin in combination with rifampicin, fusidic acid or fosfomycin against staphylococci on vein catheters. Scand J Infect Dis Suppl 1990; 72:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/78\">",
"      Guggenbichler JP, Berchtold D, Allerberger F, et al. In vitro and in vivo effect of antibiotics on catheters colonized by staphylococci. Eur J Clin Microbiol Infect Dis 1992; 11:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/79\">",
"      Ramirez de Arellano E, Pascual A, Martinez-Martinez L, Perea EJ. Activity of eight antibacterial agents on Staphylococcus epidermidis attached to Teflon catheters. J Med Microbiol 1994; 40:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/80\">",
"      Kropec A, Huebner J, Wursthorn M, Daschner FD. In vitro activity of vancomycin and teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis colonizing catheters. Eur J Clin Microbiol Infect Dis 1993; 12:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/81\">",
"      Pascual A, Ramirez de Arellano E, Mart&iacute;nez Mart&iacute;nez L, Perea EJ. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis. J Hosp Infect 1993; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/82\">",
"      Fernandez-Hidalgo N, Almirante B, Calleja R, et al. Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 2006; 57:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/83\">",
"      Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/84\">",
"      Arnow PM, Kushner R. Malassezia furfur catheter infection cured with antibiotic lock therapy. Am J Med 1991; 90:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/85\">",
"      Krishnasami Z, Carlton D, Bimbo L, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic lock solution. Kidney Int 2002; 61:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/86\">",
"      Maya ID, Carlton D, Estrada E, Allon M. Treatment of dialysis catheter-related Staphylococcus aureus bacteremia with an antibiotic lock: a quality improvement report. Am J Kidney Dis 2007; 50:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/87\">",
"      Krzywda EA, Andris DA, Edmiston CE Jr, Quebbeman EJ. Treatment of Hickman catheter sepsis using antibiotic lock technique. Infect Control Hosp Epidemiol 1995; 16:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/88\">",
"      Benoit JL, Carandang G, Sitrin M, Arnow PM. Intraluminal antibiotic treatment of central venous catheter infections in patients receiving parenteral nutrition at home. Clin Infect Dis 1995; 21:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/89\">",
"      Stovroff M, Teague WG. Intravenous access in infants and children. Pediatr Clin North Am 1998; 45:1373.",
"     </a>",
"    </li>",
"    <li>",
"     Huskins WC, Goldmann DA. Nosocomial infections. In: Textbook of Pediatric Infectious Diseases, Feigin RD, Cherry JD (Eds), WB Saunders, Philadelphia 1998. p.2545.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/20/7498/abstract/91\">",
"      Decker MD, Edwards KM. Central venous catheter infections. Pediatr Clin North Am 1988; 35:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3814 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7498=[""].join("\n");
var outline_f7_20_7498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CATHETER MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Salvage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Guidewire exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tailoring therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Coagulase negative staphylococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - S. aureus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Enterococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Gram-negative rods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Candida",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Catheter colonization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antibiotic lock therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Therapy for children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Persistent bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LOCAL SITE INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Insertion site infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Exit site infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tunnel infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/23/3454\" title=\"table 1\">",
"      IV rx IVC-related infxs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2121?source=related_link\">",
"      Antibiotic lock therapy for treatment of catheter-related bloodstream infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/23/375?source=related_link\">",
"      Diagnosis of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/33/35345?source=related_link\">",
"      Patient information: Central line infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12344?source=related_link\">",
"      Staphylococcus lugdunensis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/25/43417?source=related_link\">",
"      Superficial thrombophlebitis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40760?source=related_link\">",
"      Treatment of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3336?source=related_link\">",
"      Treatment of candidemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29834?source=related_link\">",
"      Tunneled, cuffed hemodialysis catheter-related bacteremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_20_7499="Consequences of labor pain";
var content_f7_20_7499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential effects of severe labor pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Increased oxygen consumption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperventilation leading to hypocarbia and respiratory alkalosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric inhibition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased gastric acidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased peripheral vascular resistance, cardiac output, blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased placental perfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incoordinate uterine activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postpartum psychological effects, such as posttraumatic stress disorder",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Brownridge, P. Eur J Obstet Gynecol Reprod Biol 1995; 59 Suppl:S9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7499=[""].join("\n");
var outline_f7_20_7499=null;
var title_f7_20_7500="Causes postpartum pain";
var content_f7_20_7500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of postpartum abdominal pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gastrointestinal disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bowel obstruction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postoperative ileus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute appendicitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute cholecystitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute pancreatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peptic ulceration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gynecologic disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ovarian torsion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ovarian cyst hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ovarian vein thrombosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uterine fibroid degeneration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Renal disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute pyelonephritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute urinary retention",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Renal colic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Urolithiasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bladder rupture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Pregnancy-related disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Endometritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Preeclampsia with liver distension/rupture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uterine rupture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute fatty liver",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Breastfeeding can be associated with painful uterine contractions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cardiovascular disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute myocardial infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Aortic aneurysm",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mesenteric vascular occlusion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sickle cell disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Splenic rupture",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7500=[""].join("\n");
var outline_f7_20_7500=null;
var title_f7_20_7501="Clinical findings associated with sexual abuse";
var content_f7_20_7501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings associated with sexual abuse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genital-rectal complaints",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genital, anal, or urethral trauma*, bleeding, or itching",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic genital or anal pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Genital infection or discharge",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vaginal or rectal foreign body",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vulvitis or vulvovaginitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anal inflammation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sexually transmitted infection*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dysuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Recurrent urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Medical complaints",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anorexia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Abdominal pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Headaches",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enuresis, encopresis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic constipation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Painful defecation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bruises to the soft or hard palate",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"        &nbsp;",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Behavioral changes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clinging",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Temper tantrums, aggression, self injury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sleep disturbance, nightmares",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appetite disturbance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurotic or conduct disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Excessive fears, phobias",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Depression, withdrawal, low self-esteem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Social problems with peers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            School problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Substance abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suicidal ideation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Explicit description of sexual contact*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Promiscuity, prostitution, sexual perpetration on others*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inappropriate knowledge of adult sexual behavior*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Excessive sexual curiosity, sexual acting out*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Compulsive masturbation*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *Specific, significant indicators of possible sexual abuse",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hymel, KP, Jenny, C. Child sexual abuse. Pediatr Rev 1996; 17:236 and Ludwig, S. Child abuse. In: Textbook of Pediatric Emergency Medicine, 4th ed, Fleisher, GR, Ludwig, S (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2000. p.1669.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7501=[""].join("\n");
var outline_f7_20_7501=null;
var title_f7_20_7502="Outcome with inducible VT";
var content_f7_20_7502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Induction of a ventricular tachyarrhythmia identifies a high risk patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the MUSTT trial, the outcome of 353 patients with coronary disease, a left ventricular ejection fraction &le;40 percent, and a sustained ventricular tachyarrhythmia induced during electrophysiologic study, but who did not receive antiarrhythmic therapy, was compared to that of 1397 patients without an inducible ventricular tachyarrhythmia who were entered into a registry. Kaplan-Meier analysis showed that the rate of cardiac arrest or arrhythmic death were lower in patients without inducible arrhythmia at two (12 versus 18 percent for those with inducible arrhythmia) and five years (24 versus 32 percent, adjusted P&lt;0.001). Overall mortality at five years was significantly lower in those without inducible arrhythmia (44 versus 48 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Buxon AE, Lee KL, DiCarlo L, et al. N Engl J Med 2000; 342:1937.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7502=[""].join("\n");
var outline_f7_20_7502=null;
var title_f7_20_7503="Bence Jones protein UPEP";
var content_f7_20_7503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urinary monoclonal protein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel B: This figure illustrates the cellulose acetate electrophoretic pattern of a urine sample. It reveals a dense band of protein with beta mobility. Panel A: Densitometer tracing shows a tall, narrow-based peak of beta mobility. These findings are consistent with a urine monoclonal protein (Bence Jones protein); confirmation of the diagnosis requires demonstration that the protein contains only a lambda or kappa light chain with no heavy chain reactivity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_20_7503=[""].join("\n");
var outline_f7_20_7503=null;
